GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:02:07; Search time 16.5871 Seconds

(without alignments)

3219.466 Million cell updates/sec

Title: US-09-830-972-29 COPY 990 1178

Perfect score: 931

Sequence: 1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIQAKIPGLKRKAE 189

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A_Geneseq_29Jan04:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		₹ *				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	931	100.0	893	3	AAY95012	Aay95012 Human sec
2	931	100.0	983	6	ABU11573	Abu11573 Human MDD
3	931	100.0	1178	3	AAY71311	Aay71311 Human neu
4	931	100.0	1192	3	AAY56967	Aay56967 Human MAG
5	931	100.0	1192	4	AAB82349	Aab82349 Human NOG
6	931	100.0	1192	4	AAU04591	Aau04591 Human Nog
7	931	100.0	1192	5	ABG30938	Abg30938 Human Nog
8	931	100.0	1192	5	ABP68600	Abp68600 Human pan
9	931	100.0	1192	5	ABB81078	Abb81078 Human neu

				_			
10	931	100.0	1192	6	ABR59667		Human Nog
11	928	99.7	200	4	AAB64514		Human sec
12	927	99.6	199	, 2	AAW53947		Human NSP
13	927	99.6	199	2	AAW78313	Aaw78313	-
14	927	99.6	199	3	AAB12805		Human NSP
15	927	99.6	199	4	AAB82348		Human NOG
16	927	99.6	199	5	ABB81080	Abb81080	Human neu
17	927	99.6	373	3	AAY53624	Aay53624	A bone ma
18	927	99.6	373	3	AAY56969	` Aay56969	Human MAG
19	927	99.6	373	3	AAB24242	Aab24242	Human Nog
20	927	99.6	373	4	AAB82350	Aab82350	Human NOG
21	927	99.6	373	5	AAM47954	Aam47954	Human RTN
22	927	99.6	373	5	ABG30937	Abg30937	Human Nog
23	927	99.6	373	5	ABP68601	Abp68601	Human pan
24	927	99.6	373	5	ABB81079	Abb81079	Human neu
25	923	99.1	291	4	AAM93484	Aam93484	Human pol
26	918	98.6	199	2	AAY35903	Aay35903	Extended
27	908	97.5	361	3	AAY71385		Alternati
28	908	97.5	1163	3	AAY71310	· · · · · · · · · · · · · · · · · · ·	Rat neuri
29	908	97.5	1163	3	AAY71384	-	Alternati
30	908	97.5	1163	5	ABB81074		Rat neuro
31	906	97.3	199	3	AAY71559	Aay71559 [°]	
32	906	97.3	359	3	AAY71558	Aay71558	_
33	906	97.3	403	3	AAY71563	Aay71563	_
34	906	97.3	1162	3	AAY71557	Aay71557	_
35	905	97.2	379	7	ADB85283		Rat fooce
36	904	97.1	199	5	ABB81077	Abb81077	Rat neuro
37	904	97.1	360	3	AAY71383	Aay71383	Rat neuri
38	904	97.1	360	5	ABB81076		Rat neuro
39	904	97.1	522	3	AAY71312		Rat neuri
40	894.5	96.1	642	2	AAW58383		Human sec
41	894.5	96.1	642	4	AAB90682		Human BG1
42	886	95.2	199	5	ABG30939	Abq30939	Human Nog
43	851	91.4	175	2	AAW78194		Human sec
44	682	73.3	202	4	AAB64513		Gene 27 h
45	682	73.3	208	3	AAB12808		NSPC prot
		· -	-	-			

ALIGNMENTS

```
RESULT 1
AAY95012
     AAY95012 standard; protein; 893 AA.
ID
XX
AC
     AAY95012;
XX
DT
     19-JUN-2000 (first entry)
XX
DE
     Human secreted protein vb22_1, SEQ ID NO:64.
XX
KW
     Human; secreted protein; cancer; tumour; cardiovascular disorder;
KW
     blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
KW
     infection; fungal; bacterial; viral; HIV; allergy; arthritis;
KW
     neurodegenerative disease; asthma; contraceptive.
XX
OS
     Homo sapiens.
```

```
XX
PN
     WO200011015-A1.
XX
PD
     02-MAR-2000.
XX
                    99WO-US019351.
PF
     24-AUG-1999;
XX
PR
     24-AUG-1998;
                    98US-0097638P.
     24-AUG-1998;
                    98US-0097659P.
PR
     09-SEP-1998;
                    98US-0099618P.
PR
     28-SEP-1998;
                    98US-0102092P.
PR
                    98US-0109978P.
PR
     25-NOV-1998;
PR
     23-DEC-1998;
                    98US-0113645P.
PR
     23-DEC-1998;
                    98US-0113646P.
     23-AUG-1999;
                    99US-00379246.
PR
XX
PA
     (ALPH-) ALPHAGENE INC.
XX
PI
     Valenzuela D, Yuan O, Hoffman H,
                                        Hall J, Rapiejko P;
XX
DR
     WPI; 2000-224657/19.
XX
     New secreted or transmembrane proteins and polynucleotides encoding them,
PT
PT
     useful for treating neurodegenerative disorders, autoimmune diseases and
PT
     cancer.
XX
     Claim 73; Page 322-325; 357pp; English.
PS
XX
CC
     The invention relates to 40 human secreted proteins (AAY94981-Y95020),
     and cDNA sequences encoding them (AAA23423-A23462). The secreted proteins
CC
CC
     of the invention include those that are thought to be only partially
     secreted, i.e., transmembrane proteins. The proteins of the invention may
CC
     exhibit one or more activities selected from the following: cytokine
CC
CC
     activity; cell proliferation; differentiation; immune modulation;
CC
     haematopoiesis regulation; tissue growth activity; activin/inhibin
CC
     activity; chemotactic/chemokinetic activity; haemostatic and thrombolytic
     activity; anti-inflammatory activity; and tumour inhibition activity. The
CC
CC
     proteins may be administered to patients as vaccines, and the nucleotides
CC
     may be used as part of a gene therapy regime. Diseases or conditions that
CC
     may be treated using the proteins or nucleotides of the invention include
CC
     autoimmune diseases; genetic disorders; haemophilia; cardiovascular
CC
     diseases; cancer; bacterial, fungal and viral infections, especially HIV;
CC
     multiple sclerosis; rheumatoid arthritis; pulmonary inflammation;
     Guillain-Barre syndrome; insulin dependent diabetes mellitus; and
CC
CC
     allergic reactions such as asthma and anaemia. They may also be used for
CC
     treating wounds, burns, ulcers, osteoporosis, osteoarthritis, periodontal
     diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease
CC
CC
     and amyotrophic lateral sclerosis (ALS). Proteins with activin/inhibin
CC
     activity may additionally be useful as contraceptives. Nucleic acid
CC
     sequences of the invention may be used in chromosome mapping, and as a
CC
     source of diagnostic primers and probes. The present sequence represents
CC
     one of the 40 proteins of the invention
XX
SQ
     Sequence 893 AA;
                          100.0%; Score 931; DB 3; Length 893;
  Query Match
```

100.0%; Pred. No. 4.4e-92;

Best Local Similarity

```
0;
                                 Mismatches
                                               0;
                                                  Indels
                                                               Gaps
                                                                       0;
 Matches
         189; Conservative
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
            705 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 764
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            765 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 824
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
             825 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 884
Db
         181 IPGLKRKAE 189
Qy
            Db
         885 IPGLKRKAE 893
RESULT 2
ABU11573
    ABU11573 standard; protein; 983 AA.
ID 
XX
AC
    ABU11573;
XX
    12-FEB-2003 (first entry)
DT
XX
    Human MDDT polypeptide SEQ ID 520.
DE
XX
    MDDT; human; disease detection and treatment molecule polypeptide;
KW
    anti-inflammatory; immunosuppressive; osteopathic; cytostatic; anti-HIV;
KW
    haemostatic; nephrotropic; antianaemic; antipsoriatic; hepatotropic;
KW
    gene therapy; protein replacement therapy; cell proliferative disorder;
KW
    cancer; adenocarcinoma; leukaemia; lymphoma; melanoma; myeloma; sarcoma;
KW
    anaemia; Crohn's disease; acquired immunodeficiency syndrome; AIDS;
KW
    Goodpasture's syndrome; inflammation; osteoporosis; thrombocytopaenia;
KW
KW
    psoriasis; hepatitis.
XX
OS
    Homo sapiens.
XX
PN
    WO200279449-A2.
XX
PD
    10-OCT-2002.
XX
    27-MAR-2002; 2002WO-US009944.
PF
XX
PR
    28-MAR-2001; 2001US-0279619P.
    29-MAR-2001; 2001US-0280067P.
PR
    29-MAR-2001; 2001US-0280068P.
PR
    16-MAY-2001; 2001US-0291280P.
PR
    17-MAY-2001; 2001US-0291829P.
PR
    17-MAY-2001; 2001US-0291849P.
PR
    19-JUN-2001; 2001US-0299428P.
PR
PR
    20-JUN-2001; 2001US-0299776P.
    20-JUN-2001; 2001US-0300001P.
PR
XX
    (INCY-) INCYTE GENOMICS INC.
PA
```

0:

```
XX
    Daffo A, Jones AL, Tran AB, Dahl CR, Gietzen D, Chinn J;
PΙ
    Dufour GE, Hillman JL, Yu JY, Tuason O, Yap PE, Amshey SR;
PΙ
    Daugherty SC, Dam TC, Liu TF, Nguyen DA, Kleefeld Y, Gerstin EH;
ΡI
    Peralta CH, David MH, Lewis SA, Chen AJ, Panzer SR, Harris B;
PI
    Flores V, Marwaha R, Lo A, Lan RY, Urashka ME;
PΙ
XX
    WPI; 2003-058431/05.
DR
    N-PSDB; ABX34563.
DR
XX
    New purified disease detection and treatment molecule proteins and
PT
    polynucleotides, useful for diagnosing, treating or preventing cancers
PT
    (e.g. leukemia or sarcoma), anemia, Crohn's disease, AIDS, osteoporosis
РΤ
PT
    or hepatitis.
XX
    Claim 27; SEQ ID NO 520; 339pp + Sequence Listing; English.
PS
XX
    This invention describes a novel disease detection and treatment molecule
CC
    polypeptide (MDDT) which has anti-inflammatory, immunosuppressive,
CC
    osteopathic, cytostatic, anti-HIV, haemostatic, nephrotropic,
CC
    antianaemic, antipsoriatic and hepatotropic activity. The polynucleotides
CC
CC.
    and the polypeptides of the invention can be used for gene therapy,
    protein replacement therapy and are useful for treating a variety of
CC
    diseases or conditions. These polypeptides or polynucleotides are
CC
    particularly useful for diagnosing, treating or preventing cell
CC
    proliferative disorders (e.g. cancers including adenocarcinoma,
CC
    leukaemia, lymphoma, melanoma, myeloma or sarcoma), anaemia, Crohn's
CC
    disease, acquired immunodeficiency syndrome (AIDS), Goodpasture's
CC
    syndromes, inflammation, osteoporosis, thrombocytopaenia, psoriasis or
CC
    hepatitis. ABU11450-ABU11845 represent the MDDT polynucleotides encoded
CC
    by ABU11450-ABU11845, described in the disclosure of the invention. NOTE:
CC
    The sequence data for this patent did not form part of the printed
CC
    specification, but was obtained in electronic format from WIPO at
CC
CC
    ftp.wipo.int/pub/published pct sequences
XX
    Sequence 983 AA;
SQ
                        100.0%; Score 931; DB 6; Length 983;
  Query Match
                        100.0%; Pred. No. 5e-92;
  Best Local Similarity
  Matches 189; Conservative 0; Mismatches
                                               0; Indels
                                                                        0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             795 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 854
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
             855 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 914
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             915 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 974
Db
         181 IPGLKRKAE 189
Qу
             975 IPGLKRKAE 983
```

Db

```
RESULT 3
AAY71311
     AAY71311 standard; protein; 1178 AA.
ID
XX
AC
     AAY71311;
XX
     02-NOV-2000
                  (first entry)
DT
XX
     Human neurite growth inhibitor Nogo.
DE
XX
     Human; neurite growth inhibitor; Nogo; neural cell; myelin; CNS;
KW
     central nervous system; neoplastic disease; antiproliferative; glioma;
KW
     antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
     degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
KW
     hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
     psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
     structural plasticity; screening.
KW
XX
os
     Homo sapiens.
XX
                      Location/Qualifiers
FH
     Key
     Misc-difference 187
FT
FT
                      /label= Unknown
     Misc-difference 188
FT
                      /label= Unknown
FT
     Misc-difference 189
FT
FT
                      /label= Unknown
     Misc-difference 190
FT
                      /label= Unknown
FT
     Misc-difference 221
FT
                      /label= Unknown
FT
FT
     Misc-difference 328
FT
                      /label= Unknown
     Misc-difference 477
FT
                      /label= Unknown
FT
FT
     Region
                      977. .1012
                      /note= "Region specifically described in claim 16"
FT
                      994. .1174
FT
     Region
                      /note= "Region specifically described in claim 16"
FT
FT
     Region
                      1079. .1114
                      /note= "Region specifically described in claim 16"
FT
XX
PN
     WO200031235-A2.
XX
PD
     02-JUN-2000.
XX
PF
     05-NOV-1999;
                    99WO-US026160.
XX
                    98US-0107446P.
PR
     06-NOV-1998;
XX
     (SCHW/) SCHWAB M E.
PA
PΑ
     (CHEN/) CHEN M S.
XX
PI
     Schwab ME, Chen MS;
XX
DR
     WPI; 2000-400052/34.
```

```
XX
PT
    Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
    of the central nervous system and inducing regeneration of neurons.
XX
PS
    Claim 11; Fig 13; 122pp; English.
XX
CC
    The present sequence is a human Nogo protein which is a potent neural
CC
    cell growth inhibitor and is free of all central nervous system (CNS)
CC
    myelin material with which it is natively associated. The human Nogo
CC
    sequence was derived by aligning human expressed sequence tags (ESTs)
CC
    e.g. AA158636, AA333267, AA081783, AA167765, AA322918, AA092565, AA081525
CC
    and AA081840 with the rat Nogo sequence. Nogo proteins and fragments
CC
    displaying neurite growth inhibitory activity are used in the treatment
CC
    of neoplastic disease of the CNS e.g. glioma, glioblastoma,
    medulloblastoma, craniopharyngioma, ependyoma, pinealoma,
CC.
CC
    haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma,
CC
    neuroblastoma or retinoblastoma and degenerative nerve diseases e.g.
CC
    Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo
CC
    activity can be used to treat or prevent hyperproliferative or benign
CC
    dysproliferative disorders e.g. psoriasis and tissue hypertrophy.
CC
    Ribozymes or antisense Nogo nucleic acids can be used to inhibit
CC
    production of Nogo protein to induce regeneration of neurons or to
CC
    promote structural plasticity of the CNS in disorders where neurite
CC
    growth, regeneration or maintenance are deficient or desired. The animal
CC
    models can be used in diagnostic and screening methods for predisposition
CC
    to disorders and to screen for or test molecules which can treat or
CC
    prevent disorders or diseases of the CNS. Note: SEQ ID numbers 35-42 are
    referred in claim 32 and SEQ ID NO: 29 in disclosure of the
CC
CC
    specification. However the specification does not include sequences for
CC
    these SEQ ID numbers
XX
SQ
    Sequence 1178 AA;
 Query Match
                        100.0%;
                                Score 931; DB 3; Length 1178;
  Best Local Similarity
                        100.0%;
                                Pred. No. 6.4e-92;
 Matches 189; Conservative
                               0; Mismatches
                                                                        0;
                                                0;
                                                   Indels
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOA 60
Qv
             Db
         990 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1049
          61 IQKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             1050 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1109
Db
Qу
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAK 180
             Dh
        1110 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1169
         181 IPGLKRKAE 189
Qy
             111111111
```

RESULT 4 AAY56967

Dh

ID AAY56967 standard; protein; 1192 AA.

1170 IPGLKRKAE 1178

```
XX
     AAY56967;
AC
XX
DT
     25-APR-2000
                  (first entry)
XX
DE
     Human MAGI polypeptide.
XX
     MAGI protein; neuroendocrine-specific protein; neuropathy; human;
KW
     spinal injury; neuronal degeneration; neuromuscular disorder; cancer;
KW
KW
     psychiatric disorder; developmental disorder; inflammatory disorder;
KW
     stroke; cytostatic; cerebroprotective; neuroprotective.
XX
     Homo sapiens.
OS
XX
PN
    WO200005364-A1.
XX
ΡD
     03-FEB-2000.
XX
PF
     21-JUL-1999;
                   99WO-GB002360.
XX
                   98GB-00016024.
PR
     22-JUL-1998;
PR
     19-JUL-1999;
                   99GB-00016898.
XX
PA
     (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PΙ
     Michalovich D, Prinjha RK;
XX
DR
     WPI; 2000-182693/16.
DR
     N-PSDB; AAZ56886.
XX
PT
    Novel polypeptides related to neuroendocrine-specific proteins and
PΤ
     polynucleotides useful for diagnosis of various diseases and for
PT
     treatment of cancer and neurological disorders.
XX
PS
     Claim 2; Page 20-21; 35pp; English.
XX
CC
     The invention relates to human MAGI protein, which is similar to
CC
     neuroendocrine-specific protein. The MAGI protein can be expressed by
CC
     standard recombinant methodology. The MAGI polypeptides, polynucleotides
CC
     and antibodies are useful for treating diseases, including neuropathies,
CC
     spinal injury, neuronal degeneration, neuromuscular disorders,
     psychiatric disorders and developmental disorders, cancer, stroke and
CC
CC
     inflammatory disorders. The polynucleoitde is also useful for chromosome
CC
     localization and for tissue expression studies. The present sequence
CC
     represents the human MAGI protein
XX
SQ
     Sequence 1192 AA;
  Query Match
                         100.0%; Score 931; DB 3; Length 1192;
  Best Local Similarity
                         100.0%; Pred. No. 6.5e-92;
  Matches 189; Conservative
                               0; Mismatches
                                                  0;
                                                     Indels
                                                                            0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             Dh
         1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Qу
           61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
```

```
Db
        1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
             1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qy
             11111111
        1184 IPGLKRKAE 1192
Db
RESULT 5
AAB82349
    AAB82349 standard; protein; 1192 AA.
XX
AC
    AAB82349;
XX
    23-JUL-2001 (first entry)
DT
XX
DE
    Human NOGO-A protein.
XX
KW
    NOGO-A; human; chromosome 2p21; neuropathy; spinal injury; brain injury;
    stroke; neuronal degeneration; Alzheimer's disease; Parkinson's disease;
KW
KW
    neuromuscular disorder; psychiatric disorder; developmental disorder;
    neuroprotective; nootropic; neuroleptic; antiparkinsonian;
KW
    cerebroprotective; neuroleptic; diagnosis; therapy.
KW
XX
OS
    Homo sapiens.
XX
ΡN
    WO200136631-A1.
XX
    25-MAY-2001.
PD
XX
PF
    14-NOV-2000; 2000WO-GB004345.
XX
    15-NOV-1999:
PR
                   99GB-00026995.
    24-JAN-2000; 2000GB-00001550.
PR
XX
PA
     (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PI
    Michalovich D, Prinjha R;
XX
DR
    WPI; 2001-343822/36.
DR
    N-PSDB; AAF90324.
XX
PT
    New polypeptide designated NOGO-C is a splice variant of the human NOGO
PT
    gene and may be useful in the treatment of neural disorders including
PT
    Alzheimer's and Parkinson's diseases.
XX
PS
    Disclosure; Page 26-27; 25pp; English.
XX
CC
    The present sequence is that of human NOGO-A. NOGO-A is a previously
CC
    known splice variant of the human NOGO gene on chromosome 2p21. The
CC
    invention relates to a novel splice variant, NOGO-C (see AAB82348). It
CC
    provides NOGO-C polypeptides and polynucleotides, and methods for
CC
    producing such polypeptides by recombinant techniques. Also disclosed are
```

```
CC
    treatment of diseases including neuropathies, spinal injury, brain
CC
    injury, stroke, neuronal degeneration, for example Alzheimer's disease
    and Parkinson's disease, neuromuscular disorders, psychiatric disorders
CC
    and developmental disorders. Also provided are methods for identifying
CC
    agonists and agonists for use in treating conditions associated with NOGO
CC
CC
    -C imbalance, and diagnostic assays for detecting diseases associated
    with inappropriate NOGO-C activity or levels
CC
XX
SO
    Sequence 1192 AA;
                        100.0%; Score 931; DB 4; Length 1192;
  Query Match
  Best Local Similarity
                        100.0%;
                                Pred. No. 6.5e-92;
                              0; Mismatches
 Matches 189; Conservative
                                                  Indels
                                                                Gaps
                                                                       0:
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qv
             Db
        1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
             1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Dh
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
             Db
        1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
         181 IPGLKRKAE 189
Qу
             1184 IPGLKRKAE 1192
Db
RESULT 6
AAU04591
ID
    AAU04591 standard; protein; 1192 AA.
XX
AC
    AAU04591;
XX
    26-SEP-2001 (first entry)
DT
XX
DE
    Human Nogo protein.
XX
KW
    Human; Nogo receptor; axonal growth; immunogen; antibody; nogo protein;
    cranial trauma; cerebral trauma; spinal cord injury; stroke;
KW
KW
    demyelinating disease; multiple sclerosis; monophasis demyelination;
KW
    encephalomyelitis; multifocal leukoencephalopathy; panencephalitis;
KW
    Marchiafava-Bignami disease; pontine myelinolysis; adrenoleukodystrophy;
KW
    Pelizaeus-Merzbacher disease; Spongy degeneration; Alexander's disease;
KW
    Canavan's disease; metachromatic leukodystrophy; viral infection;
    Krabbe's disease.
KW
XX
    Homo sapiens.
OS
XX
FH
                   Location/Qualifiers
    Key
FT
                   1054. .1119
    Domain
FT
                   /label= Lumenal extracellular domain
                   /note= "This sequence is specifically claimed"
FT
```

methods for utilising NOGO-C polypeptides and polynucleotides in the

```
Peptide
                     /label= Pep1
FT
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FT
                     1064. .1088
     Peptide
FT
                     /label= Pep2
\mathbf{FT}
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FT
                     1074. .1098
FT
     Peptide
                     /label= Pep3
FT
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FΤ
                     1084. .1108
FT
     Peptide
                     /label= Pep4
FT
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FT
FT
     Peptide
                     1095. .1119
FT
                     /label= Pep5
                     /note= "Receptor binding inhibitory peptide. This
FT
                     sequence is specifically claimed"
FT
XX
     WO200151520-A2.
PN
XX
PD
     19-JUL-2001.
XX
     12-JAN-2001; 2001WO-US001041.
PF
XX
     12-JAN-2000; 2000US-0175707P.
PR
     26-MAY-2000; 2000US-0207366P.
PR
     29-SEP-2000; 2000US-0236378P.
PR
XX
PA
     (UYYA ) UNIV YALE.
XX
PΙ
     Strittmatter SM;
XX
     WPI; 2001-442138/47.
DR
DR
     N-PSDB; AAS09453.
XX
     Novel Nogo receptor protein useful for identifying modulator of Nogo
PT
     protein or Nogo receptor protein, which is useful for treating central
PT
PT
     nervous system disorders.
XX
PS
     Example 1; Page 101-104; 109pp; English.
XX
CC
     The sequence is the human Nogo protein, a 250kDa myelin-associated axon
CC
     growth inhibitor. The invention relates to the use of the nogo receptor,
     nogo protein, their nucleic acids, vectors expressing them and antibodies
CC
     against them, to isolate agents which block nogo receptor mediated axonal
CC
     growth. The agent is useful for treating a central nervous system
CC
     disorder which is a result of cranial or cerebral trauma, spinal cord
CC
     injury, stroke or a demyelinating disease selected from multiple
CC
     sclerosis, monophasis demyelination, encephalomyelitis, multifocal
CC
     leukoencephalopathy, panencephalitis, Marchiafava-Bignami disease,
CC
     pontine myelinolysis, adrenoleukodystrophy, Pelizaeus-Merzbacher disease,
CC
     Spongy degeneration, Alexander's disease, Canavan's disease,
CC
     metachromatic leukodystrophy, viral infection and Krabbe's disease
CC
XX
```

1055. .1094

FΤ

```
100.0%; Score 931; DB 4; Length 1192;
                       100.0%; Pred. No. 6.5e-92;
 Best Local Similarity
                             0; Mismatches
                                              0; Indels
                                                              Gaps
                                                                     0;
 Matches 189; Conservative
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
            1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
         61 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
            1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qу
            11111111
Db
        1184 IPGLKRKAE 1192
RESULT 7
ABG30938
    ABG30938 standard; protein; 1192 AA.
XX
AC
    ABG30938;
XX
DT
    21-OCT-2002 (first entry)
XX
DE
    Human NogoA protein.
XX
    Human; Nogo; BACE; acute neuronal injury; spinal injury; head injury;
KW
    stroke; peripheral nerve damage; neoplastic disorder; glioblastoma;
KW
    neuroblastoma; hyperproliferative disorder; dysproliferative disorder;
KW
    cirrhosis; psoriasis; keloid formation; fibrocystic condition; cancer;
KW
    tissue hypertrophy; central nervous system; axon regeneration; NogoA;
KW
KW
    Nogo-associated disease; metastasis.
XX
OS
    Homo sapiens.
XX
    WO200257483-A2.
PN
XX
PD
    25-JUL-2002.
XX
    18-JAN-2002; 2002WO-GB000228.
PF
XX
    18-JAN-2001; 2001GB-00001312.
PR
XX
PA
     (GLAX ) GLAXO GROUP LTD.
     (SMIK ) SMITHKLINE BEECHAM PLC.
PA
XX
    Blackstock WP, Hale RS, Prinjha R, Rowley A;
PΙ
XX
    WPI: 2002-599722/64.
DR
    N-PSDB; ABK90134.
DR
```

XXIdentifying modulators of Nogo or BACE activity for treating acute РТ neuronal injuries, neoplastic or dysproliferative disorders, comprises PTproviding and monitoring interaction between Nogo and BACE polypeptides. PTXX Disclosure; Page 59-62; 68pp; English. PS XX CC The present invention relates to a new method of identifying modulators of Nogo function or BACE activity. The method involves providing Nogo and CC BACE polypeptides capable of binding with each other, monitoring the CC interaction between these polypeptides, and determining if the test agent CC is a modulator of Nogo or BACE activity. The method is useful in treating CC acute neuronal injuries, such as spinal or head injury, stroke, CC peripheral nerve damage, and in neoplastic (e.g. glioblastomas, CC neuroblastomas), hyperproliferative or dysproliferative disorders (e.g. CC cirrhosis, psoriasis, keloid formation, fibrocystic conditions, tissue CC CC hypertrophy) of the central nervous system. The BACE polypeptide is useful in screening methods to identify agents that may act as modulators CC of BACE activity and in particular agents that may be useful in treating CC Nogo-associated diseases. The modulators of Nogo or BACE polypeptides, CC CC and the polynucleotide encoding the BACE polypeptide are useful in manufacturing a medicament for the treatment or prevention of disorders CC responsive to the modulation of Nogo activity, in alleviating the CC symptoms or improving the condition of a patient suffering from this CC disorder, in axon regeneration, or in preventing metastasis or spreading CC of a cancer. The polynucleotide may also be an essential component in CC assays, a probe, in recombinant protein synthesis, and in gene therapy CC techniques. The present amino acid sequence represents the human NogoA CC CC protein of the invention XX SO Sequence 1192 AA; 100.0%; Score 931; DB 5; Length 1192; Query Match 100.0%; Pred. No. 6.5e-92; Best Local Similarity Matches 189; Conservative 0; Mismatches Gaps 0; Indels 1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60 Qу 1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063 Db 61 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120 Qу 1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123 Db 121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAK 180 Qу

1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183

```
RESULT 8
ABP68600
ID ABP68600 standard; protein; 1192 AA.
```

181 IPGLKRKAE 189

||||||| 1184 IPGLKRKAE 1192

Db

Qу

Db

```
ABP68600;
AC
XX
     14-JAN-2003 (first entry)
DT
XX
     Human pancreatic cancer expressed protein SEQ ID NO 71.
DΕ
XX
KW
     Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;
KW
     cytostatic; tumour.
XX
     Homo sapiens.
OS
XX
PN
     WO200260317-A2.
XX
PD
     08-AUG-2002.
XX
PF
     30-JAN-2002; 2002WO-US002781.
XX
     30-JAN-2001; 2001US-0265305P.
PR
     31-JAN-2001; 2001US-0265682P.
PR
     09-FEB-2001; 2001US-0267568P.
PR
     21-MAR-2001; 2001US-0278651P.
PR
     28-APR-2001; 2001US-0287112P.
PR
     16-MAY-2001; 2001US-0291631P.
PR
     12-JUL-2001; 2001US-0305484P.
PR
     20-AUG-2001; 2001US-0313999P.
PR
     27-NOV-2001; 2001US-0333626P.
PR
XX
PΑ
     (CORI-) CORIXA CORP.
XX
                                        Persing DH, Hepler WT,
PΙ
                            Lodes MJ,
                                                                 Jiang Y;
     Benson DR,
                Kalos MD,
XX
DR
     WPI; 2002-627435/67.
     N-PSDB; ABV94680.
DR
XX
     New isolated polynucleotide and pancreatic tumor polypeptides, useful for
PT
     diagnosing, preventing and/or treating cancer, particularly pancreatic
PT
PT
     cancer.
XX
     Claim 2; SEQ ID NO 71; 300pp + Sequence Listing; English.
PS
XX
CC
     The invention relates to an isolated polynucleotide (I) comprising: (a)
     any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)
CC
     complements of (a); (c) sequences consisting of at least 20 contiguous
CC
CC
     residues of (a); (d) sequences that hybridize to (a), under moderately
CC
     stringent conditions; (e) sequences having at least 75% or 90% identity
     to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-
CC
     ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer
CC
     in a patient and compositions comprising polypeptides, polynucleotides,
CC
CC
     antibodies, fusion proteins, T cell populations and antigen presenting
CC
     cells expressing the polypeptide are useful in treating pancreatic cancer
     and stimulating an immune response. The polynucleotides can be used as
CC
     probes or primers for nucleic acid hybridisation, in the design and
CC
     preparation of ribozyme molecules for inhibiting expression of the tumour
CC
```

polypeptides and proteins in the tumour cells, in vaccines and for gene

printed specification, but was obtained in electronic format directly

from WIPO at ftp.wipo.int/pub/published pct sequences

therapy. Note: The sequence data for this patent did not form part of the

CC

CC

```
SO
    Sequence 1192 AA;
                       100.0%; Score 931; DB 5; Length 1192;
 Query Match
 Best Local Similarity
                       100.0%; Pred. No. 6.5e-92;
 Matches 189; Conservative
                           0; Mismatches 0; Indels
                                                           0; Gaps
                                                                      0;
Qy
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
            1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
Qу
          61 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
            1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIOAK 180
Qу
            1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qу
            111111111
        1184 IPGLKRKAE 1192
Db
RESULT 9
ABB81078
ID
    ABB81078 standard; protein; 1192 AA.
XX
AC
    ABB81078;
XX
DT
    05-NOV-2002 (first entry)
XX
DΕ
    Human neurotransmitter receptor protein Nogo-A.
XX
KW
    Nerve regeneration; neuroprotection; neuronal degeneration; CNS; PNS;
    central nervous system; peripheral nervous system; tranquillizer; Nogo;
KW
    vulnerary; cerebroprotective; anti-tumour; antidiabetic; anticonvulsant;
KW
    nootropic; antiparkinsonian; ophthalmological; analgesic; hepatotropic;
KW
    osteopathic; vasotropic; nephrotropic; cytostatic; antigen; gene therapy;
KW
    neurotransmitter receptor; human; receptor.
KW
XX
OS
    Homo sapiens.
XX
PN
    US2002072493-A1.
XX
PD
    13-JUN-2002.
XX
PF
    28-JUN-2001; 2001US-00893348.
XX
PR
                  98IL-00124500.
    19-MAY-1998;
                  98WO-US014715.
PR
    21-JUL-1998;
PR
    22-DEC-1998;
                  98US-00218277.
    19-MAY-1999;
                  99US-00314161.
PR
XΧ
    (YEDA ) YEDA RES & DEV CO LTD.
PA
XX
```

Eisenbach-Schwartz M, Hauben E, Cohen IR, Beserman P, Mosonego A;

XX

PΙ

```
Moalem G;
PΙ
XX
    WPI; 2002-607255/65.
DR
    N-PSDB; ABN86601.
DR
XX
     Promoting nerve regeneration and preventing neuronal degeneration in the
PT
     central/peripheral nervous system from injury/disease, comprises
PT
PT
     administering nervous system-specific activated T cells/antigen, or
PT
     analogs/peptides.
XX
PS
     Example; Page 53-56; 93pp; English.
XX
CC
    The invention relates to promoting nerve regeneration or conferring
CC
    neuroprotection and preventing or inhibiting neuronal degeneration in the
     central/peripheral nervous system (NS). The method involves administering
CC
    NS-specific activated T cells, NS-specific antigen, its analogue or its
CC
CC
    peptide, a nucleotide sequence the NS-specific antigen or its analogue or
CC
    combinations. The method is useful for promoting nerve regeneration and
    preventing neuronal degeneration in central/peripheral nervous system
CC
     from injury/disease, where the injury is spinal cord injury, blunt
CC
CC
     trauma, penetrating trauma, hemorrhagic stroke, ischaemic stroke or
CC
    damages caused by surgery such as tumour excision. The disease is not an
CC
    autoimmune disease or neoplasm. The disease results in a degenerative
CC
    process occurring in either gray or white matter or both. The disease is
CC
    diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's
CC
    disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea,
CC
    amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and
    vitamin deficiency, intervertebral disc herniation, prion diseases such
CC
CC
    as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral
CC
    neuropathies associated with various diseases, including but not limited
CC
    to uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute
CC
    sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary
CC
    amyloidosis, obstructive lung diseases, acromegaly, malabsorption
    syndromes, polycythemia vera, immunoglobulin (Ig)A- and IgG gamma-
CC
    pathies, complications of various drugs (e.g., metronidazole) and toxins
CC
CC
     (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia
CC
     telangectasia, Friedreich's ataxia, amyloid polyneuropathies,
    adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's
CC
CC
    disease, or lipoproteinemia. The present sequence represents the human
CC
    neurotransmitter receptor protein Nogo-A, an example of NS-specific
CC
    antigen
XX
SQ
    Sequence 1192 AA;
 Query Match
                         100.0%; Score 931; DB 5; Length 1192;
                                 Pred. No. 6.5e-92;
  Best Local Similarity
                         100.0%;
                               0; Mismatches
                                                 0;
 Matches 189; Conservative
                                                               0;
                                                    Indels
                                                                  Gaps
                                                                          0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             Db
        1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             Db
        1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
```

```
1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qу
              1184 IPGLKRKAE 1192
Db
RESULT 10
ABR59667
     ABR59667 standard; protein; 1192 AA.
XX
AC
    ABR59667;
XX
DT
     22-JUL-2003 (first entry)
XX
DE
    Human NogoA protein.
XX
ΚW
     Human; Nogo receptor; NgR; CTS domain; neuroprotective; gene therapy;
     axonal growth; central nervous system; CNS; Nogo; spinal cord injury;
KW
     cranial trauma; cerebral trauma; spinal trauma; stroke; Krabbe's disease;
KW
KW
     demyelinating disease; multiple sclerosis; monophasic demyelination;
KW
     encephalomyelitis; multifocal leukoencephalopathy; panencephalitis.
XX
OS
     Homo sapiens.
XX
    W02003031462-A2.
PΝ
XX
PD
     17-APR-2003.
XX
     04-OCT-2002; 2002WO-US032007.
PF
XX
     06-OCT-2001; 2001US-00972599.
PR
XX
PA
     (UYYA ) UNIV YALE.
XX
PI
     Strittmatter SM;
XX
DR
    WPI; 2003-393433/37.
    N-PSDB; ACC81048.
DR
XX
     New human Nogo receptor polypeptides and nucleic acids, useful for
PΤ
     decreasing inhibition of axonal growth by a central nervous system
PT
PT
     neuron, or in treating central nervous system disease, disorder or
PT
     injury, e.g. spinal cord injury.
XX
PS
     Disclosure; Page 131-135; 148pp; English.
XX
     The invention relates to a novel nucleic acid encoding a polypeptide
CC
     comprising amino acid residues 27-309 of a 473 amino acid sequence (P1,
CC
CC
     human Nogo receptor (NgR) NTLRRCT domain), or residues 27-309 of P1 with
     1-20 conservative amino acid substitutions, and less than a complete CTS
CC
     domain, provided that a partial CTS domain, if present, consists of no
CC
     more than the first 39 consecutive residues. The nucleic acid of the
CC
     invention has neuroprotective activity. The polynucleotide may have a use
CC
     in gene therapy. The nucleic acid is useful for decreasing inhibition of
CC
CC
     axonal growth by a central nervous system (CNS) neuron. The NgR
```

```
CC
    dependent signal transduction in the central nervous system neuron may be
    used in treating central nervous system disease, disorder or injury, e.g.
CC
    spinal cord injury. Expression of an NgR protein may be associated with
CC
CC
    inhibition of axonal regeneration following cranial, cerebral or spinal
    trauma, stroke or a demyelinating disease, such as multiple sclerosis,
CC
    monophasic demyelination, encephalomyelitis, multifocal
CC
    leukoencephalopathy, panencephalitis, or Krabbe's disease. The present
CC
CC
    sequence is used in the exemplification of the invention
XX
SQ
    Sequence 1192 AA;
 Query Match
                        100.0%; Score 931; DB 6; Length 1192;
                        100.0%;
                                Pred. No. 6.5e-92;
 Best Local Similarity
 Matches 189; Conservative
                              0; Mismatches
                                                   Indels
                                                             0;
                                                                Gaps
                                                                        0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qy
             111111111
        1184 IPGLKRKAE 1192
Db
RESULT 11
AAB64514
    AAB64514 standard; protein; 200 AA.
ID
XX
AC
    AAB64514;
XX
DT
    23-MAR-2001 (first entry)
XX
    Human secreted protein sequence encoded by gene 28 SEQ ID NO:152.
DE
XX
    Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
KW
KW
    antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
KW
    cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
KW
     fungicide; ophthalmological; autoimmune disease; rheumatoid arthritis;
KW
    hyperproliferative disorder; neoplasm; cardiovascular disorder;
KW
     cardiac arrest; cerebrovascular disorder; cerebral ischaemia; infection;
KW
    angiogenesis; nervous system disorder; Alzheimer's disease; skin aging;
    ocular disorder; corneal infection; wound healing; food additive;
KW
KW
    preservative.
XX
OS
    Homo sapiens.
XX
ΡN
    WO200077255-A1.
XX
```

polypeptide or an agent inhibits the binding of Nogo to NgR or NgR-

```
21-DEC-2000.
PD
XX
PF
    01-JUN-2000; 2000WO-US014926.
XX
     11-JUN-1999;
                   99US-0138628P.
PR
XX
     (HUMA-) HUMAN GENOME SCI INC.
PA
XX
               Ruben SM,
                          Komatsoulis GA:
PΤ
    Rosen CA,
XX
    WPI; 2001-025337/03.
DR
XX
     Isolated nucleic acid molecule encoding a human secreted protein is used
PT
     in preventing, treating or ameliorating a medical condition.
PT
XX
     Disclosure; Page 566; 593pp; English.
PS
XX
CC
    The polynucleotide sequences given in AAF32699 to AAF32747 encode the
CC
     human secreted proteins given in AAB64422 to AAB64470. AAB64471 to
     AAB64548 represent human secreted polypeptide sequences and proteins
CC
CC
    homologous to them, which are given in the exemplification of the present
     invention. Human secreted proteins have activities based on the tissues
CC
     and cells the genes are expressed in. Examples of activities include:
CC
     antiarthritic; immunosuppressive; antirheumatic; antiproliferative;
CC
     cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
CC
CC
     neuroprotective; antibacterial; virucide; fungicide; and
     ophthalmological. The polynucleotides and polypeptides can be used to
CC
     prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC
CC
     rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
     in diagnosing a pathological condition or susceptibility to a
CC
    pathological condition. Disorders which are diagnosed or treated include
CC
     autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC
CC
     disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
     e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC
     angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC
     infections caused by bacteria, viruses and fungi and ocular disorders
CC
     e.g. corneal infection. The polypeptides can also be used to aid wound
CC
     healing and epithelial cell proliferation, to prevent skin aging due to
CC
     sunburn, to maintain organs before transplantation, for supporting cell
CC
     culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC
     polypeptides can also be used as a food additive or preservative to
CC
     increase or decrease storage capabilities. AAF32690 to AAF32698 and
CC
CC
     AAB64421 represent sequences used in the exemplification of the present
CC
     invention
XX
SO
     Sequence 200 AA;
                         99.7%;
  Query Match
                                 Score 928; DB 4; Length 200;
  Best Local Similarity
                         99.5%;
                                 Pred. No. 1.3e-92;
                                                                           0:
  Matches 188; Conservative
                                1;
                                   Mismatches
                                                 0; Indels
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
              12 AVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 71
Db
           61 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Οv
```

```
72 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 131
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
              132 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 191
Db
         181 IPGLKRKAE 189
Qy
             192 IPGLKRKAE 200
Db
RESULT 12
AAW53947
ID
    AAW53947 standard; protein; 199 AA.
XX
AC
    AAW53947;
XX
     24-JUL-1998 (first entry)
DT
XX
    Human NSPLP protein A.
DE
XX
    NSPLP; neuroendocrine-specific protein-like protein; human; gene therapy;
KW
     neurodegenerative disease; amyotrophic lateral sclerosis; cancer.
KW
XX
OS
     Homo sapiens.
XX
     WO9806841-A2.
PN
XX
     19-FEB-1998.
PD
XX
                   97WO-US013469.
     24-JUL-1997;
PF
XX
     12-AUG-1996;
                   96US-00700607.
PR
XX
     (INCY-) INCYTE PHARM INC.
PΑ
XX
PΙ
     Bandman O, Au-Young J, Goli SK,
                                       Hillman J;
XX
     WPI; 1998-159533/14.
DR
     N-PSDB; AAV23695.
DR
XX
     Human neuro-endocrine-specific protein-like proteins - useful for
PT
     diagnosis, monitoring and treatment of cancer and neuro-degenerative
PT
     disease.
PT
XX
PS
     Claim 1; Page 38; 73pp; English.
XX
     This sequence is a human neuroendocrine-specific protein-like protein
CC
     (NSPLP) of the invention. Recombinant cells transformed with the DNA are
CC
     used to express the NSPLP proteins, which are used to treat cancer and
CC
     neurodegenerative diseases such as amyotrophic lateral sclerosis. Also
CC
     antisense nucleic acids and antagonists of NSPLP can be used to inhibit
CC
     activity of the NSPLP proteins. Antibodies specific for NSPLP are used
CC
     for diagnosis and monitoring treatment of diseases associated with NSPLP
CC
     expression, in usual immunoassays, and to isolate NSPLP from natural
CC
     sources. The NSPLP proteins, or their fragments can also be used in drug
CC
     screening to identify NSPLP antagonists. The nucleic acid can be used
CC
```

```
diagnostically and for monitoring treatment (in hybridisation or
    amplification assays); to isolate closely related sequences; in gene
CC
    therapy for both sense and antisense applications (including use of
CC
    ribozymes) and for mapping the natural genomic sequence
CC
XX
    Sequence 199 AA;
SO
 Query Match
                        99.6%; Score 927; DB 2; Length 199;
 Best Local Similarity
                        100.0%; Pred. No. 1.6e-92;
 Matches 188; Conservative
                              0; Mismatches
                                               0;
                                                  Indels
                                                            0;
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
             72 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
             132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
             1111111
         192 PGLKRKAE 199
Db
RESULT 13
AAW78313
    AAW78313 standard; protein; 199 AA.
ID
XX
AC
    AAW78313;
XX
DT
                (first entry)
    13-APR-1999
XX
    Fragment of human secreted protein encoded by gene 69.
DE
XX
    Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW
    diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW
    developmental abnormality; foetal deficiency; blood; allergy; renal;
KW
    immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW
    inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW
    cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW
    osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW
KW
    endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
os
    Homo sapiens.
XX
    WO9856804-A1.
ΡN
XX
PD
    17-DEC-1998.
XX
PF
    11-JUN-1998;
                  98WO-US012125.
XX
                  97US-0049547P.
PR
    13-JUN-1997;
PR
    13-JUN-1997;
                  97US-0049548P.
```

```
PR
     13-JUN-1997;
                     97US-0049549P.
PR
     13-JUN-1997;
                     97US-0049550P.
     13-JUN-1997;
                     97US-0049566P.
PR
PR
     13-JUN-1997;
                     97US-0049606P.
                     97US-0049607P.
PR
     13-JUN-1997;
                     97US-0049608P.
PR
     13-JUN-1997;
PR
     13-JUN-1997;
                     97US-0049609P.
PR
     13-JUN-1997;
                     97US-0049610P.
PR
     13-JUN-1997;
                     97US-0049611P.
PR
     13-JUN-1997;
                     97US-0050901P.
PR
     13-JUN-1997;
                     97US-0052989P.
PR
     08-JUL-1997;
                     97US-0051919P.
PR
     18-AUG-1997;
                     97US-0055984P.
PR
     12-SEP-1997;
                     97US-0058665P.
PR
     12-SEP-1997;
                     97US-0058668P.
PR
     12-SEP-1997;
                     97US-0058669P.
                     97US-0058750P.
PR
     12-SEP-1997;
                     97US-0058971P.
PR
     12-SEP-1997;
PR
     12-SEP-1997;
                     97US-0058972P.
PR
                     97US-0058975P.
     12-SEP-1997;
PR
     02-OCT-1997;
                     97US-0060834P.
PR
                     97US-0060841P.
     02-OCT-1997;
                     97US-0060844P.
PR
     02-OCT-1997;
PR
     02-OCT-1997;
                     97US-0060865P.
PR
     02-OCT-1997;
                     97US-0061059P.
                     97US-0061060P.
     02-OCT-1997;
PR
XX
PA
     (HUMA-) HUMAN GENOME SCI INC.
XX
                Shi Y, Rosen CA, Ruben SM, Lafleur DW, Olsen HS;
PI
     Moore PA,
PΙ
     Ebner R,
               Brewer LA, Young P, Greene JM, Ferrie AM, Yu G, Ni J;
PI
     Feng P;
XX
DR
     WPI; 1999-080881/07.
     N-PSDB; AAX04379.
DR
XX
PT
     New isolated human genes and the secreted polypeptides they encode -
PT
     useful for diagnosis and treatment of e.g. cancers, neurological
PT
```

disorders, immune diseases, inflammation or blood disorders.

Disclosure; Page 62; 380pp; English.

XX PS

XX CC

CCCC

CC

CC

CC

CC

CC

CC

CCCC

CC

CC

CC

XX

This sequence represents a fragment of a secreted human protein encoded by the nucleic acid molecule detailed in the descriptor line. The gene can be used to generate fusion proteins by linking to the gene to a human immunoglobulin Fc portion (e.g. AAX04302) for increasing the stability of the fused protein as compared to the human protein only. The invention relates to 86 novel genes and their fragments (nucleic acid sequences: AAX04311-X04410; amino acid sequences AAW78126-W78225) which are useful for preventing, treating or ameliorating medical conditions e.g. by protein or gene therapy. Also, pathological conditions can be diagnosed by determining the amount of the new polypeptides in a sample or by determining the presence of mutations in the new polynucleotides. Specific uses are described for each of the 86 polynucleotides, based on which tissues they are most highly expressed in (see AAX04311 for described uses)

```
Query Match
                       99.6%; Score 927; DB 2; Length 199;
 Best Local Similarity 100.0%; Pred. No. 1.6e-92;
 Matches 188; Conservative
                           0; Mismatches
                                            0; Indels
                                                         0; Gaps
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qy
            Db
         12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qy
            Db
         72 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qy
            Db
         132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
        182 PGLKRKAE 189
Qy
            1111111
Db
         192 PGLKRKAE 199
RESULT 14
AAB12805
    AAB12805 standard; protein; 199 AA.
XX
AC
    AAB12805;
XX
DT
    24-NOV-2000 (first entry)
XX
DΕ
    Human NSPH protein sequence SEQ ID NO:4.
XX
KW
    Human; neuroendocrine-specific protein; NSPH; NSPA; NSPB; NSPC.
XX
OS
    Homo sapiens.
XX
PN
    CN1253180-A.
XX
    17-MAY-2000.
PD
XX
PF
    30-OCT-1998;
                 98CN-00121473.
XX
PR
                 98CN-00121473.
    30-OCT-1998;
XX
PA
    (UYFU-) UNIV FUDAN.
XX
PI
    Yu L, Zhao Y, Zhang H;
XX
DR
    WPI; 2000-466537/41.
DR
    N-PSDB; AAA72981.
XX
PT
    Specific protein of human neuroendocrine, coding sequence and its
PT
    preparating process and application.
XX
    Claim 4; Page 14-15; 21pp; Chinese.
PS
XX
```

```
CC
    specific protein family, designated NSPH. The present sequence represents
CC
    the human NSPH protein
XX
SQ
    Sequence 199 AA;
                       99.6%; Score 927; DB 3; Length 199;
 Query Match
 Best Local Similarity
                       100.0%; Pred. No. 1.6e-92;
 Matches 188: Conservative
                             0; Mismatches
                                              0; Indels
                                                              Gaps
                                                                      0;
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
            12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
Qy
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
            Db
          72 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
            132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
            1111111
Db
         192 PGLKRKAE 199
RESULT 15
AAB82348
ID
    AAB82348 standard; protein; 199 AA.
XX
AC
    AAB82348;
XX
DT
    23-JUL-2001 (first entry)
XX
DE
    Human NOGO-C protein.
XX
KW
    NOGO-C; human; chromosome 2p21; neuropathy; spinal injury; brain injury;
    stroke; neuronal degeneration; Alzheimer's disease; Parkinson's disease;
KW
KW
    neuromuscular disorder; psychiatric disorder; developmental disorder;
    neuroprotective; nootropic; neuroleptic; antiparkinsonian;
KW
KW
    cerebroprotective; neuroleptic; diagnosis; therapy.
XX
OS
    Homo sapiens.
XX
PN
    WO200136631-A1.
XX
PD
    25-MAY-2001.
XX
    14-NOV-2000; 2000WO-GB004345.
PF
XX
PR
    15-NOV-1999;
                  99GB-00026995.
    24-JAN-2000; 2000GB-00001550.
PR
XX
PΑ
    (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PI
    Michalovich D, Prinjha R;
```

The present invention relates to a new member of the human neuroendocrine

```
XX
DR
    WPI; 2001-343822/36.
DR
    N-PSDB; AAF90323.
XX
    New polypeptide designated NOGO-C is a splice variant of the human NOGO
PT
PT
    gene and may be useful in the treatment of neural disorders including
    Alzheimer's and Parkinson's diseases.
PT
XX
PS
    Claim 3; Page 25; 25pp; English.
XX
    The present sequence is that of human NOGO-C, encoded by a novel splice
CC
    variant of the human NOGO gene on chromosome 2p21. 2 Other splice
CC
    variants, NOGO-A and NOGO-B, have previously been identified. The
CC
    invention provides NOGO-C polypeptides and polynucleotides, and methods
CC
    for producing such polypeptides by recombinant techniques. Also disclosed
CC
    are methods for utilising NOGO-C polypeptides and polynucleotides in the
CC
CC
    treatment of diseases including neuropathies, spinal injury, brain
    injury, stroke, neuronal degeneration, for example Alzheimer's disease
CC
    and Parkinson's disease, neuromuscular disorders, psychiatric disorders
CC
    and developmental disorders. Also provided are methods for identifying
CC
CC
    agonists and agonists for use in treating conditions associated with NOGO
CC
    -C imbalance, and diagnostic assays for detecting diseases associated
CC
    with inappropriate NOGO-C activity or levels
XX
SO
    Sequence 199 AA;
                       99.6%; Score 927; DB 4; Length 199;
 Query Match
                       100.0%; Pred. No. 1.6e-92;
 Best Local Similarity
                                                                      0;
 Matches 188; Conservative
                             0; Mismatches
                                              0;
                                                  Indels
                                                               Gaps
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qy
             72 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAKI 181
Qy
             132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
             192 PGLKRKAE 199
Db
```

Search completed: September 29, 2004, 18:14:01 Job time: 17.5871 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:09:33; Search time 4.69196 Seconds

(without alignments)

2079.581 Million cell updates/sec

Title: US-09-830-972-29_COPY_990_1178

Perfect score: 931

Sequence: 1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIQAKIPGLKRKAE 189

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

1: /cgn2 6/ptodata/2/iaa/5A COMB.pep:*

2: /cgn2 6/ptodata/2/iaa/5B COMB.pep:*

3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*

4: /cgn2 6/ptodata/2/iaa/6B COMB.pep:*

5: /cgn2 6/ptodata/2/iaa/PCTUS_COMB.pep:*

6: /cgn2 6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		.8				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	927	99.6	199	2	US-08-700-607-1	Sequence 1, Appli
2	682	73.3	208.	2	US-08-700-607-7	Sequence 7, Appli
. 3	682	73.3	356	2	US-08-700-607-6	Sequence 6, Appli
4	682	73.3	776	2	US-08-700-607-5	Sequence 5, Appli
5	665	71.4	267	2	US-08-700-607-8	Sequence 8, Appli
. 6	541.5	58.2	168	4	US-09-149-476-563	Sequence 563, App
7	512	55.0	241	2	US-08-700-607-3	Sequence 3, Appli
8	285	30.6	92	4	US-09-149-476-411	Sequence 411, App
9	100	10.7	80	3	US-08-905-223-411	Sequence 411, App
10	89	9.6	468	4	US-08-487-596-8	Sequence 8, Appli
11	89	9.6	468	4	US-08-660-451A-8	Sequence 8, Appli

```
9.5
                    1278
                              US-09-462-136-2
                                                          Sequence 2, Appli
      88.5
12
                                                          Sequence 5477, Ap
13
      87.5
              9.4
                     592
                              US-09-134-000C-5477
      87.5
                              US-09-134-001C-5005
                                                          Sequence 5005, Ap
14
              9.4
                    1051
                              US-08-956-171E-5246
                                                          Sequence 5246, Ap
              9.1
                     414
                          4
15
        85
                                                          Sequence 1, Appli
                              US-09-785-381-1
16
        83
              8.9
                     744
                          4
                                                          Sequence 3, Appli
        83
              8.9
                     744
                          4
                              US-09-785-381-3
17
                                                          Sequence 27968, A
      82.5
              8.9
                     554
                          4
                              US-09-252-991A-27968
18
                                                          Sequence 53, Appl
                     598
                          2
                              US-08-853-659A-53
      81.5
              8.8
19
                                                          Sequence 7, Appli
20
              8.7
                     970
                              US-09-795-927-7
        81
                                                          Sequence 6175, Ap
21
      80.5
              8.6
                     280
                              US-09-543-681A-6175
                              US-09-328-352-4866
                                                          Sequence 4866, Ap
22
      80.5
              8.6
                     593
                                                          Sequence 30, Appl
        79
                     993
                              US-08-836-687B-30
23
              8.5
                                                          Sequence 6579, Ap
      78.5
              8.4
                     446
                              US-09-543-681A-6579
24
                                                          Sequence 12212, A
25
              8.4
                     292
                          4
                              US-09-489-039A-12212
        78
                                                          Sequence 973, App
        78
              8.4
                     349
                              US-09-198-452A-973
26
                                                          Sequence 5, Appli
                              US-08-366-783-5
27
        77
              8.3
                     154
28
        77
              8.3
                     424
                              US-09-543-681A-7510
                                                          Sequence 7510, Ap
                                                          Sequence 2858, Ap
29
        77
              8.3
                     614
                              US-09-540-236-2858
                              US-09-134-001C-3805
                                                          Sequence 3805, Ap
30
      76.5
              8.2
                     420
                     1053
                              US-09-328-352-5058
                                                          Sequence 5058, Ap
31
        76
              8.2
                          4
32
      75.5
              8.1
                     397
                              US-09-328-352-7457
                                                          Sequence 7457, Ap
33
      75.5
              8.1
                     454
                           4
                              US-09-904-615-165
                                                          Sequence 165, App
                     248
                              US-09-198-452A-1153
                                                          Sequence 1153, Ap
34
              8.1
                          4
        75
                                                          Sequence 17805, A
35
        75
                     1421
                              US-09-252-991A-17805
              8.1
                                                          Sequence 254, App
36
      74.5
              8.0
                     390
                              US-09-198-452A-254
                     289
                              US-09-540-236-2019
                                                          Sequence 2019, Ap
37
        74
              7.9
        74
              7.9
                    1160
                              US-09-328-352-6826
                                                          Sequence 6826, Ap
38
                                                          Sequence 6378, Ap
              7.9
                              US-09-107-532A-6378
39
      73.5
                     208
                                                          Sequence 2403, Ap
40
      73.5
              7.9
                     517
                              US-09-540-236-2403
                     720
                              US-09-134-000C-5631
                                                          Sequence 5631, Ap
41
      73.5
              7.9
                          4
42
        73
              7.8
                     231
                          4
                              US-09-198-452A-419
                                                          Sequence 419, App
        73
              7.8
                     379
                          4
                              US-09-491-577-6
                                                          Sequence 6, Appli
43
                     700
                              US-09-543-681A-4969
                                                           Sequence 4969, Ap
44
        73
              7.8
                          4
              7.8
                      408
                              US-09-107-532A-6198
                                                           Sequence 6198, Ap
45
      72.5
```

ALIGNMENTS

```
RESULT 1
US-08-700-607-1
; Sequence 1, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
     APPLICANT: Bandman, Olga
;
     APPLICANT: Au-Young, Janice
;
    APPLICANT: Goli, Surya K.
     APPLICANT: Hillman, Jennifer L.
     TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
     NUMBER OF SEQUENCES:
     CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
       STREET: 3174 Porter Drive
;
       CITY: Palo Alto
       STATE: CA
       COUNTRY: U.S.
       ZIP: 94304
```

```
COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 1:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 199 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY:
      CLONE: Consensus
US-08-700-607-1
                       99.6%; Score 927; DB 2; Length 199;
  Query Match
  Best Local Similarity 100.0%; Pred. No. 5.3e-93;
  Matches 188; Conservative 0; Mismatches
                                                                    0;
                                            0; Indels
                                                         0; Gaps
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
            .12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qy
            72 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAKI 181
Qy
            132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
            11111111
         192 PGLKRKAE 199
Db
RESULT 2
US-08-700-607-7
; Sequence 7, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
```

```
TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
          NUMBER OF SEQUENCES: 9
          CORRESPONDENCE ADDRESS:
              ADDRESSEE: Incyte Pharmaceuticals, Inc.
              STREET: 3174 Porter Drive
              CITY: Palo Alto
              STATE: CA
              COUNTRY: U.S.
              ZIP: 94304
          COMPUTER READABLE FORM:
              MEDIUM TYPE: Diskette
              COMPUTER: IBM Compatible
              OPERATING SYSTEM: DOS
              SOFTWARE: FastSEQ Version 1.5
          CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/700,607
              FILING DATE: Filed Herewith
         ATTORNEY/AGENT INFORMATION:
              NAME: Billings, Lucy J.
              REGISTRATION NUMBER: 36,749
              REFERENCE/DOCKET NUMBER: PF-0114 US
          TELECOMMUNICATION INFORMATION:
              TELEPHONE: 415-855-0555
              TELEFAX: 415-845-4166
     INFORMATION FOR SEQ ID NO: 7:
          SEQUENCE CHARACTERISTICS:
              LENGTH: 208 amino acids
              TYPE: amino acid
              STRANDEDNESS: single
              TOPOLOGY: linear
          MOLECULE TYPE: peptide
          IMMEDIATE SOURCE:
              LIBRARY: GenBank
              CLONE: 307311
US-08-700-607-7
                                                      73.3%; Score 682; DB 2; Length 208;
    Query Match
                                                   68.4%; Pred. No. 2.6e-66;
    Best Local Similarity
   Matches 128; Conservative 31; Mismatches 28; Indels
                                                                                                                                         0; Gaps
                                                                                                                                                                   0;
                         3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qy
                              22 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 81
Db
                       63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qy
                              1:[1]11[1:]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]11[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1:1]1[1
                       82 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 141
Db
                     123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qy
                              142 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 201
Db
                     183 GLKRKAE 189
Qy
                              1 11 11
                     202 GAKRHAE 208
Db
```

```
RESULT 3
US-08-700-607-6
; Sequence 6, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
      CITY: Palo Alto
      STATE: CA
      COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 356 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307309
US-08-700-607-6
 Query Match
                        73.3%; Score 682; DB 2; Length 356;
 Best Local Similarity
                        68.4%; Pred. No. 5.5e-66;
 Matches 128; Conservative 31; Mismatches
                                              28; Indels
                                                                         0;
                                                             0;
                                                                 Gaps
Qy
           3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
             Db
         170 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 229
          63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
QУ
             1:11111:1111 1: :|:| :||::
                                           -:|| |:||||||||||
Db
         230 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 289
```

```
123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qу
             290 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 349
Db
         183 GLKRKAE 189
Qу
             1 11 11
         350 GAKRHAE 356
Dh
RESULT 4
US-08-700-607-5
; Sequence 5, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
      CITY: Palo Alto
      STATE: CA
      COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
   INFORMATION FOR SEQ ID NO: 5:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 776 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307307
US-08-700-607-5
                        73.3%; Score 682; DB 2; Length 776;
  Query Match
  Best Local Similarity 68.4%; Pred. No. 1.6e-65;
 Matches 128; Conservative 31; Mismatches 28; Indels
                                                             0; Gaps
```

```
Qγ
          3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
            Db
        590 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 649
         63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
            Db
        650 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 709
        123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qу
            710 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 769
Db
        183 GLKRKAE 189
Qу
            1 11 11
Db
        770 GAKRHAE 776
RESULT 5
US-08-700-607-8
; Sequence 8, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surva K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
      CITY: Palo Alto
      STATE: CA
     COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
     OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 8:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 267 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
     TOPOLOGY: linear
```

```
MOLECULE TYPE: peptide
     IMMEDIATE SOURCE:
       LIBRARY: GenBank
       CLONE: 281046
US-08-700-607-8
  Query Match
                       71.4%; Score 665; DB 2; Length 267;
  Best Local Similarity 67.2%; Pred. No. 2.6e-64;
  Matches 123; Conservative 33; Mismatches 27; Indels
                                                                       0;
           3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qy
             13 IDLLYWRDIKOTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 72
 Db
           63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
             Db
           73 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDLVDSLKFAVLM 132
          123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qy
             Db
          133 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINTVVAKIQAKIP 192
          183 GLK 185
Qу
             | :
Db
          193 GAR 195
RESULT 6
US-09-149-476-563
 ; Sequence 563, Application US/09149476
 ; Patent No. 6420526
; GENERAL INFORMATION:
 ; APPLICANT: Rosen et al.
   TITLE OF INVENTION: 186 Human Secreted proteins
   FILE REFERENCE: PZ002P1
   CURRENT APPLICATION NUMBER: US/09/149,476
   CURRENT FILING DATE: 1998-09-08
   EARLIER APPLICATION NUMBER: PCT/US98/04493
   EARLIER FILING DATE: 1998-03-06
   EARLIER APPLICATION NUMBER: 60/040,162
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/040,333
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/038,621
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/040,626
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/040,334
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/040,336
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/040,163
   EARLIER FILING DATE: 1997-03-07
   EARLIER APPLICATION NUMBER: 60/047,600
   EARLIER FILING DATE: 1997-05-23
   EARLIER APPLICATION NUMBER: 60/047,615
   EARLIER FILING DATE: 1997-05-23
```

```
; EARLIER APPLICATION NUMBER: 60/047,597
```

- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,502
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,633
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,583
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,617
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,618
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,503
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,592
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,581
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,584
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,500
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,587
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,492
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,598
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,613
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,582
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,596
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,612
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,632
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,601
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,580
- : EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,568
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,314
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,569
- EARLIER FILING DATE: 1997-04-11
- EARLIER APPLICATION NUMBER: 60/043,311
- EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,671
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,674
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,669
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,312

```
; EARLIER FILING DATE: 1997-04-11
```

- EARLIER APPLICATION NUMBER: 60/043,313
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,672
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,315
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/048,974
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/056,886
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,877
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,889
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,893
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,630
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,878
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,662
- ; EARLIER FILING DATE: 1997-08-22
- EARLIER APPLICATION NUMBER: 60/056,872
- ; EARLIER FILING DATE: 1997-08-22
- EARLIER APPLICATION NUMBER: 60/056,882
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,637
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,903
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,888
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,879
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,880
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,894
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,911
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,636
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,874
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,910
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,864
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,631
- ; EARLIER FILING DATE: 1997-08-22
- EARLIER APPLICATION NUMBER: 60/056,845
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,892
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,761
- ; EARLIER FILING DATE: 1997-08-22

```
EARLIER APPLICATION NUMBER: 60/047,595
```

- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,599
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,588
- : EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,585
- ; EARLIER FILING DATE: 1997-05-23
- : EARLIER APPLICATION NUMBER: 60/047,586
- : EARLIER FILING DATE: 1997-05-23
- EARLIER APPLICATION NUMBER: 60/047,590
- ; EARLIER FILING DATE: 1997-05-23
- EARLIER APPLICATION NUMBER: 60/047,594
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,589
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,593
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,614
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,578
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,576
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/047,501
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,670
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/056,632
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,664
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,876
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,881
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,909
- ; EARLIER FILING DATE: 1997-08-22
- EARLIER APPLICATION NUMBER: 60/056,875
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,862
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,887
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,908
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/048,964
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/057,650
- EARLIER FILING DATE: 1997-09-05
- ; EARLIER APPLICATION NUMBER: 60/056,884
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,669
- ; EARLIER FILING DATE: 1997-09-05
- ; EARLIER APPLICATION NUMBER: 60/049,610
- ; EARLIER FILING DATE: 1997-06-13
- ; EARLIER APPLICATION NUMBER: 60/061,060

```
EARLIER FILING DATE: 1997-10-02
                       58.2%; Score 541.5; DB 4; Length 168;
 Query Match
 Best Local Similarity 60.5%; Pred. No. 3.7e-51;
 Matches 101; Conservative 34; Mismatches 31; Indels
                                                        1; Gaps 1;
         24 LLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEE 83
Qу
            1 MLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQAVQKSEEGHPFKAYLDVDITLSSE 60
Db
         84 LVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALI 143
Qy
                61 AFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLKLAVFMWLMTYVGAVFNGITLLILAEL 120
Db
        144 SLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGL-KRKAE 189
Qу
             :||||::||:::||:|:|:||
Db
         121 LIFSVPIVYEKYKTQIDHYVGIARDQTKSIVEKIQAKLPGIAKKKAE 167
RESULT 7
US-08-700-607-3
; Sequence 3, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
      CITY: Palo Alto
      STATE: CA
      COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEO Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 3:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 241 amino acids
      TYPE: amino acid
```

STRANDEDNESS: single

```
TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: THP1NOB01
      CLONE: 31870
US-08-700-607-3
                       55.0%; Score 512; DB 2; Length 241;
 Query Match
 Best Local Similarity 52.4%; Pred. No. 1e-47;
         98; Conservative 35; Mismatches 34; Indels
                                                          20; Gaps
Qу
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
            47 AVHDLIXWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQA 106
Db
Qу
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
            Db
         107 VQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLKLAV 166
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             167 FMWLMTYVGAVFNGITLLILAELLIXSVPIVYXKY------KVPSK 206
Db
         181 IPGLKRK 187
Qу
             1 ::1
Db
        207 TPWNRQK 213
RESULT 8
US-09-149-476-411
; Sequence 411, Application US/09149476
; Patent No. 6420526
; GENERAL INFORMATION:
 APPLICANT: Rosen et al.
 TITLE OF INVENTION: 186 Human Secreted proteins
  FILE REFERENCE: PZ002P1
  CURRENT APPLICATION NUMBER: US/09/149,476
  CURRENT FILING DATE: 1998-09-08
  EARLIER APPLICATION NUMBER: PCT/US98/04493
  EARLIER FILING DATE: 1998-03-06
  EARLIER APPLICATION NUMBER: 60/040,162
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,333
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/038,621
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,626
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,334
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,336
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/040,163
  EARLIER FILING DATE: 1997-03-07
  EARLIER APPLICATION NUMBER: 60/047,600
  EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,615
```

```
; EARLIER FILING DATE: 1997-05-23
```

- EARLIER APPLICATION NUMBER: 60/047,597
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,502
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,633
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,583
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,617
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,618
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,503
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,592
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,581
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,584
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,500
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,587
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,492
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,598
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,613
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,582
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,596
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,612
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,632
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,601
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,580
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,568
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,314
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,569
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,311
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,671
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,674
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,669
- ; EARLIER FILING DATE: 1997-04-11

```
; EARLIER APPLICATION NUMBER: 60/043,312
```

- EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,313
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,672
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,315
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/048,974
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/056,886
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,877
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,889
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,893
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,630
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,878
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,662
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,872
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,882
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,637
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,903
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,888
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,879
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,880
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,894
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,911
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,636
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,874
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,910
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,864
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,631
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,845
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,892
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,761

```
; EARLIER FILING DATE: 1997-08-22
```

- EARLIER APPLICATION NUMBER: 60/047,595
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,599
- : EARLIER FILING DATE: 1997-05-23
- : EARLIER APPLICATION NUMBER: 60/047,588
- : EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,585
- : EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,586
- EARLIER FILING DATE: 1997-05-23
- : EARLIER APPLICATION NUMBER: 60/047,590
- EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,594
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,589
- EARLIER FILING DATE: 1997-05-23
- EARLIER APPLICATION NUMBER: 60/047,593
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,614
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,578
- EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,576
- ; EARLIER FILING DATE: 1997-04-11
- EARLIER APPLICATION NUMBER: 60/047,501
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,670
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/056,632
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,664
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,876
- ; EARLIER FILING DATE: 1997-08-22
- : EARLIER APPLICATION NUMBER: 60/056,881
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,909
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,875
- EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,862
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,887
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,908
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/048,964
- ; EARLIER FILING DATE: 1997-06-06
- EARLIER APPLICATION NUMBER: 60/057,650
- ; EARLIER FILING DATE: 1997-09-05
- EARLIER APPLICATION NUMBER: 60/056,884
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,669
- ; EARLIER FILING DATE: 1997-09-05
- ; EARLIER APPLICATION NUMBER: 60/049,610
- ; EARLIER FILING DATE: 1997-06-13

```
EARLIER APPLICATION NUMBER: 60/061,060
; EARLIER FILING DATE: 1997-10-02
 Query Match 30.6%; Score 285; DB 4; Length 92; Best Local Similarity 57.1%; Pred. No. 1.3e-23;
          52; Conservative 20; Mismatches 19; Indels
                                                              0; Gaps
                                                                         0;
 Matches
          90 NSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVP 149
Qу
             2 NAAMVHINRALKLIIRLFLVEDLVDSLKLAVFMWLMTYVGAVFNGITLLILAELLIFSVP 61
Db
         150 VIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             62 IVYEKYKTQIDHYVGIARDQTKSIVEKIPSK 92
Db
RESULT 9
US-08-905-223-411
; Sequence 411, Application US/08905223
; Patent No. 6222029
  GENERAL INFORMATION:
    APPLICANT: Edwards, Jean-Baptiste D.
    APPLICANT: Duelert, Aymeric
    APPLICANT: Lacroix, Bruno
    TITLE OF INVENTION: 5' ESTs FOR SECRETED PROTEINS
    NUMBER OF SEQUENCES: 503
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Knobbe, Martens, Olson & Bear
      STREET: 501 West Broadway
      CITY: San Diego
      STATE: California
      COUNTRY: USA
      ZIP: 92101-3505
     COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy Disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: Win95
      SOFTWARE: Word
     CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/905,223
      FILING DATE:
      CLASSIFICATION: 536
    ATTORNEY/AGENT INFORMATION:
      NAME: Israelsen, Ned A.
      REGISTRATION NUMBER: 29,655
      REFERENCE/DOCKET NUMBER:
     TELECOMMUNICATION INFORMATION:
      TELEPHONE: (619) 235-8550
       TELEFAX: (619) 235-0176
   INFORMATION FOR SEQ ID NO: 411:
     SEQUENCE CHARACTERISTICS:
     LENGTH: 80 amino acids
       TYPE: AMINO ACID
       TOPOLOGY: LINEAR
     MOLECULE TYPE: PROTEIN
     ORIGINAL SOURCE:
```

ORGANISM: Homo Sapiens

```
TISSUE TYPE: Brain
    FEATURE:
      NAME/KEY: sig peptide
      LOCATION: -78..-1
      IDENTIFICATION METHOD: Von Heijne matrix
      OTHER INFORMATION: score 6.3
      OTHER INFORMATION: seq TLIMLLSWQLSVS/SV
US-08-905-223-411
                        10.7%; Score 100; DB 3; Length 80;
 Query Match
 Best Local Similarity 57.1%; Pred. No. 0.0015;
 Matches 20; Conservative 8; Mismatches 5; Indels 2; Gaps
           1 SVVDLLYWRDIKKTGVVFGASLFLLLS--LTVFSI 33
Qу
             46 AVHDLIFWRDVKKTGFVFGTTLIMLLSWQLSVSSV 80
RESULT 10
US-08-487-596-8
; Sequence 8, Application US/08487596
; Patent No. 6440681
  GENERAL INFORMATION:
    APPLICANT: Elliot, Kathryn J.
    APPLICANT: Ellis, Steven B.
    APPLICANT: Harpold, Michael M.
    TITLE OF INVENTION: METHODS FOR IDENTIFYING AGONISTS AND
    TITLE OF INVENTION: ANTAGONISTS FOR HUMAN NEURONAL
    TITLE OF INVENTION: NICOTINIC ACETYLCHOLINE RECEPTORS
    NUMBER OF SEQUENCES: 18
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Brown, Martin, Haller & McClain
      STREET: 1660 Union Street
     CITY: San Diego
    STATE: CA
      COUNTRY: USA
      ZIP: 92101
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/487,596
      FILING DATE: 07-JUN-1995
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: WO US94/02447
      FILING DATE: 08-MAR-1994
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/149,503
      FILING DATE: 08-NOV-1993
     PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/028,031
      FILING DATE: 08-MAR-1993
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/938,154
```

```
FILING DATE: 30-NOV-1992
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/504,455
      FILING DATE: 03-APR-1990
    ATTORNEY/AGENT INFORMATION:
      NAME: Seidman, Stephanie L.
      REGISTRATION NUMBER: 33,779
      REFERENCE/DOCKET NUMBER: 6362-9951
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 619-238-0999
      TELEFAX: 619-238-0062
  INFORMATION FOR SEQ ID NO: 8:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 468 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-487-596-8
 Query Match
                        9.6%; Score 89; DB 4; Length 468;
 Best Local Similarity 20.9%; Pred. No. 0.28;
 Matches 40; Conservative 29; Mismatches 66; Indels 56; Gaps 5;
          24 LLLSLTVFSIV-----SVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 70
Qу
             :|:|||| :|
                                   : |: :: ||:| : |
                                                             : |
Db
         288 VLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNA 347
                                     ----ESEVAISEELVQKYSNSALGHVNCTIKEL 103
Qу
              1 1
                                          1:1
                                               : : :|| :
Db
         348 MAPLVRKIFLHTLPKLLCMRSHVDRYFTQKEETESGSGPKSSRNTLEAALNSIRYITRHI 407
         104 RRLFLVDDLVDSLKF-----AVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQA 157
Qу
              : | ::|: || ::| |:| |: :|| |||:|:
Db
         408 MKENDVREVVEDWKFIAQVLDRMFLWTFLFVS-----IVGSLGLF-VPVIYKWANI 457
         158 QIDHYLGLANK 168
QУ
             1 :: 1 111
         458 LIPVHIGNANK 468
Db
RESULT 11
US-08-660-451A-8
; Sequence 8, Application US/08660451A
; Patent No. 6524789
  GENERAL INFORMATION:
    APPLICANT: Elliott, Kathryn J.
    APPLICANT: Harpold, Michael M.
    TITLE OF INVENTION: HUMAN NEURONAL NICOTINIC ACETYLCHOLINE
    TITLE OF INVENTION: RECEPTOR COMPOSITIONS AND METHODS EMPLOYING SAME
    NUMBER OF SEQUENCES: 20
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Brown, Martin, Haller & McClain
      STREET: 1660 Union Street
      CITY: San Diego
      STATE: CA
      COUNTRY: USA
      ZIP: 92101-2926
```

```
COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/660,451A
      FILING DATE: June 7, 1996
     CLASSIFICATION: 435
   PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 08/484,722
      FILING DATE: 06/07/95
   ATTORNEY/AGENT INFORMATION:
     NAME: Seidman, Stephanie L
      REGISTRATION NUMBER: 33,779
      REFERENCE/DOCKET NUMBER: 6362-9370B
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 619-238-0999
      TELEFAX: 619-238-0062
      TELEX:
  INFORMATION FOR SEQ ID NO: 8:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 468 amino acids
     TYPE: amino acid
     STRANDEDNESS: single
     TOPOLOGY: linear
   MOLECULE TYPE: protein
    HYPOTHETICAL: NO
  ANTI-SENSE: NO
    FRAGMENT TYPE: N-terminal
    ORIGINAL SOURCE:
US-08-660-451A-8
 Query Match
                      9.6%; Score 89; DB 4; Length 468;
 Best Local Similarity 20.9%; Pred. No. 0.28;
 Matches 40; Conservative 29; Mismatches 66; Indels 56; Gaps
         24 LLLSLTVFSIV-----SVTAYIALALLSVTISFRIYKGVIOAIOKSDEGHPF 70
Qv
            :|:|||||:|
Db
        288 VLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNA 347
         71 RAYL-----ESEVAISEELVOKYSNSALGHVNCTIKEL 103
Qу
            |:| :: :|| : ::
        348 MAPLVRKIFLHTLPKLLCMRSHVDRYFTQKEETESGSGPKSSRNTLEAALNSIRYITRHI 407
Db
Qу
        104 RRLFLVDDLVDSLKF-----AVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQA 157
            : | ::|: || ::| :| ||:|
Dh
        408 MKENDVREVVEDWKFIAQVLDRMFLWTFLFVS-----IVGSLGLF-VPVIYKWANI 457
       158 QIDHYLGLANK 168
Qу
            -----
Db
        458 LIPVHIGNANK 468
RESULT 12
US-09-462-136-2
; Sequence 2, Application US/09462136
```

```
; Patent No. 6426198
; GENERAL INFORMATION:
  APPLICANT: Carstea, et al.
  TITLE OF INVENTION: Genes for Niemann-Pick Type C Disease
  FILE REFERENCE: 4239-53894
  CURRENT APPLICATION NUMBER: US/09/462,136
 CURRENT FILING DATE: 2000-06-01
  PRIOR APPLICATION NUMBER: PCT/US98/13862
  PRIOR FILING DATE: 1998-07-02
  PRIOR APPLICATION NUMBER: US 60/051,682
  PRIOR FILING DATE: 1997-07-03
 NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
   LENGTH: 1278
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-462-136-2
 Query Match 9.5%; Score 88.5; DB 4; Length 1278; Best Local Similarity 25.7%; Pred. No. 1.3;
         39; Conservative 25; Mismatches 51; Indels 37; Gaps
                                                                       7;
          46 SVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRR 105
Qу
             598 NLTISFTAERSIEDELNRESDSDVF-----TVVISYAIMFLYISLALGH----IKSCRR 647
         106 LFLVDD-----LVDSLKFAVLMWVFTYVGALFNGLTLLILALI-----SLF 146
Qу
             Db
         648 L-LVDSKVSLGIAGILIVLSSVACSLGVFSYIGL---PLTLIVIEVIPFLVLAVGVDNIF 703
         147 SVPVIYERHQ----AQIDHYLGLANKNVKDAM 174
Qу
              : |:| : :| ||
                                   1 :1
         704 ILVQAYQRDERLQGETLDQQLGRVLGEVAPSM 735
RESULT 13
US-09-134-000C-5477
; Sequence 5477, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
  TITLE OF INVENTION: ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS
  FILE REFERENCE: 032796-032
  CURRENT APPLICATION NUMBER: US/09/134,000C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/055,778
; PRIOR FILING DATE: 1997-08-15
; NUMBER OF SEQ ID NOS: 6812
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5477
  LENGTH: 592
   TYPE: PRT
   ORGANISM: Enterococcus faecalis
US-09-134-000C-5477
```

```
9.4%; Score 87.5; DB 4; Length 592;
 Query Match
 Best Local Similarity 20.8%; Pred. No. 0.56;
         48; Conservative 41; Mismatches 65; Indels 77; Gaps
 Matches
          7 YWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFR-----IYK 55
Qу
            45 FWKTVKR-----LFRYMSKRMLSIIAV---LVLAIAAVVFQIQTPKVLGQATTEIFK 93
Db
         56 GVIQAIQKSDEGHPFRA----A 79
Qу
            11:: : : : :
                                         Db
         94 GVMKGAAEMKQGLKITSFPIDFDKIGQILLIVIAMYLISAVFNFLQQVIMTRVSQRTVYE 153
         80 ISEELVQKYSNSALG----HVNCTIKELRRLFLVDDLVDSLK---FAVLMWVFTYVGALF 132
Qу
            ::|| | : : : | | | | : :|:: :|: :: : :|:|| | ::
Db
        154 LRQELEAKMNKVPISYYDIHSNGDIMS-RAINDMDNIASTLQQNLTQLITSIVTFVGVLW 212
        133 NGLTL-LILALISLFSVPVIY-----ERHOAOIDHYLGLANKNVKD 172
Qу
              Db
        213 MMLTISWQLTLIALATVPLSLIVVMVVAPRSQKHFAAQQKSLGLLNNQVEE 263
RESULT 14
US-09-134-001C-5005
; Sequence 5005, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
  FILE REFERENCE: GTC-007
  CURRENT APPLICATION NUMBER: US/09/134,001C
  CURRENT FILING DATE: 1998-08-13
  PRIOR APPLICATION NUMBER: US 60/064,964
  PRIOR FILING DATE: 1997-11-08
  PRIOR APPLICATION NUMBER: US 60/055,779
  PRIOR FILING DATE: 1997-08-14
 NUMBER OF SEQ ID NOS: 5674
 SEQ ID NO 5005
   LENGTH: 1051
   TYPE: PRT
   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-5005
 Query Match 9.4%; Score 87.5; DB 4; Length 1051; Best Local Similarity 22.9%; Pred. No. 1.2;
 Matches 44; Conservative 35; Mismatches
                                         68; Indels
                                                                  8;
                                                           Gaps
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSV----TAYIALALLSVTISFRIYKG 56
Qу
            Db
        380 IVILLFLRNIRTTAI-----SIVSIPMSILIALIALKLSNVSLNILTLGA 424
         57 VIQAIQKSDEGHPFRAYLESEVAISEELVQKYS--NSALGHVNCTIKELRRLF---LVDD 111
Qу
            425 LTVAIGR-----VIDDSIVVVENIFRRLSDPNEKLKGENLIISATREVFKPIMSST 475
Db
        112 LVDSLKFAVLMWVFTYVGALFN----GLTLLILA--LISLFSVPVIYERHQAQIDHYLGL 165
Qу
```

```
476 LVTIVVFLPLVFVSGSVGEMFRPFALAITFSLLASLLVSITLVPSLGATFFKN-----GV 530
Db
         166 ANKNVKDAMAKI 177
Qy
               1: 1: : :
         531 KNREQKEGLGTV 542
Db
RESULT 15
US-08-956-171E-5246
; Sequence 5246, Application US/08956171E
; Patent No. 6593114
    GENERAL INFORMATION:
        APPLICANT: Charles Kunsch
                   Gil H. Choi
                   Patrick S. Dillon
                   Craig A. Rosen
                   Steven C. Barash
                   Michael R. Fannon
        TITLE OF INVENTION: Staphylococcus aureus Polynucleotides and Sequences
        NUMBER OF SEQUENCES: 5256
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: Human Genome Sciences, Inc.
             STREET: 9410 Key West Avenue
             CITY: Rockville
             STATE: Maryland
             COUNTRY: USA
             ZIP: 20850
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Diskette, 3.50 inch, 1.4Mb storage
             COMPUTER: HP Vectra 486/33
             OPERATING SYSTEM: MSDOS version 6.2
             SOFTWARE: ASCII Text
         CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/08/956,171E
             FILING DATE: 20-Oct-1997
             CLASSIFICATION: <Unknown>
         PRIOR APPLICATION DATA:
             APPLICATION NUMBER: 60/009,861
             FILING DATE: January 5, 1996
             APPLICATION NUMBER: 08/781,986
             FILING DATE: January 3, 1997
        ATTORNEY/AGENT INFORMATION:
             NAME: Mark J. Hyman
             REGISTRATION NUMBER: 46,789
             REFERENCE/DOCKET NUMBER: PB248P1
         TELECOMMUNICATION INFORMATION:
             TELEPHONE: (240) 314-1224
             TELEFAX: (301) 309-8439
    INFORMATION FOR SEQ ID NO: 5246:
         SEQUENCE CHARACTERISTICS:
             LENGTH: 414 amino acids
              TYPE: amino acid
              STRANDEDNESS: single
             TOPOLOGY: linear
         MOLECULE TYPE: protein
         SEQUENCE DESCRIPTION: SEQ ID NO: 5246:
```

US-08-956-171E-5246

Query Ma	atch	9.1%; Score 85; DB 4; Length 414;	
Best Lo	cal S	imilarity 21.8%; Pred. No. 0.63;	
Matches	42	; Conservative 36; Mismatches 75; Indels 40; Gaps	7;
QУ	2	VVDLLYWRDIKKTGV-VFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60	
		: : : : ::: :::	
Db	3	IVILLFLRNIRTTAISIISIPLSLLMALIALKLSDVSLNILTLGALTVA 51	,
0	<i>C</i> 1	IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDS 11	5
QУ		: :: : : : :: :	_
Db		IGRVIDDSIVVVENIYRRLTDSEEQLKGENLIISATTEVFKPIMSSTLVTI 10	2
Qу	116	LKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDH 16	1
		:	_
Db	103	IVFLPLVFVSGSVGEMFRPFALAIAFSLLASLLVSITLVPALAATLFKKGVKRRNKQHQE 16	2
_	1.60	W CT ANYON WOM 174	
Qу	162	YLGLANKNVKDAM 174	
Db	163	:: :: :::GLGVVSTTYKKVL 175	
טט	102	GEGV VSTITIKIVE 173	

Search completed: September 29, 2004, 18:21:05 Job time: 5.69196 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:05:43; Search time 4.62587 Seconds

(without alignments)

3930.111 Million cell updates/sec

Title: US-09-830-972-29 COPY 990 1178

Perfect score: 931

Sequence: 1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIQAKIPGLKRKAE 189

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : PIR_78:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

			8				
Re	sult		Query				
	No.	Score	Match	Length	DB	ID	Description
	1	682	73.3	. 208	2	I60904	neuroendocrine-spe
	2	682	73.3	776	2	A46583	neuroendocrine-spe
	3	665	71.4	267	2	A60021	tropomyosin-relate
	4	- 335	36.0	2484	2	T26216	hypothetical prote
	5	335	36.0	2607	- 2	T26215	hypothetical prote
	6	334	35.9	222	2	T26213	hypothetical prote
	7	191	20.5	255	2	E84899.	hypothetical prote
	8	182	19.5	271	2	T13013	hypothetical prote
	9	163	17.5	275	2	T05595	hypothetical prote
	10	147	15.8	393	2	s67763	probable membrane
	11	144.5	15.5	242	2	B85016	hypothetical prote
	12	131	14.1	183	2	A84527	hypothetical prote
	13	127.5	13.7	295	2	S59439	probable membrane

		10.0		_	m011F0
14	124	13.3	206	2	T01153
15	109.5	11.8	264	2	T47948
16	104.5	11.2	203	2	T47571
17	95	10.2	288	2	B90043
18	94.5	10.2	458	2	A72258
19	93	10.0	160	2	C84422
20	92.5	9.9	527	2	A84645
21	88.5	9.5	405	2	н71692
22	88	9.5	224	2	D71915
23	87.5	9.4	296	2	S46018
24	85.5	9.2	442	2	C75057
25	85.5	9.2	823	2	н83724
26	85.5	9.2	1065	2	E69795
27	85	9.1	224	1	A64599
28	85	9.1	459	2	G86264
29	85	9.1	468	2	A38223
30	85	9.1	1055	2	Н90023
31	84.5	9.1	151	2	G96705
32	84.5	9.1	457	2	н85095
33	84.5	9.1	464	2	C70414
34	84.5	9.1	677	2	F95232
35	84.5	9.1	680	2	Н98096
36	84	9.0	299	2	B69155
37	82.5	8.9	570	2	S52765
38	82.5	8.9	955	2	T33040
39	82	8.8	589	2	F64201
40	81.5	8.8	324	2	AE1700
41	81.5	8.8	369	2	н90587
42	81.5	8.8	598	2	T14886
43	81.5	8.8	822	2	Т41622
44	81.5	8.8	937	2	T41400
45	81	8.7	537	2	G82873

probable seed matu hypothetical prote hypothetical prote conserved hypothet hypothetical prote hypothetical prote probable cytochrom hypothetical prote hydrogenase, cytoc probable membrane hypothetical prote hypothetical prote acriflavin resista hydrogenase (EC 1. F3F19 hypothetical nicotinic acetylch hypothetical prote unknown protein, 7 hypothetical prote NADH2 dehydrogenas immunity protein, conserved hypothet hypothetical prote secD protein - Str hypothetical prote transport ATP-bind phospho-N-acetylmu hypothetical prote leukotoxin express probable ABC trans probable peroxisom conserved hypothet

ALIGNMENTS

RESULT 1

I60904

neuroendocrine-specific protein C - human

C; Species: Homo sapiens (man)

C;Date: 24-May-1996 #sequence revision 24-May-1996 #text change 05-Nov-1999

C; Accession: 160904

R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers, F.C.; Van de Ven, W.J.

J. Biol. Chem. 268, 13439-13447, 1993

A; Title: Cloning and expression of alternative transcripts of a novel

neuroendocrine-specific gene and identification of its 135-kDa translational product.

A; Reference number: A46583; MUID: 93293865; PMID: 7685762

A; Accession: I60904

A; Status: preliminary; translated from GB/EMBL/DDBJ

A; Molecule type: mRNA A; Residues: 1-208 < RES>

A; Cross-references: GB:L10335; NID:g307310; PIDN:AAA59952.1; PID:g307311

C; Genetics:

A; Gene: GDB: RTN1; NSP

A; Cross-references: GDB:203968; OMIM:600865 A; Map position: 14q21-14q22 Query Match 73.3%; Score 682; DB 2; Length 208; Best Local Similarity 68.4%; Pred. No. 3.3e-54; 31; Mismatches Matches 128; Conservative 28; Indels 0; 3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62 Qу Db 22 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 81 63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122 Qу |:||||:||:||||||::|:|:|:|:|::|: 82 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 141 Db 123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182 Qу 142 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 201 Db 183 GLKRKAE 189 Qy 202 GAKRHAE 208 Db RESULT 2 A46583 neuroendocrine-specific protein, splice form A - human N; Contains: neuroendocrine-specific protein, splice form B C; Species: Homo sapiens (man) C; Date: 24-May-1996 #sequence revision 24-May-1996 #text change 05-Nov-1999 C; Accession: A46583; I60903 R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers, F.C.; Van de Ven, W.J. J. Biol. Chem. 268, 13439-13447, 1993 A; Title: Cloning and expression of alternative transcripts of a novel neuroendocrine-specific gene and identification of its 135-kDa translational product. A; Reference number: A46583; MUID: 93293865; PMID: 7685762 A; Accession: A46583 A; Status: preliminary; translated from GB/EMBL/DDBJ A; Molecule type: mRNA A; Residues: 1-776 < ROE1> A; Cross-references: GB:L10333; NID:g307306; PIDN:AAA59950.1; PID:g307307 A; Accession: 160903 A; Status: preliminary; translated from GB/EMBL/DDBJ A; Molecule type: mRNA A; Residues: 421-776 < ROE2> A; Cross-references: GB:L10334; NID:g307308; PIDN:AAA59951.1; PID:g307309 C; Genetics: A; Gene: GDB: RTN1; NSP A; Cross-references: GDB:203968; OMIM:600865 A; Map position: 14q21-14q22

73.3%; Score 682; DB 2; Length 776;

28; Indels

0;

Gaps

0:

68.4%; Pred. No. 1.5e-53;

Query Match

Best Local Similarity

Matches 128; Conservative 31; Mismatches

```
3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qy
            590 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 649
Db
         63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
            650 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 709
Db
        123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIOAKIP 182
Qv
            ::
Db
        710 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 769
        183 GLKRKAE 189
Qy
            I = I + I + I + I
        770 GAKRHAE 776
Db
RESULT 3
A60021
tropomyosin-related protein, neuronal - rat
C; Species: Rattus norvegicus (Norway rat)
C;Date: 03-Mar-1993 #sequence revision 03-Mar-1993 #text change 05-Nov-1999
C; Accession: A60021
R; Wieczorek, D.F.; Hughes, S.R.
Brain Res. Mol. Brain Res. 10, 33-41, 1991
A; Title: Developmentally regulated cDNA expressed exclusively in neural tissue.
A; Reference number: A60021; MUID: 91278684; PMID: 1647480
A; Accession: A60021
A; Molecule type: mRNA
A; Residues: 1-267 <WIE>
A;Cross-references: EMBL:X52817; NID:g456549; PIDN:CAA37001.1; PID:g456550
C; Comment: This neuronal-specific mRNA was identified by hybridization to an
alpha-tropomyosin probe but does not show homology in amino acid sequence.
 Query Match
                      71.4%; Score 665; DB 2; Length 267;
 Best Local Similarity
                      67.2%; Pred. No. 1.5e-52;
 Matches 123; Conservative 33; Mismatches
                                          27; Indels
                                                        0;
                                                           Gaps
          3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOAIO 62
Qу
            13 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 72
Db
         63 KSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qy
            Db
         73 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDLVDSLKFAVLM 132
        123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qy
            ::
Db
        133 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINTVVAKIQAKIP 192
Qy
        183 GLK 185
            | :
Db
        193 GAR 195
```

RESULT 4 T26216

```
hypothetical protein W06A7.3c - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26216
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26216
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2484 <WIL>
A; Cross-references: EMBL: Z78066; PIDN: CAB51467.1; GSPDB: GN00023; CESP: W06A7.3c
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3c
A; Map position: 5
A; Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2339/2; 2463/2
                         36.0%; Score 335; DB 2; Length 2484;
  Best Local Similarity 33.7%; Pred. No. 1.1e-21;
           62; Conservative 46; Mismatches
                                                76; Indels
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             11::1
        2289 VLDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQI 2348
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
                       :|::| |: ::|:|| ::
        2349 KKTDSEHPFSEILAQDLTLPQEKVHAQADVFVEHATCIANKLKKLVFVESPLESIKFGLV 2408
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
             Db
        2409 LWSLTYIASWFSGFTLAILGLLGVFSVPKVYESNQEAIDPHLATISGHLKNVQNIIDEKL 2468
         182 PGLK 185
Qу
             1 1:
Db
        2469 PFLR 2472
RESULT 5
T26215
hypothetical protein W06A7.3a - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26215
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26215
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2607 <WIL>
A; Cross-references: EMBL: Z78066; PIDN: CAB01522.2; GSPDB: GN00023; CESP: W06A7.3a
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3a
A; Map position: 5
```

```
2586/2
                       36.0%; Score 335; DB 2; Length 2607;
 Query Match
 Best Local Similarity 33.7%; Pred. No. 1.2e-21;
          62; Conservative 46; Mismatches 76; Indels
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qv
            2412 VLDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQI 2471
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
            :|:| || | | | | | ::::| | | :::| | | :|:|| |:::|:|| |:::|:|| |:::|
        2472 KKTDSEHPFSEILAQDLTLPQEKVHAQADVFVEHATCIANKLKKLVFVESPLESIKFGLV 2531
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
            Dh
        2532 LWSLTYIASWFSGFTLAILGLLGVFSVPKVYESNQEAIDPHLATISGHLKNVQNIIDEKL 2591
         182 PGLK 185
Qу
            1.1:
        2592 PFLR 2595
Dh
RESULT 6
T26213
hypothetical protein W06A7.3b - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26213
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A:Accession: T26213
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-222 <WIL>
A; Cross-references: EMBL: Z78066; PIDN: CAB01523.1; GSPDB: GN00023; CESP: W06A7.3b
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3b
A; Map position: 5
A; Introns: 27/1; 77/2; 201/2
                       35.9%; Score 334; DB 2; Length 222;
 Best Local Similarity
                       33.2%; Pred. No. 8.6e-23;
 Matches
         61; Conservative 47; Mismatches 76; Indels
                                                           0; Gaps
                                                                      0;
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             27 ILDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQI 86
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
             87 KKTDSEHPFSEILAQDLTLPQEKVHAQADVFVEHATCIANKLKKLVFVESPLESIKFGLV 146
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qv
```

A;Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2412/1; 2462/2;

```
147 LWSLTYIASWFSGFTLAILGLLGVFSVPKVYESNOEAIDPHLATISGHLKNVQNIIDEKL 206
Db
         182 PGLK 185
Qу
             1 1:
Dh
         207 PFLR 210
RESULT 7
E84899
hypothetical protein At2q46170 [imported] - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 02-Feb-2001 #sequence revision 02-Feb-2001 #text change 02-Feb-2001
C; Accession: E84899
R; Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.;
Fujii, C.Y.; Mason, T.M.; Bowman, C.L.; Barnstead, M.E.; Feldblyum, T.V.; Buell,
C.R.; Ketchum, K.A.; Lee, J.J.; Ronning, C.M.; Koo, H.; Moffat, K.S.; Cronin,
L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L.J.; Gill, J.E.; Adams,
M.D.; Carrera, A.J.; Creasy, T.H.; Goodman, H.M.; Somerville, C.R.; Copenhaver,
G.P.; Preuss, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser,
C.M.; Venter, J.C.
Nature 402, 761-768, 1999
A; Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis
A; Reference number: A84420; MUID: 20083487; PMID: 10617197
A; Accession: E84899
A; Status: preliminary
A; Molecule type: DNA
A:Residues: 1-255 <STO>
A; Cross-references: GB: AE002093; NID: g3702332; PIDN: AAC62889.1; GSPDB: GN00139
C; Genetics:
A; Gene: At2g46170
A; Map position: 2
  Query Match
                         20.5%; Score 191; DB 2; Length 255;
  Best Local Similarity 27.9%; Pred. No. 8e-10;
          55; Conservative 40; Mismatches
                                                 78; Indels
                                                               24; Gaps
                                                                            6;
            4 DLLYWRDIKKTGVVFG--ASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
              1: ||| | :| | | :::: | | :::!: :|:: |
           70 DVFLWRDKKLSGAVLGVATAIWVLFELVEYHLLSLLCHISILALG---GLFLWSNAHTLI 126
Db
           62 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
                            1::11
                                        ::1
                                               : |
                                                      11:11
               1:
          127 NKTSPQIP-----EIHVPEEAFLVVASSLRNELNQAFVILRSIALGRDLKKFLMVVVG 179
Db
          122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAM----- 174
Qy-
              :1: : || || || || || : : | : || :|| ::| ::|
                                                        || | :|:
          180 LWIISVVGNWFNFLTLVYICFVILHTVPMLYEKHEDKVD---PLAEKAMKELQKQYVVFD 236
Db
          175 AKIQAKIP--GLKRKAE 189
Qу
               1: :|||
                        11 11:
Db
          237 EKVLSKIPIASLKAKAK 253
```

RESULT 8 T13013

```
hypothetical protein F8L21.10 - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 13-Aug-1999 #sequence revision 13-Aug-1999 #text change 22-Oct-1999
C; Accession: T13013
R; Bevan, M.; Peters, S.A.; van Staveren, M.; Dirkse, W.; Stiekema, W.; Bancroft,
I.; Mewes, H.W.; Mayer, K.F.X.; Lemcke, K.; Schueller, C.
submitted to the Protein Sequence Database, July 1999
A; Reference number: Z17587
A; Accession: T13013
A; Molecule type: DNA
A; Residues: 1-271 <BEV>
A;Cross-references: EMBL:AL096882; GSPDB:GN00062; ATSP:F8L21.10
A; Experimental source: cultivar Columbia; BAC clone F8L21
C; Genetics:
A; Gene: ATSP: F8L21.10
A; Map position: 4
A; Introns: 85/1; 145/2; 192/3; 216/1
                          19.5%; Score 182; DB 2; Length 271;
  Query Match
  Best Local Similarity 26.1%; Pred. No. 5.6e-09;
  Matches
            47; Conservative 42; Mismatches 79; Indels
                                                                12; Gaps
            4 DLLYWRDIKKTGVVFGAS--LFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
              1: |:| | :| || : | || || : ::: |:|
Db
           87 DIFMWKDKKMSGGVFGGATVAWVLFELMEYHLLTLLCHVMIVALAVLF---LWSNATMFI 143
           62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
                             11 1 11 : : ::
                                              :| | || :
                                                               1:
Db
          144 HKSPPKIP----EVHIPEEPLLQLASGLRIEINRGISSLREIASGRDIKKFLSAIAG 196
          122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
              :|| : :| :: ||| :||: ||:||: |:::: ::| | | | :|
          197 LWVLSILGGCYSFLTLAYIALVLLFTVPLFYDKYEDKVDSYGEKAMAELKKQYAVLDAKV 256
Db
RESULT 9
T05595
hypothetical protein F9D16.100 - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 23-Apr-1999 #sequence revision 23-Apr-1999 #text change 23-Jul-1999
C; Accession: T05595
R; Bevan, M.; Wedler, H.; Wedler, E.; Wambutt, R.; Hoheisel, J.; Mewes, H.W.;
Mayer, K.F.X.; Schueller, C.
submitted to the Protein Sequence Database, February 1999
A; Reference number: Z15419
A; Accession: T05595
A; Molecule type: DNA
A; Residues: 1-275 <BEV>
A; Cross-references: EMBL:AL035394
A; Experimental source: cultivar Columbia; BAC clone F9D16
C; Genetics:
A; Map position: 4
A; Introns: 89/1; 149/2; 196/3; 220/1
A; Note: F9D16.100
                                  Score 163; DB 2; Length 275;
  Query Match
                          17.5%;
  Best Local Similarity
                          26.0%; Pred. No. 2.9e-07;
```

```
50; Conservative
                               42; Mismatches
                                                     Indels
                                                              18; Gaps
 Matches
           4 DLLYWRDIKKTGVVFG--ASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             |: |::|:||| : |::||
          91 DIFMWKNKKMSGGVLGGATAAWVVFELMEYHLLTLLCHVMIVVLAVLF---LWSNATMFI 147
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
                                                     || :
                            11 1 11 : : ::
                                              : |
         148 NKSPPKIP----EVHIPEEPILQLASGLRIEINRGFSSLREIASGRDLKKFLIAIAG 200
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMA----KI 177
Qу
             :|| : :| || || :||: ||:||: |:::: ::|
                                                       : |
         201 LWVLSILGGCFNFLTLAYIALVLLFTVPLAYDKYEDKVDPLGEKAMIELKKQYAVLDEKV 260
Db
         178 QAKIP--GLKRK 187
Qу
              :111
                    -11
         261 LSKIPLGPLKNK 272
Db
RESULT 10
s67763
probable membrane protein YDL204w - yeast (Saccharomyces cerevisiae)
N; Alternate names: hypothetical protein D1062
C; Species: Saccharomyces cerevisiae
C;Date: 12-Jul-1996 #sequence revision 12-Jul-1996 #text change 19-Apr-2002
C; Accession: S67763
R; Schmidt, E.R.; Bahr, A.; Kraemer, C.; Hankeln, T.; Moeller-Rieker, S.
submitted to the Protein Sequence Database, July 1996
A; Reference number: S67756
A; Accession: S67763
A; Molecule type: DNA
A; Residues: 1-393 <SCH>
A; Cross-references: EMBL: Z74252; NID: g1431337; PID: e253109; PID: g1431338;
GSPDB:GN00004; MIPS:YDL204w
A; Experimental source: strain S288C
C; Genetics:
A; Gene: MIPS: YDL204w
A; Cross-references: SGD: S0002363
A; Map position: 4L
C; Keywords: transmembrane protein
F;50-66/Domain: transmembrane #status predicted <TM1>
F;150-166/Domain: transmembrane #status predicted <TM2>
                         15.8%; Score 147; DB 2; Length 393;
  Query Match
                         27.0%; Pred. No. 1.2e-05;
  Best Local Similarity
                             34; Mismatches
                                                              42;
                                                                   Gaps
  Matches
           47; Conservative
                                                51; Indels
           5 LLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKS 64
Qу
              1:11: 1:1 1:1 11 1
                                       :::||
                                              | :| :
          33 LIYWTNPSKSGASFAATLVSLLILRNVNVISVLLKIGYMVLFTS----- 76
Db
           65 DEGHPFRAYLESEVAISEELVQKY----SNSALG----HVNCTIKELRRLFLVDDLVDSL 116
Qу
                      | ::| ::|:: | :| |:: :||||
           77 ----FAVELSTKVLFDKGVVSRFGMQESPDLVGVLKPHID---RELDRLPALEDRIRKL 128
Db
          117 KFA-----VLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQID 160
Qу
                          ] :: : |:|: |:||: | |::||:||:||:||
               11
```

```
RESULT 11
B85016
hypothetical protein AT4g01230 [imported] - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 16-Feb-2001 #sequence revision 16-Feb-2001 #text change 16-Feb-2001
C; Accession: B85016
R; anonymous, The European Union Arabidopsis Genome Sequencing Consortium, The
Cold Spring Harbor, Washington University in St Louis and PE Biosystems
Arabidopsis Sequencing Consortium.
Nature 402, 769-777, 1999
A; Title: Sequence and analysis of chromosome 4 of the plant Arabidopsis
thaliana.
A; Reference number: A85001; MUID: 20083488; PMID: 10617198
A; Accession: B85016
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-242 <STO>
A;Cross-references: GB:NC 001268; NID:q7267620; PIDN:CAB80932.1; GSPDB:GN00140
C; Genetics:
A; Gene: AT4q01230
A; Map position: 4
                          15.5%; Score 144.5; DB 2;
                                                      Length 242;
  Query Match
  Best Local Similarity
                          24.7%; Pred. No. 1.2e-05;
                                                       Indels
                                                                             6;
           47; Conservative 47; Mismatches
                                                  67;
                                                                29;
                                                                     Gaps
            4 DLLYWRDIKKTGVVFGASLFLLLSLTVFSIV-----SVTAYIALALLSVTISFRIYKG 56
Qу
                               | || ::|| ::
              1:1 111 1 1
                                                     : | :
                                                           ::|::||::
           70 DVLLWRDKKVT-----LGLLSAVTVIWLLFGFGGRRLLTSLCRGSILFLLLSF-LWS- 120
Db
           57 VIOAIOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSL 116
Qу
                 1: 11 1
                                  :: | |: : : :::
                                                     : | |
                                                            H: \Gamma
                                                                   |:::
          121 --NALNKSPEN-----MMDIYIPEKPLLQAASAMTFELNCAFATLRSIALERDIKNFV 171
Db
Qу
          117 KFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLA----NKNVKD 172
                 ::|:::| |: |:|| : ::||::||:::||
                                                               - 1
          172 MAVIGLWLVSVIGNWFSFLSLLYICFVLIHTVPMLYEKYEDEIDPIAEKAVIEMKKHYQV 231
Db
Qу
          173 AMAKIQAKIP 182
                11:11
          232 FEAKFLSKIP 241
Db
RESULT 12
A84527
hypothetical protein At2g15280 [imported] - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C; Date: 02-Feb-2001 #sequence revision 02-Feb-2001 #text change 02-Feb-2001
C; Accession: A84527
R; Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.;
Fujii, C.Y.; Mason, T.M.; Bowman, C.L.; Barnstead, M.E.; Feldblyum, T.V.; Buell,
C.R.; Ketchum, K.A.; Lee, J.J.; Ronning, C.M.; Koo, H.; Moffat, K.S.; Cronin,
L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L.J.; Gill, J.E.; Adams,
```

M.D.; Carrera, A.J.; Creasy, T.H.; Goodman, H.M.; Somerville, C.R.; Copenhaver,

```
G.P.; Preuss, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser,
C.M.; Venter, J.C.
Nature 402, 761-768, 1999
A; Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis
thaliana.
A; Reference number: A84420; MUID: 20083487; PMID: 10617197
A; Accession: A84527
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-183 <STO>
A;Cross-references: GB:AE002093; NID:q4662633; PIDN:AAD26905.1; GSPDB:GN00139
C:Genetics:
A; Gene: At2g15280
A; Map position: 2
 Query Match
                         14.1%; Score 131; DB 2; Length 183;
 Best Local Similarity 24.0%; Pred. No. 0.00014;
                             38; Mismatches
                                              80; Indels
                                                                  Gaps
 Matches
           43; Conservative
                                                              18;
           8 WRDIKKTGVVFGAS----LFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qу
                              1:::: :: |::
           2 WKNRRGGFLLLGSTTLLWFLFEKCGYSFFPFV-----VNTQLLSVVILFLWAKSAI---- 52
Db
          63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
                            |:|| | ::: :| : | ::: :
                     11
          53 LFNRPMPQLPNLE----ITEEFVFMVADAIRVWINTVLAVAREIYVGRNAKQLFRVSVVL 108
Db
         123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
                     11 ::
         109 WTVSFVGNFLNFLTILYLGVVLSLLIPFLYERYQDLIDEKLSLTHRVIQTQYRKIDERL 167
Db
RESULT 13
S59439
probable membrane protein YDR233c - yeast (Saccharomyces cerevisiae)
N; Alternate names: hypothetical protein YD9934.17c
C; Species: Saccharomyces cerevisiae
C;Date: 30-Nov-1995 #sequence revision 16-Feb-1996 #text change 19-Apr-2002
C; Accession: S59439
R; Murphy, L.; Harris, D.
submitted to the EMBL Data Library, March 1995
A; Reference number: S59423
A; Accession: S59439
A; Molecule type: DNA
A; Residues: 1-295 <MUR>
A;Cross-references: EMBL:Z48612; NID:g728671; PID:g728688; GSPDB:GN00004;
MIPS:YDR233c
A; Experimental source: strain AB972
C; Genetics:
A; Gene: MIPS: YDR233c
A; Cross-references: SGD: S0002641
A; Map position: 4R
C; Keywords: transmembrane protein
F;40-56/Domain: transmembrane #status predicted <TM1>
F;146-162/Domain: transmembrane #status predicted <TM2>
```

13.7%; Score 127.5; DB 2; Length 295;

Query Match

```
Best Local Similarity
                        21.6%; Pred. No. 0.0005;
           45; Conservative 43; Mismatches
                                               69; Indels
                                                                         5;
           4 DLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQK 63
Qу
             Db
          22 DLLLWRNPVQTGKYFGGSLLALLILKKVNLITFFLKVAYTILFTT-----GSIEFV-- 72
          64 SDEGHPFRAYLESEVAISEELVQKY-----SNSALGHVNCTIKEL-----RRLFL 108
Qу
                        Db
          73 -----SKLFLGQGLITKYGPKECPNIAGFIKPHIDEALKQLPVFQAHIRKTVF 120
         109 VDDLVDSLKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQID----- 160
Qу
                   121 AQVPKHTFKTAVALFLLHKFFSWFSIWTIVFVADIFTFTLPVIYHSYKHEIDATVAQGVE 180
Db
Qу
         161 -----HYLGLANKNVKDAMAKIQAKI 181
                    : :|: | : |:::|:
         181 ISKQKTQEFSQMACEKTKPYLDKVESKL 208
Db
RESULT 14
T01153
probable seed maturation protein [imported] - Arabidopsis thaliana
N; Alternate names: hypothetical protein F27L4.17
C; Species: Arabidopsis thaliana (mouse-ear cress)
C; Date: 12-Feb-1999 #sequence revision 12-Feb-1999 #text change 16-Feb-2001
C; Accession: T01153; T02426; C84627
R; Rounsley, S.D.; Kaul, S.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.;
Sýkes, S.M.; Mason, T.M.; Kerlavage, A.R.; Adams, M.D.; Somerville, C.R.;
Venter, J.C.
submitted to the EMBL Data Library, June 1998
A; Description: Arabidopsis thaliana chromosome II BAC F26B6 genomic sequence.
A; Reference number: Z14198
A; Accession: T01153
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-206 < ROU>
A; Cross-references: EMBL: AC003040; NID: q3242700; PID: q3242725
A; Experimental source: cultivar Columbia
R; Rounsley, S.D.; Kaul, S.; Lin, X.; Ketchum, K.A.; Crosby, M.L.; Brandon, R.C.;
Sykes, S.M.; Mason, T.M.; Kerlavage, A.R.; Adams, M.D.; Somerville, C.R.;
Venter, J.C.
submitted to the EMBL Data Library, May 1998
A; Description: Arabidopsis thaliana chromosome II BAC F27L4 genomic sequence.
A; Reference number: Z14658
A; Accession: T02426
A; Status: translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-206 < RO2>
A; Cross-references: EMBL: AC004482; NID: q3152602; PIDN: AAC17096.1; PID: q3152617
R; Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.;
Fujii, C.Y.; Mason, T.M.; Bowman, C.L.; Barnstead, M.E.; Feldblyum, T.V.; Buell,
C.R.; Ketchum, K.A.; Lee, J.J.; Ronning, C.M.; Koo, H.; Moffat, K.S.; Cronin,
L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L.J.; Gill, J.E.; Adams,
M.D.; Carrera, A.J.; Creasy, T.H.; Goodman, H.M.; Somerville, C.R.; Copenhaver,
G.P.; Preuss, D.; Nierman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser,
C.M.; Venter, J.C.
```

```
Nature 402, 761-768, 1999
A; Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis
thaliana.
A; Reference number: A84420; MUID: 20083487; PMID: 10617197
A; Accession: C84627
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-206 <STO>
A;Cross-references: GB:AE002093; NID:g3152617; PIDN:AAC17096.1; GSPDB:GN00139
C; Genetics:
A; Gene: At2q23640; F26B6.29; F27L4.17
A; Map position: 2
A; Introns: 14/1; 76/2; 147/1
C; Superfamily: Arabidopsis thaliana hypothetical protein F27L4.17
  Query Match
                       13.3%; Score 124; DB 2; Length 206;
  Best Local Similarity 24.4%; Pred. No. 0.00069;
 Matches
          48; Conservative 44; Mismatches
                                               75; Indels
                                                              30; Gaps
                                                                           8:
           2 VVDLLYWRDIKK--TGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQ 59
Qу
              | |: || | ::: | ::|||
                                          |: ::: ::| :|::|:
          16 VEDIYLWRRKKLAFSTLLVSTSTWILLSFYGFTTITIVSWIGIAVVSMIF---LWGSLLR 72
Db
          60 AIQKSDEGHPFRAYLESEVA---ISEELVQKYSNSALGHVNCTI---KELRRLFLVDDLV 113
Qу
                           : | |::
                                   : | | | | :
                                             - 1
                                                    73 LLSK-----VEPELSGLEVSEEFVVETVRS-----CRMLMEEMVRWMFRVGAES 116
Db
         114 DSLKFA--VL-MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNV 170
Qу
                 Db
         117 EWFVFARTVLGFWILSRIGNLLDFHTCLFIGLVMGLTVPKLWEEYGDQIQKHLGSLKDKS 176
         171 KDAMAKIQAKIPGLKRK 187
Qy
             1 1
                      || :| |
Db
         177 KGAYNTTHEKILEMKNK 193
RESULT 15
T47948
hypothetical protein F2A19.160 - Arabidopsis thaliana
C; Species: Arabidopsis thaliana (mouse-ear cress)
C;Date: 20-Apr-2000 #sequence revision 20-Apr-2000 #text change 20-Apr-2000
C; Accession: T47948
R; De Haan, M.; Maarse, A.C.; Grivell, L.A.; Mewes, H.W.; Lemcke, K.; Mayer,
K.F.X.; Quetier, F.; Salanoubat, M.
submitted to the Protein Sequence Database, January 2000
A; Reference number: Z24480
A; Accession: T47948
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-264 < DEH>
A; Cross-references: EMBL: AL132962
A; Experimental source: cultivar Columbia; BAC clone F2A19
C; Genetics:
A; Map position: 3
A; Introns: 68/1; 128/2; 164/1; 210/1
A; Note: F2A19.160
```

	atch				Length	264;		
Best Lo	cal Similarity	25.2%; Pred.	No. 0.01	.9;				
Matches	55; Conservat.	ive 37; Mi	smatches	69;	Indels	57 ;	Gaps	14;
Qy .	4 DLLYWRDIKKTG	VVFGASLFLLL	SLTVFSIVS	VTAYI	ALA	ALLSVTI	SFRIYK	55
	1: :	::::	1 : :1	: :	11	111	: :	
Db	70 DVFLWRDKKLSA							128
Qy	56 GVIOAIO	KSDEGHP	FRAYLESEV	AISEELV	OK-YSN-	-SALGHV	NCTIKE	102
~3	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	:::	1 11	11 11:	Ĩ	1:11	1	
Db	129 GTFPYDCFCTEK							182
			•		~		<u>.</u>	
Qy	103 LRRLFLVDDLVD	SLKFAVLMWVF	TYVGALFNG	LTLLI	LALISLE	SVPVIY	ERHQAQ	158
		l: : l	:1 1	: 11	:	: : :	1:1::	
Db	183							227
	•			~				
Qу	159 IDHYLGLANKNV	KDAMAK	IOAKIPGLK	RKAE 18	19			
~4	: : :	l: I	: ::::	11:				
Db	228 VDPVAEKTLI				52			

Search completed: September 29, 2004, 18:16:05 Job time: 6.62587 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on:

September 29, 2004, 18:16:15; Search time 20.2878 Seconds

(without alignments)

2997.869 Million cell updates/sec

Title:

US-09-830-972-29 COPY 990 1178

Perfect score:

931

Sequence:

1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIOAKIPGLKRKAE 189

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1351062 seqs, 321799191 residues

Total number of hits satisfying chosen parameters:

1351062

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

Published Applications AA: *

- /cgn2 6/ptodata/2/pubpaa/US07 PUBCOMB.pep:*
- /cgn2 6/ptodata/2/pubpaa/PCT NEW_PUB.pep:*
- 3: /cgn2 6/ptodata/2/pubpaa/US06 NEW PUB.pep:*
- 4: /cgn2 6/ptodata/2/pubpaa/US06 PUBCOMB.pep:*
- 5: /cqn2 6/ptodata/2/pubpaa/US07 NEW PUB.pep:*
- 6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
- 7: /cgn2 6/ptodata/2/pubpaa/US08 NEW PUB.pep:*
- /cgn2 6/ptodata/2/pubpaa/US08 PUBCOMB.pep:* /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:* 9:
- 10: /cgn2 6/ptodata/2/pubpaa/US09B PUBCOMB.pep:*
- /cgn2_6/ptodata/2/pubpaa/US09C PUBCOMB.pep:* 11: 12: /cgn2 6/ptodata/2/pubpaa/US09 NEW PUB.pep:*
- 13: /cqn2 6/ptodata/2/pubpaa/US10A PUBCOMB.pep:*
- 14: /cgn2 6/ptodata/2/pubpaa/US10B PUBCOMB.pep:*
- /cgn2 6/ptodata/2/pubpaa/US10C PUBCOMB.pep:* 15:
- /cgn2 6/ptodata/2/pubpaa/US10 NEW PUB.pep:* 16:
- /cgn2 6/ptodata/2/pubpaa/US60 NEW PUB.pep:* 17:
- /cgn2 6/ptodata/2/pubpaa/US60 PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

કૃ

Result Query

> No. Score Match Length DB ID

Description

1	931	100.0	1192	9	US-09-789-386-2	Sequence 2, Appli
2	931	100.0	1192	9	US-09-758-140-6	Sequence 6, Appli
3	931	100.0	1192	9	US-09-893-348-23	Sequence 23, Appl
4	931	100.0	1192	9	US-09-972-599A-6	Sequence 6, Appli
5	931	100.0	1192	12	US-10-267-502-429	Sequence 429, App
6	931	100.0	1192	14	US-10-060-036-71	Sequence 71, Appl
7	931	100.0	1192	16	US-10-327-213-9	Sequence 9, Appli
8	931	100.0	1192	16	US-10-466-258-9	Sequence 9, Appli
9	927	99.6	199	9	US-09-893-348-25	Sequence 25, Appl
10	927	99.6	199	12	US-10-660-946-1	Sequence 1, Appli
11	927	99.6	373	9	US-09-789-386-6	Sequence 6, Appli
12	927	99.6	373	9	US-09-765-205-6	Sequence 6, Appli
13	927	99.6	373	9.	US-09-893-348-24	Sequence 24, Appl
14	927	99.6	373	12	US-10-408-967-8	Sequence 8, Appli
15	927	99.6	373	14	US-10-060-036-72	Sequence 72, Appl
16	927	99.6	373	16	US-10-466-258-4	Sequence 4, Appli
17	924	99.2	1192	12	US-10-408-967-7	Sequence 7, Appli
18	920	98.8	199	12	US-10-408-967-9	Sequence 9, Appli
19	918	98.6	199	12	US-09-978-360A-467	Sequence 467, App
20	908	97.5	1163	9	US-09-893-348-18	Sequence 18, Appl
21	905	97.2	379	14	US-10-205-194-164	Sequence 164, App
22	904.5	97.2	1163	12	US-10-267-502-431	Sequence 431, App
23	904	97.1	199	9	US-09-893-348-21	Sequence 21, Appl
24	904	97.1	360	9	US-09-893-348-20	Sequence 20, Appl
25	886	95.2	199	16	US-10-466-258-11	Sequence 11, Appl
26	682	73.3	208	12	US-10-660-946-7	Sequence 7, Appli
27	682	73.3	356	12	US-10-660-946-6	Sequence 6, Appli
28	682	73.3	776	12	US-10-660-946-5	Sequence 5, Appli
29	682	73.3	776	12	US-10-267-502-430	Sequence 430, App
30	681	73.1	777	14	US-10-205-219-93	Sequence 93, Appl
31	681	73.1	780	12	US-10-267-502-432	Sequence 432, App
32	665	71.4	267	12	US-10-660-946-8	Sequence 8, Appli
33	665	71.4	267	14	US-10-205-194-127	Sequence 127, App
34	624.5	67.1	236	9	US-09-729-674-20	Sequence 20, Appl
35	624.5	67.1	236	9	US-09-765-205-26	Sequence 26, Appl
36	624.5	67.1	236	12	US-10-408-967-2	Sequence 2, Appli
37	624.5	67.1	266	12	US-10-276-774-2330	Sequence 2330, Ap
38	624.5	67.1	269	14	US-10-106-698-6222	Sequence 6222, Ap
39	619.5	66.5	593	15	US-10-108-260A-2892	Sequence 2892, Ap
40	541.5	58.2	168	10	US-09-809-391-563	Sequence 563, App
41	541.5	58.2	168	10	US-09-882-171-563	Sequence 563, App
42	541.5	58.2	168	12	US-10-164-861-563	Sequence 563, App
43	520	55.9	222	12	US-10-267-502-428	Sequence 428, App
44	512	55.0	241	12	US-10-660-946-3	Sequence 3, Appli
45	508.5	54.6	234	12	US-10-424-599-200840	Sequence 200840,

ALIGNMENTS

RESULT 1 US-09-789-386-2

- ; Sequence 2, Application US/09789386
 ; Patent No. US20020010324A1
- ; GENERAL INFORMATION:
- ; APPLICANT: MICHALOVICH, DAVID

```
APPLICANT: PRINJHA, RABINDER KUMAR
  TITLE OF INVENTION: NOVEL COMPOUNDS
  FILE REFERENCE: GP-30165-C1
  CURRENT APPLICATION NUMBER: US/09/789,386
  CURRENT FILING DATE: 2001-02-21
  PRIOR APPLICATION NUMBER: U.K. 9916898.1
  PRIOR FILING DATE: 1999-07-19
  PRIOR APPLICATION NUMBER: U.K. 9816024.5
  PRIOR FILING DATE: 1998-07-22
  PRIOR APPLICATION NUMBER: US 09/359,208
  PRIOR FILING DATE: 1999-07-22
  NUMBER OF SEQ ID NOS: 6
  SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 2
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: HOMO SAPIENS
US-09-789-386-2
 Query Match
                       100.0%; Score 931; DB 9; Length 1192;
 Best Local Similarity 100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative 0; Mismatches
                                                                     0:
                                            0;
                                                 Indels 0; Gaps
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
            1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
          61 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
            1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
            1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
        181 IPGLKRKAE 189
Qу
            1184 IPGLKRKAE 1192
Db
RESULT 2
US-09-758-140-6
; Sequence 6, Application US/09758140
; Patent No. US20020012965A1
; GENERAL INFORMATION:
  APPLICANT: Strittmatter, Stephen M.
  TITLE OF INVENTION: No. US20020012965A1o Receptor-Mediated Blockade of
Axonal Growth
  FILE REFERENCE: 44574-5073-US
  CURRENT APPLICATION NUMBER: US/09/758,140
  CURRENT FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: US 60/175,707
  PRIOR FILING DATE: 2000-01-12
  PRIOR APPLICATION NUMBER: US 60/207,366
  PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: US 60/236,378
  PRIOR FILING DATE: 2000-09-29
```

```
SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-758-140-6
 Query Match
                       100.0%; Score 931; DB 9; Length 1192;
 Best Local Similarity 100.0%; Pred. No. 1.6e-86;
                           0; Mismatches
 Matches 189; Conservative
                                             0; Indels
                                                                     0;
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
            Db
        1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            Db
        1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
            1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
        181 IPGLKRKAE 189
Qу
            11111111
Db
        1184 IPGLKRKAE 1192
RESULT 3
US-09-893-348-23
; Sequence 23, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
  APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
 APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
; FILE REFERENCE: EIS-SCHWARTZ=2A
; CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
   LENGTH: 1192
   TYPE: PRT
```

NUMBER OF SEQ ID NOS: 20

```
US-09-893-348-23
 Query Match
                       100.0%; Score 931; DB 9; Length 1192;
 Best Local Similarity
                       100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative
                           0; Mismatches 0; Indels
                                                          0; Gaps
                                                                     0;
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
            Db
        1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
            Db
        1064 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
            Db
        1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAK 1183
         181 IPGLKRKAE 189
Qу
            Db
        1184 IPGLKRKAE 1192
RESULT 4
US-09-972-599A-6
; Sequence 6, Application US/09972599A
; Patent No. US20020077295A1
; GENERAL INFORMATION:
  APPLICANT: STRITTMATTER, STEPHEN M.
  TITLE OF INVENTION: NOGO-RECEPTOR-MEDIATED BLOCKADE OF AXONAL GROWTH
  FILE REFERENCE: C077 CIP US
  CURRENT APPLICATION NUMBER: US/09/972,599A
  CURRENT FILING DATE: 2001-10-06
  PRIOR APPLICATION NUMBER: PCT/US01/01041
  PRIOR FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: 09/758,140
  PRIOR FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: 60/236,378
  PRIOR FILING DATE: 2000-09-29
  PRIOR APPLICATION NUMBER: 60/207,366
  PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: 60/175,707
  PRIOR FILING DATE: 2000-01-12
  NUMBER OF SEQ ID NOS: 57
  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-972-599A-6
 Query Match
                       100.0%; Score 931; DB 9;
                                                Length 1192;
 Best Local Similarity
                       100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative
                           0; Mismatches
                                             0;
                                                 Indels
                                                              Gaps
                                                                     0;
```

1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60

ORGANISM: Homo sapiens

Qy

```
1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
           1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
           1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
        181 IPGLKRKAE 189
Qy
           H \cap H \cap H
       1184 IPGLKRKAE 1192
Db
RESULT 5
US-10-267-502-429
; Sequence 429, Application US/10267502
; Publication No. US20040071700A1
; GENERAL INFORMATION:
  APPLICANT: Kim, Jaeseob
  APPLICANT: Galant, Ron
  TITLE OF INVENTION: Obesity Linked Genes
  FILE REFERENCE: LSD-07416
  CURRENT APPLICATION NUMBER: US/10/267,502
  CURRENT FILING DATE: 2003-01-27
  NUMBER OF SEO ID NOS: 439
  SOFTWARE: PatentIn version 3.2
 SEO ID NO 429
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-267-502-429
 Query Match
                     100.0%;
                            Score 931; DB 12;
                                            Length 1192;
 Best Local Similarity
                     100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative
                          0; Mismatches
                                         0;
                                                               0;
                                             Indels
                                                        Gaps
                                                     0;
         1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
           Db
       1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
         61 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
           Db
       1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIOAK 180
Qy
           1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
Qy
        181 IPGLKRKAE 189
           Db
       1184 IPGLKRKAE 1192
```

```
US-10-060-036-71
; Sequence 71, Application US/10060036
 Publication No. US20030073144A1
; GENERAL INFORMATION:
  APPLICANT: Benson, Darin R.
  APPLICANT: Kalos, Michael D.
  APPLICANT: Lodes, Michael J.
  APPLICANT: Persing, David H.
  APPLICANT: Hepler, William T.
  APPLICANT: Jiang, Yuqiu
  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
  TITLE OF INVENTION: AND DIAGNOSIS OF PANCREATIC CANCER
  FILE REFERENCE: 210121.566
  CURRENT APPLICATION NUMBER: US/10/060,036
  CURRENT FILING DATE: 2002-01-30
  NUMBER OF SEQ ID NOS: 4560
  SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO 71
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-060-036-71
 Query Match
                       100.0%; Score 931; DB 14; Length 1192;
 Best Local Similarity 100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative 0; Mismatches
                                            0;
                                                 Indels
                                                          0; Gaps
                                                                     0;
Qу
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
            Db
        1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Qy
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
            Db
        1064 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
            Db
        1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
        181 IPGLKRKAE 189
Qу
            Db
        1184 IPGLKRKAE 1192
RESULT 7
US-10-327-213-9
; Sequence 9, Application US/10327213
; Publication No. US20040121341A1
; GENERAL INFORMATION:
  APPLICANT: FILBIN, MARIE T.
 APPLICANT: DOMENICONI, MARCO
 APPLICANT: CAO, ZIXUAN
 TITLE OF INVENTION: INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN (MAG)
  TITLE OF INVENTION: ACTIVITY FOR REGULATING NEURAL GROWTH AND REGENERATION
 FILE REFERENCE: CUNY/003
  CURRENT APPLICATION NUMBER: US/10/327,213
  CURRENT FILING DATE: 2002-12-20
```

```
SOFTWARE: PatentIn Ver. 2.1
 SEO ID NO 9
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-327-213-9
 Query Match
                     100.0%; Score 931; DB 16; Length 1192;
 Best Local Similarity
                     100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative 0; Mismatches
                                          0;
                                             Indels
                                                      0;
                                                         Gaps
                                                                0;
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
           1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
           1064 IQKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIOAK 180
Qу
           1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
        181 IPGLKRKAE 189
Qy
           1184 IPGLKRKAE 1192
Db
RESULT 8
US-10-466-258-9
; Sequence 9, Application US/10466258
; Publication No. US20040132096A1
; GENERAL INFORMATION:
  APPLICANT: GLAXO GROUP LIMITED
  TITLE OF INVENTION: ASSAY
  FILE REFERENCE: P80966 GCW
  CURRENT APPLICATION NUMBER: US/10/466,258
  CURRENT FILING DATE: 2003-07-15
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-466-258-9
 Query Match
                     100.0%; Score 931; DB 16; Length 1192;
 Best Local Similarity 100.0%; Pred. No. 1.6e-86;
 Matches 189; Conservative
                         0; Mismatches
                                          0:
                                            Indels
                                                                0;
                                                        Gaps
         1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
           Db
       1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
```

NUMBER OF SEQ ID NOS: 43

```
1064 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
            Db
       1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
        181 IPGLKRKAE 189
Qу
            Db
       1184 IPGLKRKAE 1192
RESULT 9
US-09-893-348-25
; Sequence 25, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
  APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
  APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
  FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
 SEO ID NO 25
   LENGTH: 199
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-893-348-25
 Query Match
                      99.6%; Score 927; DB 9; Length 199;
 Best Local Similarity
                      100.0%; Pred. No. 3.8e-87;
 Matches 188; Conservative
                            0; Mismatches
                                           0; Indels
                                                                   0;
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qy
            Db
         12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qγ
            Db
         72 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
        122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qy
            Db
        132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
```

```
182 PGLKRKAE 189
Qу
              Db
          192 PGLKRKAE 199
RESULT 10
US-10-660-946-1
; Sequence 1, Application US/10660946
; Publication No. US20040063131A1
    GENERAL INFORMATION:
         APPLICANT: Bandman, Olga
                    Au-Young, Janice
                    Goli, Surya K.
                    Hillman, Jennifer L.
         TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
         NUMBER OF SEQUENCES: 9
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: Incyte Pharmaceuticals, Inc.
              STREET: 3174 Porter Drive
              CITY: Palo Alto
              STATE: CA
              COUNTRY: U.S.
              ZIP: 94304
         COMPUTER READABLE FORM:
              MEDIUM TYPE: Diskette
              COMPUTER: IBM Compatible
              OPERATING SYSTEM: DOS
              SOFTWARE: FastSEO Version 1.5
         CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/10/660,946
              FILING DATE: 12-Sep-2003
         PRIOR APPLICATION DATA:
              APPLICATION NUMBER: US/09/228,213A
              FILING DATE: <Unknown>
              APPLICATION NUMBER: 08/700,607
              FILING DATE: <Unknown>
         ATTORNEY/AGENT INFORMATION:
              NAME: Billings, Lucy J.
              REGISTRATION NUMBER: 36,749
              REFERENCE/DOCKET NUMBER: PF-0114 US
         TELECOMMUNICATION INFORMATION:
              TELEPHONE: 415-855-0555
              TELEFAX: 415-845-4166
    INFORMATION FOR SEQ ID NO: 1:
         SEQUENCE CHARACTERISTICS:
              LENGTH: 199 amino acids
              TYPE: amino acid
              STRANDEDNESS: single
              TOPOLOGY: linear
        MOLECULE TYPE: peptide
         IMMEDIATE SOURCE:
              LIBRARY: <Unknown>
              CLONE: Consensus
```

SEQUENCE DESCRIPTION: SEQ ID NO: 1:

US-10-660-946-1

```
Query Match
                     99.6%; Score 927; DB 12; Length 199;
 Best Local Similarity 100.0%; Pred. No. 3.8e-87;
 Matches 188; Conservative
                           0; Mismatches
                                          0: Indels
                                                       0; Gaps
                                                                 0:
Qy
         2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
           12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
           72 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 131
Db
        122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIQAKI 181
Qy
           132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 191
Db
        182 PGLKRKAE 189
Qy
           192 PGLKRKAE 199
Db
RESULT 11
US-09-789-386-6
; Sequence 6, Application US/09789386
; Patent No. US20020010324A1
; GENERAL INFORMATION:
  APPLICANT: MICHALOVICH, DAVID
  APPLICANT: PRINJHA, RABINDER KUMAR
  TITLE OF INVENTION: NOVEL COMPOUNDS
  FILE REFERENCE: GP-30165-C1
  CURRENT APPLICATION NUMBER: US/09/789,386
  CURRENT FILING DATE: 2001-02-21
  PRIOR APPLICATION NUMBER: U.K. 9916898.1
  PRIOR FILING DATE: 1999-07-19
  PRIOR APPLICATION NUMBER: U.K. 9816024.5
  PRIOR FILING DATE: 1998-07-22
  PRIOR APPLICATION NUMBER: US 09/359,208
  PRIOR FILING DATE: 1999-07-22
  NUMBER OF SEQ ID NOS: 6
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
   LENGTH: 373
   TYPE: PRT
   ORGANISM: HOMO SAPIENS
US-09-789-386-6
 Query Match
                     99.6%; Score 927; DB 9; Length 373;
 Best Local Similarity 100.0%; Pred. No. 8.8e-87;
 Matches 188; Conservative 0; Mismatches 0; Indels
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qy
           Db
        186 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 245
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qy
           Db
        246 OKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 305
```

```
Qy
        122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
            306 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 365
Db
        182 PGLKRKAE 189
Qу
            Db
        366 PGLKRKAE 373
RESULT 12
US-09-765-205-6
; Sequence 6, Application US/09765205
; Patent No. US20020034800A1
; GENERAL INFORMATION:
  APPLICANT: Cao, Li
  TITLE OF INVENTION: BONE MARROW SECRETED PROTEINS AND POLYNUCLEOTIDES
  FILE REFERENCE: 1458.004/200130.449
  CURRENT APPLICATION NUMBER: US/09/765,205
  CURRENT FILING DATE: 2001-01-17
  PRIOR APPLICATION NUMBER: US/09/212,440
 PRIOR FILING DATE: 1998-12-16
  NUMBER OF SEQ ID NOS: 46
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 6
   LENGTH: 373
   TYPE: PRT
   ORGANISM: human
US-09-765-205-6
 Query Match
                      99.6%; Score 927; DB 9; Length 373;
 Best Local Similarity 100.0%; Pred. No. 8.8e-87;
 Matches 188; Conservative
                           0; Mismatches
                                           0;
                                              Indels
                                                           Gaps
                                                                  0;
                                                        0:
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
            Db
        186 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOAI 245
Qу
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
            Db
        246 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 305
        122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
            Db
        306 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 365
Qy
        182 PGLKRKAE 189
            Db
        366 PGLKRKAE 373
RESULT 13
US-09-893-348-24
; Sequence 24, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
; APPLICANT: EISENBACH-SCHWARTZ, Michal
```

```
APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
; APPLICANT: MOSONEGO, Alon
; APPLICANT: MOALEM, Gila
; TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
; FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
 SEQ ID NO 24
   LENGTH: 373
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-893-348-24
 Query Match
                       99.6%; Score 927; DB 9; Length 373;
 Best Local Similarity 100.0%; Pred. No. 8.8e-87;
 Matches 188; Conservative 0; Mismatches 0; Indels
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
QУ
            Db
        186 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 245
Qу
         62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
            Db
        246 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 305
        122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
QУ
            Db
        306 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 365
Qу
        182 PGLKRKAE 189.
            366 PGLKRKAE 373
RESULT 14
US-10-408-967-8
; Sequence 8, Application US/10408967
; Publication No. US20040063161A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia & Upjohn Company
; APPLICANT: Yan, Rigiang
; APPLICANT: Lu, Yifeng
; TITLE OF INVENTION: Compositions and Methods of Treating Alzheimer's Disease
; FILE REFERENCE: 00925
; CURRENT APPLICATION NUMBER: US/10/408,967
```

```
NUMBER OF SEO ID NOS: 9
  SOFTWARE: PatentIn version 3.1
 SEQ ID NO 8
   LENGTH: 373
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-408-967-8
 Query Match
                       99.6%; Score 927; DB 12; Length 373;
 Best Local Similarity
                       100.0%; Pred. No. 8.8e-87;
 Matches 188; Conservative
                             0; Mismatches
                                              0; Indels
                                                          0; Gaps
                                                                     0;
Qу
          2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
             Db
         186 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOAI 245
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
            Db
         246 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 305
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
            Db
         306 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 365
         182 PGLKRKAE 189
Qу
            1111111
Db
         366 PGLKRKAE 373
RESULT 15
US-10-060-036-72
; Sequence 72, Application US/10060036
 Publication No. US20030073144A1
 GENERAL INFORMATION:
 APPLICANT: Benson, Darin R.
  APPLICANT: Kalos, Michael D.
  APPLICANT: Lodes, Michael J.
  APPLICANT: Persing, David H.
  APPLICANT: Hepler, William T.
  APPLICANT:
             Jiang, Yuqiu
  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
  TITLE OF INVENTION: AND DIAGNOSIS OF PANCREATIC CANCER
  FILE REFERENCE: 210121.566
  CURRENT APPLICATION NUMBER: US/10/060,036
  CURRENT FILING DATE: 2002-01-30
  NUMBER OF SEQ ID NOS: 4560
  SOFTWARE: FastSEQ for Windows Version 4.0
 SEQ ID NO 72
   LENGTH: 373
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-060-036-72
 Query Match
                       99.6%; Score 927; DB 14; Length 373;
 Best Local Similarity
                       100.0%; Pred. No. 8.8e-87;
 Matches 188; Conservative
                            0; Mismatches
                                             0;
                                                Indels
                                                                     0;
                                                          0; Gaps
```

CURRENT FILING DATE: 2003-04-08

Qy	2	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI	61
Db	186	VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI	245
Qу	62	QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL	121
Db	246	QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL	305
Qу	122	MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI	181
Db	306	MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI	365
Qу	182	PGLKRKAE 189	
Db	366	PGLKRKAE 373	

Search completed: September 29, 2004, 18:48:19 Job time : 21.2878 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on:

September 29, 2004, 18:06:43; Search time 14.8689 Seconds

(without alignments)

4010.587 Million cell updates/sec

Title:

US-09-830-972-29 COPY 990 1178

Perfect score:

Sequence:

1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIQAKIPGLKRKAE 189

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1017041 segs, 315518202 residues

Total number of hits satisfying chosen parameters:

1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL 25:*

1: sp archea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp invertebrate:*

sp mammal:*

7: sp mhc:*

8: sp organelle:*

9: sp phage:*

10: sp plant:*

11: sp_rodent:*

12: sp virus:*

13: sp vertebrate:*

14: sp unclassified:*

15: sp rvirus:*

16: sp bacteriap:*

17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result Query

No. Score Match Length DB ID

용

Description

1	931	100.0	986	4	Q8IUA4	Q8iua4 homo sapien
2	928	99.7	392	4	Q96B16	Q96b16 homo sapien
3	915	98.3	578	11	Q80W95	Q80w95 mus musculu
4	915	98.3	639	11	Q8K290	Q8k290 mus musculu
5	915	98.3	1046	11	Q8BGK7	Q8bgk7 mus musculu
6	915	98.3	1162	11	Q8BGM9	Q8bgm9 mus musculu
7	912	98.0	375	11	Q8BHF5	Q8bhf5 mus musculu
8	911	97.9	356	11	Q8BH78	Q8bh78 mus musculu
9	904.5	97.2	1163	11	Q8K3G8	Q8k3g8 mus musculu
10	901	96.8	184	6	Q7YRW9	Q7yrw9 bos taurus
11	900.5	96.7	357	11	Q8K3G7	Q8k3g7 mus musculu
12	882	94.7	199	13	Q7T224	Q7t224 gallus gall
13	867	93.1	179	6	Q9GM33	
14	750	80.6	214	13	Q7T222	Q7t222 carassius a
15	682	73.3	199	4	Q9BQ59	Q9bq59 homo sapien
16	681	73.1	780	11	Q8K4S4	Q8k4s4 mus musculu
17	681	73.1	780	11	Q8K0T0	Q8k0t0 mus musculu
18	672	72.2	760	13	Q90638	Q90638 gallus gall
19	668	71.8	208	13	Q90637	Q90637 gallus gall
20	665	71.4	267	11	Q63765	Q63765 rattus sp.
21	623.5	67.0	236	11	Q8VBU0	Q8vbu0 rattus norv
22	623.5	67.0	237	11	Q8C6D5	Q8c6d5 mus musculu
23	622.5	66.9	643	11	Q8CCU2	Q8ccu2 mus musculu
24	583	62.6	221	13	Q7ZUD6	Q7zud6 brachydanio
25	521	56.0	224	5	Q9VMW1	Q9vmwl drosophila
26	520	55.9	222	5	Q9VMW4	Q9vmw4 drosophila
27	520	55.9	234	5	Q9VMW3	Q9vmw3 drosophila
28	520	55.9	595	5	Q9VMV9	Q9vmv9 drosophila
29	518	55.6	202	5	Q9VMW2	Q9vmw2 drosophila
30	343	36.8	107	13	Q7T223	Q7t223 carassius a
31	335	36.0	2484	5	Q9U347	Q9u347 caenorhabdi
32	335	36.0	2607	5	Q23187	Q23187 caenorhabdi
33	334	35.9	222	5	Q23188	Q23188 caenorhabdi
34	199.5	21.4	154	5	Q9VIB7	Q9vib7 drosophila
35	199.5	21.4	158	5	Q24199	Q24199 drosophila
36	191	20.5	255	10	082352	082352 arabidopsis
37	187	20.1	255	10	Q9SH59	Q9sh59 arabidopsis
38	182	19.5	271	10	Q9SUT9	Q9sut9 arabidopsis
39	165.5	17.8	197	5	Q9NJS2	Q9njs2 leishmania
40	164	17.6	257	10	Q9FFS0	Q9ffs0 arabidopsis
41	163	17.5	275	10	Q9SUR3	Q9sur3 arabidopsis
42	159	17.1	200	10	Q9LT71	Q9lt71 arabidopsis
43	158	17.0	279	10	Q9AWY7	Q9awy7 oryza sativ
44	157	16.9	200	10	Q8LAT8	Q8lat8 arabidopsis
45	154.5	16.6	192	10	Q7XR59	Q7xr59 oryza sativ

ALIGNMENTS

```
RESULT 1
Q8IUA4

ID Q8IUA4

AC Q8IUA4;

DT 01-MAR-2003 (TrEMBLrel. 23, Created)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
```

```
RNT4 (RTN4).
DE
GN
     RTN4.
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC.
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
     Oertle T., Schwab M.E.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
RA
     Van der Putten H.;
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Testis;
     MEDLINE=22376540; PubMed=12488097;
RX
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT.
     J. Mol. Biol. 325:299-323(2003).
DR
     EMBL; AY102285; AAM64244.1; -.
     EMBL; AY123245; AAM64249.1; -.
DR
     EMBL; AY123246; AAM64250.1; -.
DR
     EMBL; AY123247; AAM64251.1; -.
DR
     EMBL; AY123248; AAM64252.1; -.
DR
     EMBL; AY123249; AAM64253.1; -.
DR
     EMBL; AY123250; AAM64254.1; -.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
     InterPro; IPR003388; Reticulon.
DR
DR
     Pfam; PF02453; Reticulon; 1.
     PROSITE; PS50845; RETICULON; 1.
DR
               986 AA; 108449 MW; 0CDE8F647036415A CRC64;
SQ
     SEQUENCE
                        100.0%; Score 931; DB 4;
                                                   Length 986;
  Query Match
  Best Local Similarity
                        100.0%; Pred. No. 2.7e-75;
  Matches 189; Conservative
                               0; Mismatches
                                                                         0;
                                                0;
                                                    Indels
                                                                 Gaps
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             798 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 857
Db
          61 IOKSDEGHPFRAYLESEVAISEELVOKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             858 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 917
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
             Db
          918 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 977
```

```
181 IPGLKRKAE 189
Qу
              Db
          978 IPGLKRKAE 986
RESULT 2
096B16
                                           392 AA.
     Q96B16
                 PRELIMINARY;
                                   PRT;
ID
AC
     Q96B16;
     01-DEC-2001 (TrEMBLrel. 19, Created)
DT
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
     01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
     Hypothetical protein (RTN4).
DE
GN
     RTN4.
OS
     Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Kidney;
RA
     Strausberg R.;
     Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
RA
     Oertle T., Schwab M.E.;
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [4]
RP
     SEQUENCE FROM N.A.
     Van der Putten H.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [5]
     SEQUENCE FROM N.A.
RP
     MEDLINE=22376540; PubMed=12488097;
RX
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     J. Mol. Biol. 325:299-323(2003).
RL
     EMBL; BC016165; AAH16165.1; -.
DR
     EMBL; AY102285; AAM64242.1; -.
DR
     EMBL; AY102278; AAM64247.1; -.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
DR
KW
     Hypothetical protein.
     SEQUENCE 392 AA; 42274 MW; D7B2AA5E839E58AD CRC64;
SQ
                          99.7%; Score 928; DB 4; Length 392;
  Query Match
                          99.5%; Pred. No. 1.8e-75;
  Best Local Similarity
                                 1; Mismatches
                                                    0; Indels
                                                                  0; Gaps
                                                                               0;
```

Matches 188; Conservative

```
Qу
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOA 60
             204 AVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 263
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            Db
         264 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 323
Qу
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
            324 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 383
Db
         181 IPGLKRKAE 189
Qу
            Db
         384 IPGLKRKAE 392
RESULT 3
Q80W95
ID
    Q80W95
               PRELIMINARY;
                               PRT;
                                     578 AA.
AC
    080W95;
DT
    01-JUN-2003 (TrEMBLrel. 24, Created)
    01-JUN-2003 (TrEMBLrel. 24, Last sequence update) 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DT
DE
    Nogo-A (Fragment).
GN
    NOGO-A.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Tozaki H., Hirata T.;
    "The partial sequence of mouse nogo-A cDNA clone#4109.";
RT
RT.
    Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AB073672; BAC75974.1; -.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
    InterPro; IPR003388; Reticulon.
DR
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
FT
    NON TER
SQ
    SEQUENCE
              578 AA;
                      63696 MW; 832670C171E4AC61 CRC64;
 Query Match
                       98.3%; Score 915; DB 11;
                                               Length 578;
 Best Local Similarity
                       98.4%; Pred. No. 4.2e-74;
 Matches 186; Conservative
                             2; Mismatches
                                             1; Indels
                                                          0;
Qу
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOA 60
            Db
         390 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 449
Qу
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
            Db
         450 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 509
        121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
```

```
510 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOAOIDHYLGLANKSVKDAMAKIOAK 569
Db
         181 IPGLKRKAE 189
QУ
            1111111
         570 IPGLKRKAE 578
Db
RESULT 4
08K290
ID
    Q8K290
               PRELIMINARY;
                               PRT:
                                     639 AA.
AC
    Q8K290;
DT
    01-OCT-2002 (TrEMBLrel. 22, Created)
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Hypothetical protein.
GN
    RTN4.
    Mus musculus (Mouse).
OS
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
    NCBI TaxID=10090;
OX
RN
    [1]
RP
    SEQUENCE FROM N.A.
    Strausberg R.;
RA
    Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; BC032192; AAH32192.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam: PF02453: Reticulon: 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Hypothetical protein.
    SEQUENCE
SO
              639 AA; 70312 MW; 309A19DA37603F11 CRC64;
                       98.3%; Score 915; DB 11; Length 639;
 Query Match
 Best Local Similarity
                       98.4%; Pred. No. 4.7e-74;
 Matches 186; Conservative
                             2; Mismatches
                                             1; Indels
          1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
            Db
         451 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 510
         61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            Db
         511 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 570
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
            Db
         571 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOAOIDHYLGLANKSVKDAMAKIOAK 630
        181 IPGLKRKAE 189
Qу
            Db
         631 IPGLKRKAE 639
```

```
O8BGK7
ID
                                 PRT; 1046 AA.
    Q8BGK7
                PRELIMINARY;
AC
    Q8BGK7;
DT
     01-MAR-2003 (TrEMBLrel. 23, Created)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
    RTN4.
DE
    RTN4.
GN
    Mus musculus (Mouse).
OS
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
    NCBI TaxID=10090;
OX
RN
     [1]
    SEQUENCE FROM N.A.
RΡ
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., van der Putten H., Schwab M.E.;
RA
RT
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [2]
RP
    SEQUENCE FROM N.A.
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., Schwab M.E.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7;
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129SvcJ7;
    Van der Putten H., Mir A.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY102280; AAM73502.1; -.
DR
    EMBL; AY102286; AAM73507.1; -.
DR
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
    InterPro; IPR003388; Reticulon.
DR
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
SQ
    SEQUENCE
               1046 AA;
                        114221 MW;
                                    8CE2E2238ED51222 CRC64;
 Query Match
                        98.3%; Score 915; DB 11; Length 1046;
 Best Local Similarity
                        98.4%; Pred. No. 8e-74;
 Matches 186; Conservative
                               2; Mismatches
                                                1; Indels
                                                                         0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
             Db
         858 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 917
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             Db
         918 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 977
Qу
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
```

```
978 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAK 1037
Db
         181 IPGLKRKAE 189
Qу
             1038 IPGLKRKAE 1046
Db
RESULT 6
Q8BGM9
                                  PRT; 1162 AA.
                PRELIMINARY;
    Q8BGM9
ID
AC
    Q8BGM9;
     01-MAR-2003 (TrEMBLrel. 23, Created)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    RTN4.
    RTN4.
GN
    Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
     NCBI TaxID=10090;
OX
RN
     [1]
     SEOUENCE FROM N.A.
RP
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [2]
     SEQUENCE FROM N.A.
RP
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
     Oertle T., Schwab M.E.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [3]
     SEQUENCE FROM N.A.
RΡ
     STRAIN=129/SvcJ7;
RC
     Van der Putten H.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
     STRAIN=129SvcJ7;
RC
RA
     Van der Putten H., Mir A.;
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AY102284; AAM73506.1; -.
DR
     EMBL; AY102286; AAM73511.1; -.
DR
     MGD; MGI:1915835; Rtn4.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
     GO; GO:0007399; P:neurogenesis; IDA.
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
DR
                1162 AA; 126613 MW; 855697FBEE11781F CRC64;
SQ
     SEOUENCE
                          98.3%; Score 915; DB 11; Length 1162;
  Query Match
                         98.4%; Pred. No. 9e-74;
  Best Local Similarity
                                                                    Gaps
                                                                            0;
  Matches 186; Conservative
                                2; Mismatches
                                                  1; Indels
```

```
1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             974 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1033
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             1034 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 1093
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             1094 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAK 1153
Db
         181 IPGLKRKAE 189
Qv
             11111111
        1154 IPGLKRKAE 1162
Db
RESULT 7
Q8BHF5
                                PRT;
                                       375 AA.
TD
    Q8BHF5
               PRELIMINARY;
AC
    O8BHF5;
    01-MAR-2003 (TrEMBLrel. 23, Created)
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DΤ
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    RTN4.
DE
    RTN4.
GN
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
     [1]
RN
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., van der Putten H., Schwab M.E.;
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [2]
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
     Oertle T., Schwab M.E.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
     STRAIN=129/SvcJ7;
RC
     Van der Putten H.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [4]
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=129SvcJ7;
     Van der Putten H., Mir A.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AY102282; AAM73504.1; -.
DR
     EMBL; AY102286; AAM73509.1; -.
DR
     MGD; MGI:1915835; Rtn4.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
     GO; GO:0007399; P:neurogenesis; IDA.
DR
```

```
InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
              375 AA; 40300 MW; 23D9EB19BE671AE6 CRC64;
SO
                                                 Length 375;
                        98.0%; Score 912; DB 11;
 Query Match
                       97.9%; Pred. No. 4.8e-74;
 Best Local Similarity
                                                  Indels
                                                                       0;
                              3; Mismatches
                                               1;
 Matches 185; Conservative
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             187 AVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 246
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
QУ
             247 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 306
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             307 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAK 366
Db
         181 IPGLKRKAE 189
Qу
             11111111
         367 IPGLKRKAE 375
Dh
RESULT 8
Q8BH78
                                PRT:
                                       356 AA.
                PRELIMINARY;
ID
    Q8BH78
AC
    Q8BH78;
    01-MAR-2003 (TrEMBLrel. 23, Created)
DΤ
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    RTN4.
GN
    RTN4.
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7, and 129SvcJ7;
RC
     Oertle T., Schwab M.E.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
     STRAIN=129/SvcJ7;
RC
     Van der Putten H.;
RA
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [4]
```

```
SEQUENCE FROM N.A.
RP
    STRAIN=129SvcJ7;
RC
RA
    Van der Putten H., Mir A.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY102281; AAM73503.1; -.
DR
    EMBL; AY102286; AAM73508.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
              356 AA; 38403 MW; 4366C03BA9630B56 CRC64;
    SEQUENCE
SO
                        97.9%; Score 911; DB 11; Length 356;
 Query Match
                        98.4%;
                              Pred. No. 5.6e-74;
 Best Local Similarity
 Matches 185; Conservative
                              2; Mismatches
                                               1; Indels
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             169 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 228
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
             229 OKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVL 288
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
             289 MWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAKI 348
Db
         182 PGLKRKAE 189
Qy
             349 PGLKRKAE 356
Db
RESULT 9
08K3G8
               PRELIMINARY;
                                PRT;
                                      1163 AA.
ID
    Q8K3G8
AC
    Q8K3G8;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Nogo-A.
    RTN4.
GN
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
     [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=BALB/c;
RC
RA
     Jin W., Long M., Li R., Ju G.;
     "Cloning and expression of the mouse Nogo-A protein.";
RT
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AY114152; AAM77068.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
```

```
GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
SO
              1163 AA; 126691 MW; 6B5F362799417EA4 CRC64;
 Query Match
                       97.2%; Score 904.5; DB 11; Length 1163;
                       97.9%; Pred. No. 8e-73;
 Best Local Similarity
 Matches 186; Conservative
                             2: Mismatches
                                              1; Indels
                                                           1; Gaps
                                                                      1;
          1 SVVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQ 59
Qу
            974 SVVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQ 1033
Db
          60 AIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFA 119
Qу
            1034 AIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFA 1093
Db
         120 VLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHOAOIDHYLGLANKNVKDAMAKIOA 179
Qy
            1094 VLMWVFTYVGALFNGLTLLILALISLFSIPVIYERHOAOIDHYLGLANKSVKDAMAKIOA 1153
Db
         180 KIPGLKRKAE 189
Qу
            1154 KIPGLKRKAE 1163
Db
RESULT 10
O7YRW9
    Q7YRW9
ID
               PRELIMINARY;
                               PRT:
                                      184 AA.
AC
    Q7YRW9;
    01-OCT-2003 (TrEMBLrel. 25, Created)
DΤ
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    RTN4w (Fragment).
GN
    RTN4.
OS
    Bos taurus (Bovine).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
OC
    Bovidae; Bovinae; Bos.
    NCBI TaxID=9913;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    MEDLINE=22715887; PubMed=12832288;
RX
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
RT
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
    RTN/Nogo gene family.";
    FASEB J. 17:1238-1247(2003).
RL
DR
    EMBL; AY164744; AAP47319.1; -.
FT
    NON TER
                 1
                       1
    SEOUENCE
SO
              184 AA; 20671 MW; DE990E03BBAF84A1 CRC64;
                       96.8%; Score 901; DB 6; Length 184;
 Best Local Similarity
                       98.9%; Pred. No. 2.1e-73;
 Matches 182; Conservative
                             0; Mismatches 2; Indels
                                                           0; Gaps
                                                                      0;
Qу
           6 LYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOAIOKSD 65
```

```
1 LYWRDIKKTGVVFGXXLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSD 60
Db
         66 EGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVF 125
Qy
            61 EGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVF 120
Db
        126 TYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLK 185
Qу
            121 TYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLK 180
Db
        186 RKAE 189
Qy
            IIIII
        181 RKAE 184
Db
RESULT 11
08K3G7
                                    357 AA.
              PRELIMINARY;
                              PRT:
ID
    08K3G7
    08K3G7;
AC
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Nogo-B.
DE.
    RTN4.
GN ·
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=BALB/c;
RC
    Jin W., Li R., Long M., Shen J., Ju G.;
RA
    "Cloning and expression of the mouse Nogo-B protein.";
RT
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AY114153; AAM77069.1; -.
DR
    MGD: MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    SEQUENCE 357 AA; 38566 MW; 73BB3D17DFDBDF15 CRC64;
SQ
                       96.7%; Score 900.5; DB 11; Length 357;
  Query Match
  Best Local Similarity
                      97.9%; Pred. No. 5e-73;
                                                                   1;
  Matches 185: Conservative
                            2; Mismatches
                                            1; Indels
          2 VVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
            169 VVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 228
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
            229 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 288
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qy
```

```
289 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAK 348
Db
         181 IPGLKRKAE 189
Qу
            11111111
         349 IPGLKRKAE 357
Db
RESULT 12
Q7T224
                                     199 AA.
                               PRT;
               PRELIMINARY;
    O7T224
ID
    Q7T224;
AC
    01-OCT-2003 (TrEMBLrel. 25, Created)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    RTN4-C.
DE
    RTN4.
GN
    Gallus gallus (Chicken).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
    Gallus.
OC
    NCBI TaxID=9031;
OX
    [1]
RN
    SEQUENCE FROM N.A.
RP
    MEDLINE=22715887; PubMed=12832288;
RX
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
    RTN/Nogo gene family.";
RT
    FASEB J. 17:1238-1247(2003).
RL
    EMBL; AY164737; AAP47312.1; -.
DR
    SEQUENCE 199 AA; 22293 MW; 07CF4E4EF2723251 CRC64;
SO
                       94.7%; Score 882; DB 13; Length 199;
  Query Match
  Best Local Similarity 93.6%; Pred. No. 1.2e-71;
                                                                    0;
                             7; Mismatches
                                                         0; Gaps
  Matches 176; Conservative
                                             5; Indels
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
             72 QKSDEGHPFRAYLESDVAVSEDLIQKYSSVVLGHINGTVKELRRLFLVDDLVDSLKFAVL 131
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
             132 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLVNKNVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
             111111 1
         192 PGLKRKTE 199
Db
RESULT 13
09GM33
               PRELIMINARY;
                               PRT;
                                     179 AA.
ΙD
     Q9GM33
```

AC

Q9GM33;

```
01-MAR-2001 (TrEMBLrel. 16, Created)
DT
    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Hypothetical protein.
DE
    Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC
    Cercopithecinae; Macaca.
OC
    NCBI TaxID=9541;
OX
RN
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Brain;
    Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
RA
    Suzuki Y., Sugano S., Hashimoto K.;
RA
    "Isolation of full-length cDNA clones from macaque brain cDNA
RT
    libraries.";
RT
    Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AB049853; BAB16739.1; -.
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Hypothetical protein.
KW
    SEQUENCE 179 AA; 19949 MW; 5F8CD4383FEE9E02 CRC64;
SQ -
                        93.1%; Score 867; DB 6; Length 179;
  Query Match
                        98.3%; Pred. No. 2.4e-70;
  Best Local Similarity
                                             0; Indels
                                                             0;
                              3; Mismatches
  Matches 176; Conservative
          11 IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 70
Qу
             1 MKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYRGVIQAIQKSDEGHPF 60
Db
          71 RAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLMWVFTYVGA 130
Qу
             61 RAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLRFAVLMWVFTYVGA 120
Db
         131 LFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 189
Qу
             121 LFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIPGLKRKAE 179
Db
RESULT 14
07T222
                PRELIMINARY;
                                 PRT;
                                       214 AA.
ID
     O7T222
AC
     O7T222;
     01-OCT-2003 (TrEMBLrel. 25, Created)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DΤ
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DΤ
     RTN4-M.
DE
GN
     RTN4.
OS
     Carassius auratus (Goldfish).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC.
     Cyprinidae; Carassius.
OC.
     NCBI TaxID=7957;
OX .
RN
     [1]
```

```
SEQUENCE FROM N.A.
RP
    MEDLINE=22715887; PubMed=12832288;
RX
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
    RTN/Nogo gene family."
RT
    FASEB J. 17:1238-1247(2003).
RT.
    EMBL; AY164754; AAP47329.1; -.
DR
             214 AA; 24063 MW; E9B603B043159DD9 CRC64;
    SEQUENCE
SO
                        80.6%; Score 750; DB 13; Length 214;
 Query Match
                        75.0%; Pred. No. 1e-59;
 Best Local Similarity
                                                                       0;
 Matches 141; Conservative 24; Mismatches 23;
                                                            0; Gaps
                                                   Indels
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             27 VVDLLYWRDLQRTGVVFGASLLLLLSLSVCSIISVISYVALALLSVTISFRIYKGILQAV 86
Db
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
             87 QKSEDGHPFKMYLDKDIGISSELVQKYSDTALAHINCVIKELRRLFLVEDLVDSLKFAVF 146
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
             147 MWILTYVGALFNGLTLLIMGLIGTFSWPVIYEKHQAQIDHYYGLVNKQIKDVMGKIQAKI 206
Db
         182 PGLKRKAE 189
Qу
             H + H
         207 PGAKPKTE 214
Db
RESULT 15
Q9BQ59
                                       199 AA.
                                 PRT:
                PRELIMINARY;
ID
     Q9BQ59
AC
     09B059;
     01-JUN-2001 (TrEMBLrel. 17, Created)
DT
     01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
     Similar to reticulon 1.
DE
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Lung;
RA
     Strausberg R.;
     Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; BC003003; AAH03003.1; -.
DR
     EMBL; BC000314; AAH00314.1; -.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
     GO; GO:0000786; C:nucleosome; IEA.
DR
     GO; GO:0005634; C:nucleus; IEA.
DR
     GO; GO:0003677; F:DNA binding; IEA.
DR
     GO; GO:0007001; P:chromosome organization and biogenesis (sen. . .; IEA.
DR
     GO; GO:0006334; P:nucleosome assembly; IEA.
DR
     InterPro; IPR001951; Histone H4.
DR
     InterPro; IPR003388; Reticulon.
DR
```

```
Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS00047; HISTONE H4; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
            199 AA; 22642 MW; 7CFA44CC568DF6D8 CRC64;
    SEOUENCE
SQ
                     73.3%; Score 682; DB 4; Length 199;
 Query Match
                     68.4%; Pred. No. 1.3e-53;
 Best Local Similarity
                                                                 0;
                                         28; Indels
                                                       0; Gaps
 Matches 128; Conservative 31; Mismatches
          3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qу
            13 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 72
Db
         63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
            |:||||:||:||:|
                                     73 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 132
Db
        123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qу
            ::
        133 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 192
Db
        183 GLKRKAE 189
Qу
            1 11 11
        193 GAKRHAE 199
Db
```

Search completed: September 29, 2004, 18:19:48
Job time: 15.8689 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:04:48; Search time 2.70944 Seconds

(without alignments)

3632.211 Million cell updates/sec

Title: US-09-830-972-29 COPY 990 1178

Perfect score: 931

Sequence: 1

1 SVVDLLYWRDIKKTGVVFGA.....VKDAMAKIQAKIPGLKRKAE 189

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched:

141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: SwissProt 42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		용				
Result		Query				•
No.	Score	Match	Length	DB	ID	Description
1	931	100.0	1192	1	RTN4_HUMAN	Q9nqc3 homo sapien
2	911	97.9	199	1	RTN4 MOUSE	Q99p72 mus musculu
3	908	97.5	1163	1	RTN4 RAT	Q9jk11 rattus norv
4	682	73.3	776	1	RTN1_HUMAN	Q16799 homo sapien
5	681	73.1	777	1	RTN1 RAT	Q64548 rattus norv
6	624.5	67.1	236	1	RTN3 HUMAN	095197 homo sapien
. 7	623.5	67.0	237	1	RTN3 MOUSE	Q9es97 mus musculu
8	473.5	50.9	545	- 1	RTN2_HUMAN	075298 homo sapien
9	473	50.8	471	1	RTN2 MOUSE	070622 mus musculu
10	93.5	10.0	197	1	AR61_DROME	Q9ves1 drosophila
11	88.5	9.5	1278	1	NPC1 HUMAN	015118 homo sapien
12	88	9.5	468	1	ACH5 HUMAN	P30532 homo sapien
13	87.5	9.4	296	1	YBZ7_YEAST	P38279 saccharomyc
14	84	9.0	744	1	PRES RAT	Q9eph0 rattus norv
15	83	8.9	578	1	MDLB BUCBP	Q89a96 buchnera ap
16	83	8.9	744	1	PRES MERUN	Q9jkq2 meriones un
17	83	8.9	744	1	PRES_MOUSE	Q99nh7 mus musculu

18	82.5	8.9	570	1	SECD_STRCO	Q53955	streptomyce
19	82	8.8	589	1	Y015 MYCGE		mycoplasma
20	81.5	8.8	324	1	MRAY_LISIN		listeria in
21	81	8.7	329	1	O5T2 HUMAN	Q8ngg2	homo sapien
22	81	8.7	993	1	NISB LACLA		lactococcus
23	80.5	8.6	299	1	Y779 METJA	Q58189	methanococc
24	80.5	8.6	470	1	YMP8 CAEEL	P53993	caenorhabdi
25	80.5	8.6	502	1	OXAA AQUAE	066561	aquifex aeo
26	80.5	8.6	839	1	TLR4 PANPA		pan paniscu
27	80	8.6	744	1	PRES HUMAN		homo sapien
28	79.5	8.5	499	1	UBPG YEAST		saccharomyc
29	79	8.5	312	1	OLF2_CHICK		gallus gall
30	79	8.5	388	1	YUBA_BACSU	032086	bacillus su
31	79	8.5	839	1	TLR4 HUMAN	000206	homo sapien
32	78	8.4	349	1	MRAY_CHLPN		chlamydia p
33	78	8.4	507	1	TLCB_RICPR		rickettsia
34	78	8.4	607	1	GLMS_AGRT5	Q8ueh1	a glucosami
35	77.5	8.3	267	1	YTXD_BACME	P46826	bacillus me
36	77.5	8.3	503	1	C72R_ARATH	Q9sae1	arabidopsis
37	77.5	8.3	1277	1	NPC1_PIG		sus scrofa
38	77	8.3	580	1		P57552	buchnera ap
39	76.5	8.2	221	1	YA78_AQUAE	067171	aquifex aeo
40	76	8.2	284	1	HTPX_METJA	Q59076	methanococc
41	76	8.2	286	1	YL33_ARCFU	028147	archaeoglob
42	76	8.2	556	1	NU2M_PODAN	P15578	podospora a
43	76	8.2	4351	1	FAT2_RAT	088277	rattus norv
44	75.5	8.1	307	1	OXA2_LACPL	Q88wr8	lactobacill
45	.75.5	8.1	328	1	YM31_ARCFU	028052	archaeoglob

ALIGNMENTS

```
RESULT 1
RTN4_HUMAN
ID
     RTN4 HUMAN
                    STANDARD;
                                    PRT; 1192 AA.
     Q9NQC3; 094962; Q9BXG5; Q9H212; Q9H3I3; Q9UQ42; Q9Y293; Q9Y2Y7;
AC
AC
     Q9Y5U6;
DT
     28-FEB-2003 (Rel. 41, Created)
DT
     28-FEB-2003 (Rel. 41, Last sequence update)
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
DΕ
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DΕ
     (Neuroendocrine-specific protein) (NSP) (Neuroendocrine specific
     protein C homolog) (RTN-x) (Reticulon 5) (My043 protein).
DE
GN
     RTN4 OR NOGO OR ASY OR KIAA0886.
os
     Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
     [1]
RΡ
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RX
    MEDLINE=20129242; PubMed=10667780;
RA
     Prinjha R., Moore S.E., Vinson M., Blake S., Morrow R., Christie G.,
    Michalovich D., Simmons D.L., Walsh F.S.;
RA
     "Inhibitor of neurite outgrowth in humans.";
RT
RL
    Nature 403:383-384(2000).
RN
     [2]
```

```
SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RP
RC
     TISSUE=Brain;
     MEDLINE=21010696; PubMed=11126360;
RX
     Tagami S., Eguchi Y., Kinoshita M., Takeda M., Tsujimoto Y.;
RA
RT
     "A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on
RT
     endoplasmic reticulum and reduces their anti-apoptotic activity.";
     Oncogene 19:5736-5746(2000).
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
     MEDLINE=20237542; PubMed=10773680;
RX
RA
     Yang J., Yu L., Bi A.D., Zhao S.-Y.;
RT
     "Assignment of the human reticulon 4 gene (RTN4) to chromosome
RT
     2p14-->2p13 by radiation hybrid mapping.";
     Cytogenet. Cell Genet. 88:101-102(2000).
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 4).
RA
     Jin W.-L., Ju G.;
RT
     "Developmentally-regulated alternative splicing in a novel Nogo-A.";
RL
     Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RC
     TISSUE=Placenta, and Skeletal muscle;
     Ito T., Schwartz S.M.;
RA
RT
     "Cloning of a member of the reticulon gene family in human.";
     Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 2).
RC
     TISSUE=Fibroblast;
     Yutsudo M.;
RA
     "Isolation of a cell death-inducing gene.";
RT
RL
     Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
RC
     TISSUE=Pituitary;
RA
     Song H., Peng Y., Zhou J., Huang Q., Dai M., Mao Y.M., Yu Y., Xu X.,
RA
     Luo B., Hu R., Chen J.;
RT
     "Human neuroendocrine-specific protein C (NSP) homolog gene.";
RL
     Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
RA
     Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P.,
RA
     Qin W.X., Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y.,
     Yu J., Han L.H.;
RA
RT
     "Novel human cDNA clone with function of inhibiting cancer cell
RT
     growth.";
RL
     Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RC
     TISSUE=Brain;
RX
    MEDLINE=99156230; PubMed=10048485;
RA
    Nagase T., Ishikawa K.-I., Suyama M., Kikuno R., Hirosawa M.,
RA
    Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT
     "Prediction of the coding sequences of unidentified human genes. XII.
RT
     The complete sequences of 100 new cDNA clones from brain which code
RT
     for large proteins in vitro.";
RL
     DNA Res. 5:355-364(1998).
RN
     [10]
```

```
SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RP
     TISSUE=Brain, Ovary, Pancreas, Placenta, and Skeletal muscle;
RC
    MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [11]
     SEQUENCE FROM N.A. (ISOFORM 3).
RP
     MEDLINE=20499367; PubMed=11042152;
RX
RA
     Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA
     Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
     Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RA
     "Cloning and functional analysis of cDNAs with open reading frames for
RT
     300 previously undefined genes expressed in CD34+ hematopoietic
RT
RT
     stem/progenitor cells.";
RL
     Genome Res. 10:1546-1560(2000).
RN
     [12]
     SEQUENCE OF 482-1192 FROM N.A. (ISOFORM 1/4).
RP
RC
     TISSUE=Brain;
RA
     Mao Y.M., Xie Y., Zheng Z.H.;
     Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE OF 186-1192 FROM N.A. (ISOFORM 1).
RP
RC
     TISSUE=Testis;
RA
     Sha J.H., Zhou Z.M., Li J.M.;
RL
     Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RN
     [14]
RP
     TOPOLOGY.
RC
     TISSUE=Brain;
     MEDLINE=20129259; PubMed=10667797;
RX
     GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M.;
RA
     "Identification of the Nogo inhibitor of axon regeneration as a
RT
RT
     Reticulon protein.";
     Nature 403:439-444(2000).
RL
RN
     [15]
· RP
     FUNCTION.
RC
     TISSUE=Brain;
RX
     MEDLINE=21069055; PubMed=11201742;
     Fournier A.E., Grandpre T., Strittmatter S.M.;
RA
     "Identification of a receptor mediating Nogo-66 inhibition of axonal
RT
```

```
RT
     regeneration.";
RL
     Nature 409:341-346(2001).
RN
     [16]
     REVIEW.
RP
RX
    MEDLINE=21888956; PubMed=11891768;
RA
     Ng C.E.L., Tang B.L.;
RT
     "Nogos and the Nogo-66 receptor: factors inhibiting CNS neuron
     regeneration.";
RT
     J. Neurosci. Res. 67:559-565(2002).
RL
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
        block the regeneration of the nervous central system in adults.
CC
         Isoform 2 reduces the anti-apoptotic activity of Bcl-xl and Bcl-2.
CC
         This is likely consecutive to their change in subcellular
CC
CC
         location, from the mitochondria to the endoplasmic reticulum,
         after binding and sequestration.
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2.
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
CC
         reticulum. Anchored to the membrane of the endoplasmic reticulum
CC
         through 2 putative transmembrane domains.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=4;
CC
         Name=1; Synonyms=RTN 4A, Nogo-A, RTN-xL;
CC
           IsoId=Q9NQC3-1; Sequence=Displayed;
         Name=2; Synonyms=RTN 4B, Nogo-B, RTN-xS, Foocen-M;
CC
           IsoId=Q9NQC3-2; Sequence=VSP 005655;
CC
         Name=3; Synonyms=RTN 4C, Nogo-\overline{C}, Foocen-S;
CC
           IsoId=Q9NQC3-3; Sequence=VSP 005652, VSP 005653;
CC
CC
           IsoId=Q9NQC3-4; Sequence=VSP 005654;
CC
     -!- TISSUE SPECIFICITY: Isoform 1 is specifically expressed in brain
CC
         and testis and weakly in heart and skeletal muscle. Isoform 2 is
CC
         widely expressed excepted for the liver. Isoform 3 is expressed in
CC
         brain, skeletal muscle and adipocytes. Isoform 4 is testis-
CC
CC
         specific.
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     -!- CAUTION: Ref.11 sequence differs from that shown due to
CC
         frameshifts in positions 1149 and 1156.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
CC
     EMBL; AJ251383; CAB99248.1; -.
DR
DR
     EMBL; AJ251384; CAB99249.1; -.
DR
     EMBL; AJ251385; CAB99250.1; -.
     EMBL; AB040462; BAB18927.1; -.
DR
     EMBL; AB040463; BAB18928.1; -.
DR
     EMBL; AF148537; AAG12176.1; -.
DR
     EMBL; AF148538; AAG12177.1; -.
DR
     EMBL; AF087901; AAG12205.1; -.
DR
     EMBL; AF320999; AAG40878.1; -.
DR
     EMBL; AF132047; AAD31021.1; -.
DR
     EMBL; AF132048; AAD31022.1; -.
```

```
EMBL; AB015639; BAA83712.1; -.
DR
    EMBL; AF077050; AAD27783.1; -.
DR
    EMBL; AF177332; AAG17976.1; -.
DR
    EMBL; AB020693; BAA74909.1; -.
DR
DR
    EMBL; BC001035; AAH01035.1; -.
    EMBL; BC007109; AAH07109.1; -.
DΒ
    EMBL; BC014366; AAH14366.1; -.
DR
                        100.0%; Score 931; DB 1; Length 1192;
 Query Match
                        100.0%; Pred. No. 1.8e-71;
 Best Local Similarity
                             0; Mismatches
                                              0; Indels
                                                                Gaps
                                                                       0;
 Matches 189; Conservative
                                                            0;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qу
             1004 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1063
Db
          61 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qу
             1064 IOKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 1123
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             1124 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 1183
Db
         181 IPGLKRKAE 189
Qу
             1184 IPGLKRKAE 1192
Db
RESULT 2
RTN4 MOUSE
    RTN4 MOUSE
ID
                  STANDARD;
                                PRT;
                                       199 AA.
AC.
    Q99P72; Q9CTE3;
DΤ
    28-FEB-2003 (Rel. 41, Created)
DT
    28-FEB-2003 (Rel. 41, Last sequence update)
    28-FEB-2003 (Rel. 41, Last annotation update)
DΤ
DE
    Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein).
GN
    RTN4 OR NOGO.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
RC
    STRAIN=3T3-L1; TISSUE=Adipocyte;
RA
    Coulson A.C., Craggs P.D., Morris N.J.;
RT
     "Mouse vp20/RTN4C cDNA.";
    Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE OF 170-199 FROM N.A.
    STRAIN=C57BL/6J; TISSUE=Embryo;
RC
    MEDLINE=21085660; PubMed=11217851;
RX
    Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA
    Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA
    Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA
    Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA
    Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA
```

```
RA
     Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
     Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA
RA
     Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
     Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
RA
     Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA
     Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA
     Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
     Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
RA
     Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
     Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
     Hayashizaki Y.;
RT
     "Functional annotation of a full-length mouse cDNA collection.";
RL
     Nature 409:685-690(2001).
CC
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
         block the regeneration of the nervous central system in adults (By
CC
         similarity).
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
CC
         membrane of the endoplasmic reticulum through 2 putative
CC
         transmembrane domains (By similarity).
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=1;
CC
           Comment=A number of isoforms may be produced;
CC
         Name=1;
CC
           IsoId=Q99P72-1; Sequence=Displayed;
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
СC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
     modified and this statement is not removed. Usage by and for commercial
CC
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
DR
     EMBL; AF326337; AAK08076.1; -.
DR
     EMBL; AK003859; -; NOT ANNOTATED CDS.
DR
    MGD; MGI:1915835; Rtn4.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
     GO; GO:0030176; C:integral to endoplasmic reticulum membrane; ISS.
DR
     GO; GO:0005635; C:nuclear membrane; ISS.
DR.
     GO; GO:0005515; F:protein binding; ISS.
     GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
DR
     GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
DR
     GO; GO:0007399; P:neurogenesis; IDA.
     InterPro; IPR003388; Reticulon.
DR
DR
     Pfam; PF02453; Reticulon; 1.
     PROSITE; PS50845; RETICULON; 1.
DR
KW
     Endoplasmic reticulum; Alternative splicing; Transmembrane.
FT
     DOMAIN
                  1
                         25
                                  CYTOPLASMIC (Potential).
FT
     TRANSMEM
                  26
                         50
                                  POTENTIAL.
FT
     DOMAIN
                  51
                        137
                                  LUMENAL (Potential).
FT
     TRANSMEM
                 138
                        162
                                  POTENTIAL.
FT
     DOMAIN
                 163
                        199
                                  CYTOPLASMIC (Potential).
```

```
SQ
     SEQUENCE
               199 AA;
                       22466 MW; 07BE5D580059ED9C CRC64;
  Query Match
                        97.9%; Score 911; DB 1; Length 199;
  Best Local Similarity
                       98.4%; Pred. No. 1.4e-70;
  Matches 185; Conservative
                             2; Mismatches
                                               1; Indels
                                                             0; Gaps
                                                                        0:
Qy
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
             Db
          12 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 71
Qу
          62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
             Db
          72 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAVL 131
Qу
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
             132 MWVFTYVGALFNGLTLLILALISLFSIPVIYERHQAQIDHYLGLANKSVKDAMAKIQAKI 191
Db
         182 PGLKRKAE 189
Qу
             Db
         192 PGLKRKAE 199
RESULT 3
RTN4 RAT
ΙD
    RTN4 RAT
                  STANDARD;
                                PRT; 1163 AA.
AC
    Q9JK11; Q9JK10; Q9R0D9; Q9WUE9; Q9WUF0;
DT
    28-FEB-2003 (Rel. 41, Created)
DT
    28-FEB-2003 (Rel. 41, Last sequence update)
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
    Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DE
    (Glut4 vesicle 20 kDa protein).
DE
GN
    RTN4 OR NOGO.
OS
    Rattus norvegicus (Rat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
    NCBI TaxID=10116;
RN
    [1]
    SEQUENCE FROM N.A. (ISOFORM 3), AND PARTIAL SEQUENCE.
RP
RC
    STRAIN=Sprague-Dawley; TISSUE=Adipocyte;
RX
    MEDLINE=99249816; PubMed=10231557;
    Morris N.J., Ross S.A., Neveu J.M., Lane W.S., Lienhard G.E.;
RA
RT
    "Cloning and characterization of a 22 kDa protein from rat adipocytes:
RT
    a new member of the reticulon family.";
RL
    Biochim. Biophys. Acta 1450:68-76(1999).
RN
    SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RP
RX
    MEDLINE=20129258; PubMed=10667796;
    Chen M.S., Huber A.B., Van der Haar M.E., Frank M., Schnell L.,
RA
RA
    Spillmann A.A., Christ F., Schwab M.E.;
RT
    "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an
RT
    antigen for monoclonal antibody IN-1.";
    Nature 403:434-439(2000).
RL
RN
RP
    SEQUENCE FROM N.A. (ISOFORMS 2 AND 4).
RC
    STRAIN=Wistar Kyoto; TISSUE=Vascular smooth muscle;
```

RETICULON.

FT

DOMAIN

12

199

```
RA
     Ito T., Schwartz S.M.;
RT
     "Cloning of a member of the reticulon gene family in rat: one of two
RT
     minor splice variants.";
RL
     Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN
RP
     FUNCTION.
RX
     MEDLINE=22033691; PubMed=12037567;
RA
     GrandPre T., Li S., Strittmatter S.M.;
RT
     "Nogo-66 receptor antagonist peptide promotes axonal regeneration.";
RL
     Nature 417:547-551(2002).
CC
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
         block the regeneration of the nervous central system in adults (By
CC
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
CC
         membrane of the endoplasmic reticulum through 2 putative
         transmembrane domains (By similarity).
CC
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=4;
CC
         Name=1; Synonyms=Nogo-A, NI-220-250;
CC
           IsoId=Q9JK11-1; Sequence=Displayed;
CC
         Name=2; Synonyms=Nogo-B, Foocen-M1;
CC
           IsoId=Q9JK11-2; Sequence=VSP 005658;
CC
         Name=3; Synonyms=Nogo-C, VP20;
CC
           IsoId=Q9JK11-3; Sequence=VSP 005656, VSP 005657;
CC
         Name=4; Synonyms=Foocen-M2;
CC
           IsoId=Q9JK11-4; Sequence=VSP 005659;
CC
     -!- TISSUE SPECIFICITY: Isoforms 1, 2 and 3 are present in optic
CC
         nerve, spinal cord and cerebral cortex. Isoforms 1 and 2 are
CC
         present in dorsal root ganglion, sciatic nerve and PC12 cells
CC
         after longer exposure. Isoforms 2 and 3 are detected in kidney,
CC
         cartilage, skin, lung and spleen. Isoform 3 is expressed at high
CC
         level in skeletal muscle. In adult animals isoform 1 is expressed
CC
        mainly in the nervous system.
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; AF051335; AAF01564.1; -.
DR
     EMBL; AJ242961; CAB71027.1; -.
DR
     EMBL; AJ242962; CAB71028.1; -.
DR
     EMBL; AJ242963; CAB71029.1; -.
DR
     EMBL; AF132045; AAD31019.1; -.
     EMBL; AF132046; AAD31020.1; -.
DR
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; IDA.
    GO; GO:0005635; C:nuclear membrane; ISS.
DR
DR
    GO; GO:0005515; F:protein binding; ISS.
DR
    GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
DR
    GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
    InterPro; IPR003388; Reticulon.
```

```
Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
KW
                      989
FΤ
    DOMATN
                 1
                                CYTOPLASMIC (Potential).
                990
                     1010
FT
    TRANSMEM
                                POTENTIAL.
    DOMAIN
               1011
                     1104
                                LUMENAL (Potential).
FT
    TRANSMEM
                                POTENTIAL.
               1105
                     1125
FT
               1126
                     1163
                                CYTOPLASMIC (Potential).
FT
    DOMAIN
FT
    DOMAIN
                976
                     1163
                                RETICULON.
FT
    DOMAIN
                33
                       46
                                POLY-GLU.
                73
                       76
                                POLY-ALA.
FT
    DOMAIN
    DOMAIN
                140
                      145
                                POLY-PRO.
FΤ
FT
    VARSPLIC
                      964
                               Missing (in isoform 3).
                 1
                                /FTId=VSP 005656.
FT
    VARSPLIC
                                AVLSAELSKTS -> MDGQKKHWKDK (in isoform
FT
                965
                      975
FT
                                3).
FT
                                /FTId=VSP 005657.
                               Missing (in isoform 2).
FT
    VARSPLIC
               173
                      975
FT
                                /FTId=VSP 005658.
                               Missing (in isoform 4).
FT
    VARSPLIC
               192
                      975
FT
                                /FTId=VSP 005659.
                               MISSING (IN REF. 3; AAD31020).
FT
    CONFLICT
              1130
                     1131
    SEQUENCE
              1163 AA; 126386 MW; 8CB894B09E94F0B6 CRC64;
SQ
                               Score 908; DB 1; Length 1163;
 Query Match
                        97.5%;
 Best Local Similarity
                               Pred. No. 1.6e-69;
                        97.4%;
 Matches 184; Conservative
                               3; Mismatches
                                                2; Indels
                                                             0;
                                                                Gaps
                                                                        0:
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
             975 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 1034
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
             Db
        1035 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNSTIKELRRLFLVDDLVDSLKFAV 1094
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
             Db
        1095 LMWVFTYVGALFNGLTLLILALISLFSIPVIYERHQVQIDHYLGLANKSVKDAMAKIQAK 1154
Qу
         181 IPGLKRKAE 189
             1111111:
Db ·
        1155 IPGLKRKAD 1163
RESULT 4
RTN1 HUMAN
    RTN1 HUMAN
ID
                  STANDARD;
                                PRT:
                                       776 AA.
AC
    Q16799; Q16800; Q16801;
DT
    16-OCT-2001 (Rel. 40, Created)
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
DE
    Reticulon 1 (Neuroendocrine-specific protein).
GN
    RTN1 OR NSP.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OC

```
NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORMS RTN1-A; RTN1-B AND RTN1-C).
RP
RC
     TISSUE=Lung carcinoma;
RX
    MEDLINE=93293865; PubMed=7685762;
     Roebroek A.J.M., Van de Velde H.J.K., Van Bokhoven A., Broers J.L.V.,
RA
     Ramaekers F.C.S., Van de Ven W.J.M.;
RA
     "Cloning and expression of alternative transcripts of a novel
RT
RT
     neuroendocrine-specific gene and identification of its 135-kDa
     translational product.";
RT
     J. Biol. Chem. 268:13439-13447(1993).
RL
RN
RP
     ALTERNATIVE SPLICING.
RX
    MEDLINE=96429995; PubMed=8833145;
     Roebroek A.J.M., Ayoubi T.A.Y., Van de Velde H.J.K.,
RA
     Schoenmakers E.F.P.M., Pauli I.G.L., Van de Ven W.J.M.;
RA
RT
     "Genomic organization of the human NSP gene, prototype of a novel gene
RT
     family encoding reticulons.";
RL
     Genomics 32:191-199(1996).
RN
     [3]
RP
     TISSUE SPECIFICITY.
    MEDLINE=98228245; PubMed=9560466;
RX
    Hens J., Nuydens R., Geerts H., Senden N.H., Van de Ven W.J.M.,
RA
     Roebroek A.J., van de Velde H.J.K., Ramaekers F.C., Broers J.L.;
RA
RT
     "Neuronal differentiation is accompanied by NSP-C expression.";
RL
     Cell Tissue Res. 292:229-237(1998).
CC
     -!- FUNCTION: May be involved in neuroendocrine secretion or in
         membrane trafficking in neuroendocrine cells.
CC
CC
     -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=3;
CC
         Name=RTN1-A; Synonyms=NSP-A;
CC
           IsoId=Q16799-1; Sequence=Displayed;
CC
         Name=RTN1-B; Synonyms=NSP-B;
CC
           IsoId=Q16799-2; Sequence=VSP 005644;
CC
         Name=RTN1-C; Synonyms=NSP-C;
           IsoId=Q16799-3; Sequence=VSP 005645, VSP 005646;
CC
CC
     -!- TISSUE SPECIFICITY: EXPRESSED IN NEURAL AND NEUROENDOCRINE TISSUES
CC
         AND CELL CULTURES DERIVED THEREFROM. EXPRESSION OF ISOFORM RTN1-C
CC
         IS STRONGLY CORRELATED WITH NEURONAL DIFFERENTIATION.
CC
     -!- PTM: Isoforms RTN1-A and RTN1-B are phosphorylated.
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; L10333; AAA59950.1; -.
DR
     EMBL; L10334; AAA59951.1; -.
DR
     EMBL; L10335; AAA59952.1; -.
DR
     PIR; A46583; A46583.
DR
     PIR; 160904; 160904.
DR
     Genew; HGNC:10467; RTN1.
```

```
DR
    MIM; 600865; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; TAS.
    GO; GO:0004871; F:signal transducer activity; NAS.
DR
    GO; GO:0030182; P:neuron differentiation; TAS.
DR
DR
    GO; GO:0007165; P:signal transduction; NAS.
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
    Phosphorylation.
KW
    TRANSMEM
                603
                      623
                               POTENTIAL.
FT
                726
                      746
FT
    TRANSMEM
                               POTENTIAL.
                589
                      776
                               RETICULON.
FT
    DOMAIN
                609
                      612
                               POLY-LEU.
    DOMAIN
FT
                               Missing (in isoform RTN1-B).
                      420
FT
    VARSPLIC
                 1
                               /FTId=VSP 005644.
FT
                      568
                               Missing (in isoform RTN1-C).
FT
    VARSPLIC
                 1
                               /FTId=VSP 005645.
FT
                               GPGPLGPGAPPPLLFLNKQK -> MQATADSTKMDCVWSNW
               569
                      588
FT
    VARSPLIC
                               KSQ (in isoform RTN1-C).
FT
                               /FTId=VSP 005646.
FT
               776 AA; 83617 MW; CA5B6232353096FE CRC64;
SQ
    SEQUENCE
                        73.3%; Score 682; DB 1; Length 776;
 Query Match
 Best Local Similarity
                        68.4%; Pred. No. 1.7e-50;
 Matches 128; Conservative 31; Mismatches
                                                                        0;
                                              28: Indels
           3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qγ
             590 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 649
Db
          63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qy
             650 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQFYVNSTLKELRRLFLVQDLVDSLKFAVLM 709
Db
         123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qу
             Db
         710 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQIDQYLGLVRTHINAVVAKIQAKIP 769
         183 GLKRKAE 189
Qу
             1 11 11
Db
         770 GAKRHAE 776
RESULT 5
RTN1 RAT
    RTN1 RAT
                  STANDARD;
                                PRT;
                                       777 AA.
ID
    Q64548; Q64547;
AC
DT
    16-OCT-2001 (Rel. 40, Created)
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
    Reticulon 1 (Neuroendocrine-specific protein) (S-rex).
DE
GN
    RTN1 OR NSP.
OS
    Rattus norvegicus (Rat).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX
    NCBI TaxID=10116;
```

```
RN
     SEQUENCE FROM N.A. (ISOFORMS RTN1-B AND RTN1-S).
RP
     STRAIN=Wistar; TISSUE=Brain cortex;
RC
    MEDLINE=96386034; PubMed=8793864;
RX
     Baka I.D., Ninkina N.N., Pinon L.G.P., Adu J., Davies A.M.,
RA
     Georgiev G.P., Buchman V.L.;
RA
     "Intracellular compartmentalization of two differentially spliced s-
RT
RT
     rex/NSP mRNAs in neurons.";
RL
    Mol. Cell. Neurosci. 7:289-303(1996).
CC
     -!- FUNCTION: May be involved in neuroendocrine secretion or in
        membrane trafficking in neuroendocrine cells.
CC
     -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane (By
CC
CC
         similarity).
     -!- ALTERNATIVE PRODUCTS:
CC
CC
        Event=Alternative splicing; Named isoforms=2;
         Name=RTN1-B; Synonyms=S-RexB;
CC
           IsoId=Q64548-1; Sequence=Displayed;
CC
         Name=RTN1-S; Synonyms=S-RexS;
CC
           IsoId=Q64548-2; Sequence=VSP 005647, VSP 005648;
CC
     -!- TISSUE SPECIFICITY: EXPRESSED PREDOMINANTLY IN CENTRAL AND
CC
         PERIPHERAL NERVOUS SYSTEM OF NEWBORN AND ADULT RATS. LOW LEVELS
CC
CC
         HAVE BEEN ALSO DETECTED IN HEART, ADRENAL GLAND AND SPLEEN.
CC
         EXPRESSION OF ISOFORM RTN1-B IS RESTRICTED TO PARTICULAR NEURONAL
CC
         TYPES.
     -!- DEVELOPMENTAL STAGE: DETECTED ON EMBRYONIC DAY E10 IN THE
CC
CC
         HINDBRAIN AND IN E11 IN THE FOREBRAIN. DURING THE NEXT 3 EMBRYONIC
CC
         DAYS THE LEVELS OF S-REXS INCREASES AND REMAINS STABLE AT E13 IN
CC
         THE HINDBRAIN AND AT E14 IN THE FOREBRAIN. THE LEVELS OF S-REXB
         DOES NOT CHANGE AS SIGNIFICANTLY DURING DEVELOPMENT OF THE
CC
CC
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     CC
     EMBL; U17604; AAC53046.1; -.
DR
DR
     EMBL; U17603; AAC53045.1; -.
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
DR
     Endoplasmic reticulum; Alternative splicing; Transmembrane.
KW
     TRANSMEM
                 604
                        624
                                 POTENTIAL.
FT
FT
     TRANSMEM
                 727
                        747
                                  POTENTIAL.
                        777
                 590
                                  RETICULON.
FT
     DOMAIN
                 610
                        613
FT
     DOMAIN
                                  POLY-LEU.
                                 Missing (in isoform RTN1-S).
FT
     VARSPLIC
                 1
                        569
                                  /FTId=VSP 005647.
FT
                                  IPGPLGSDLVPPLPFFNKQK -> MQATADSTKMDCVWSNW
                 570
                        589
FT
     VARSPLIC
                                  KSQ (in isoform RTN1-S).
FT
                                 /FTId=VSP 005648.
FT
                777 AA; 83001 MW; AF7479C50F28D0AC CRC64;
SO
     SEQUENCE
```

```
Query Match
                        73.1%;
                                Score 681; DB 1; Length 777;
  Best Local Similarity
                        67.9%; Pred. No. 2.1e-50;
  Matches 127; Conservative 32; Mismatches
                                               28: Indels
                                                                 Gaps
                                                                       0:
           3 VDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQ 62
Qу
             591 IDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVLQAVQ 650
          63 KSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVLM 122
Qу
             Db
         651 KTDEGHPFKAYLELEITLSQEQIQKYTDCLQLYVNSTLKELRRLFLVQDLVDSLKFAVLM 710
         123 WVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKIP 182
Qу
             ::
                                                             : | | | | | | | |
         711 WLLTYVGALFNGLTLLLMAVVSMFTLPVVYVKHQAQVDQYLGLVRTHINTVVAKIQAKIP 770
Db
         183 GLKRKAE 189
Qγ
             1 11 11
         771 GAKRHAE 777
Db
RESULT 6
RTN3 HUMAN
    RTN3 HUMAN
ID
                  STANDARD;
                                       236 AA.
                                 PRT;
AC
    095197;
DT
    16-OCT-2001 (Rel. 40, Created)
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DE
    Reticulon protein 3 (Neuroendocrine-specific protein-like 2) (NSP-like
DE
    protein II) (NSPLII).
GN
    RTN3 OR NSPL2.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RC
    TISSUE=Retina;
    MEDLINE=99265974; PubMed=10331947;
RX
RA
    Moreira E.F., Jaworski C.J., Rodriguez I.R.;
RT
    "Cloning of a novel member of the reticulon gene family (RTN3): gene
    structure and chromosomal localization to 11q13.";
RT
RL
    Genomics 58:73-81(1999).
RN
    [2]
RP
    SEQUENCE FROM N.A.
    Huang X., Zhou Y., Du G., Yuan J., Qiang B.;
RA
RT
    "Cloning and expression analysis of a cDNA encoding a novel
RT
    neuroendocrine-specific protein-like protein 1: NSPL1.";
    Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [3]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Brain, Eye, and Lymph;
RX
    MEDLINE=22388257; PubMed=12477932;
RA
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
```

```
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RТ
     human and mouse cDNA sequences.";
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum (Potential).
CC
     -!- TISSUE SPECIFICITY: WIDELY EXPRESSED WITH HIGHEST EXPRESSION IN
CC
        BRAIN. THREE TIMES MORE ABUNDANT IN MACULA THAN IN PERIPHERAL
CC
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
     ______
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     EMBL; AF059524; AAC99319.1; -.
DR
DR
     EMBL; AF059529; AAD20951.1; -.
DR
     EMBL; AF059525; AAD20951.1; JOINED.
DR
     EMBL; AF059526; AAD20951.1; JOINED.
DR
     EMBL; AF059527; AAD20951.1; JOINED.
DR
     EMBL; AF059528; AAD20951.1; JOINED.
DR
     EMBL; AF119297; AAD26810.1; -.
DR
     EMBL; BC000634; AAH00634.1; -.
    EMBL; BC010556; AAH10556.1; -.
DR
DR
    EMBL; BC011394; AAH11394.1; -.
    EMBL; BC022993; AAH22993.1; -.
DR
DR
    Genew; HGNC:10469; RTN3.
    MIM; 604249; -.
DR
DR
    GO; GO:0005615; C:extracellular space; TAS.
DR
     InterPro; IPR003388; Reticulon.
     Pfam; PF02453; Reticulon; 1.
DR
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Transmembrane; Endoplasmic reticulum.
FT
    TRANSMEM
                 68
                        88
                                 POTENTIAL.
FT
    TRANSMEM
                177
                       197
                                 POTENTIAL.
FT
    DOMAIN
                 48
                       236
                                 RETICULON.
SQ
    SEQUENCE
               236 AA; 25609 MW; DDC6A4544ABCDFB7 CRC64;
  Query Match
                         67.1%; Score 624.5; DB 1;
                                                      Length 236;
  Best Local Similarity
                         60.5%; Pred. No. 3.9e-46;
 Matches 115; Conservative 39; Mismatches
                                                 35;
                                                      Indels
                                                                1;
                                                                            1;
                                                                    Gaps
```

Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA

```
1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qy
             47 AVHDLIFWRDVKKTGFVFGTTĹIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQA 106
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy.
             Db
         107 VQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHINRALKLIIRLFLVEDLVDSLKLAV 166
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
              | : |||||
Db
         167 FMWLMTYVGAVFNGITLLILAELLIFSVPIVYEKYKTQIDHYVGIARDQTKSIVEKIQAK 226
         181 IPGL-KRKAE 189
Qу
             : | | : | | |
Db
         227 LPGIAKKKAE 236
RESULT 7
RTN3 MOUSE
    RTN3 MOUSE
                   STANDARD;
                                 PRT;
                                        237 AA.
AC
    09ES97;
    16-OCT-2001 (Rel. 40, Created)
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DΤ
DE
    Reticulon protein 3.
GN
    RTN3.
    Mus musculus (Mouse).
OS
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Huang X., Zhou Y., Qiang H., Yuan J., Qiang B.;
RT
    "Cloning and expression profile of a novel mouse cDNA encoding a human
RT
    RTN3 homolog.";
RL
    Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Eye;
RX
    MEDLINE=22388257; PubMed=12477932;
RA
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
    Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
```

```
Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
    "Generation and initial analysis of more than 15,000 full-length
RT
    human and mouse cDNA sequences.";
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
CC
        reticulum (Potential).
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
    EMBL; AF195940; AAG31360.1; -.
DR
    EMBL; BC014697; AAH14697.1; -.
DR
    MGD; MGI:1339970; Rtn3.
DR
    InterPro; IPR003388; Reticulon.
DR
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Transmembrane; Endoplasmic reticulum.
    TRANSMEM
               69
                      89
                               POTENTIAL.
FT
    TRANSMEM
               167
                      187
                               POTENTIAL.
FT
    DOMAIN
               49
                      237
                               RETICULON.
              237 AA; 25428 MW; EB60A0A7AC45F0DE CRC64;
    SEQUENCE
SO
 Query Match
                       67.0%; Score 623.5; DB 1;
  Best Local Similarity 60.5%; Pred. No. 4.7e-46;
 Matches 115; Conservative 39; Mismatches 35; Indels
                                                            1; Gaps
                                                                       1;
           1 SVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 60
Qγ
             48 AVHDLIFWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRVYKSVIQA 107
Db
          61 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAV 120
Qy
             108 VQKSEEGHPFKAYLDVDITLSSEAFHNYMNAAMVHVNKALKLIIRLFLVEDLVDSLKLAV 167
Db
         121 LMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAK 180
Qу
              168 FMWLMTYVGAVFNGITLLILAELLVFSVPIVYEKYKTQIDHYVGIARDQTKSIVEKIQAK 227
Db
Qy
         181 IPGL-KRKAE 189
             : | | : | : | |
         228 LPGIAKKKAE 237
Dh
RESULT 8
RTN2 HUMAN
    RTN2 HUMAN
                  STANDARD;
                               PRT;
                                      545 AA.
    075298; 060509;
AC
    16-OCT-2001 (Rel. 40, Created)
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
    Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
```

```
protein 1) (NSPLI).
DE
GN
     RTN2 OR NSPL1.
OS
     Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RP
     TISSUE=Lung carcinoma;
RC
     MEDLINE=98360096; PubMed=9693037;
RX
     Roebroek A.J.M., Contreras B., Pauli I.G.L., Van de Ven W.J.M.;
RA
     "cDNA cloning, genomic organization, and expression of the human RTN2
RT
     gene, a member of a gene family encoding reticulons.";
RT
     Genomics 51:98-106(1998).
RL
RN
     SEQUENCE OF 108-545 FROM N.A. (ISOFORM RTN2-B).
RP
RC
     TISSUE=Brain;
     MEDLINE=98191726; PubMed=9530622;
RX
     Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
RA
     "Molecular cloning of a novel mouse gene with predominant muscle and
RT
     neural expression.";
RT
     Mamm. Genome 9:274-282(1998).
RL
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum (Potential).
CC
CC
     -!- ALTERNATIVE PRODUCTS:
         Event=Alternative splicing; Named isoforms=2;
CC
CC
         Name=RTN2-A;
           IsoId=075298-1; Sequence=Displayed;
CC
           Note=Isoform RTN2-C is produced by alternative initiation at
CC
CC
           Met-341 of isoform RTN2-A;
CC
         Name=RTN2-B;
CC
           IsoId=075298-2; Sequence=VSP 005649;
         Event=Alternative initiation;
CC
CC
           Comment=2 isoforms, RTN2-A (shown here) and RTN2-C, are produced
           by alternative initiation at Met-1 and Met-341;
CC
     -!- TISSUE SPECIFICITY: ISOFORM RTN2-C IS HIGHLY EXPRESSED IN SKELETAL
CC
         MUSCLE.
CC
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     EMBL; AF004222; AAC32542.1; -.
DR
     EMBL; AF004223; AAC32543.1; -.
DR
     EMBL; AF004224; AAC32544.1; -.
DR
DR
     EMBL; AF038540; AAC14910.1; -.
DR
     Genew; HGNC:10468; RTN2.
DR
     MIM; 603183; -.
     GO; GO:0030176; C:integral to endoplasmic reticulum membrane; NAS.
DR
     GO; GO:0004871; F:signal transducer activity; NAS.
DR
     GO; GO:0007165; P:signal transduction; NAS.
DR
     InterPro; IPR003388; Reticulon.
DR
```

```
Pfam; PF02453; Reticulon; 1.
     PROSITE; PS50845; RETICULON; 1.
DR
KW
     Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
     Alternative initiation.
FT
    CHAIN
                 1
                       545
                                RETICULON PROTEIN 2, ISOFORM RTN2-A.
FT
     CHAIN
                341
                       545
                                RETICULON PROTEIN 2, ISOFORM RTN2-C.
    INIT MET
FT
                341
                       341
                                FOR ISOFORM RTN2-C.
    TRANSMEM
FT
                368
                       388
                                POTENTIAL.
FT
    TRANSMEM
                463
                       483
                                POTENTIAL.
FT
    DOMAIN
                345
                       545
                                RETICULON.
FT
    VARSPLIC
                272
                                Missing (in isoform RTN2-B).
                       344
                                /FTId=VSP 005649.
FT
                       59263 MW; 971FD2F909E1E9E6 CRC64;
SQ
    SEQUENCE
               545 AA;
 Query Match
                         50.9%; Score 473.5; DB 1; Length 545;
 Best Local Similarity
                        47.3%; Pred. No. 6.3e-33;
           95; Conservative 37; Mismatches
 Matches
                                                   Indels
                                                56;
           2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
Qу
             Db
         345 VADLLYWKDTRTSGVVFTGLMVSLLCLLHFSIVSVAAHLALLLLCGTISLRVYRKVLQAV 404
         .62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
Qу
              405 HRGDGANPFQAYLDVDLTLTREQTERLSHQITSRVVSAATQLRHFFLVEDLVDSLKLALL 464
Db
         122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
Qу
              :: |:|||:||:||:|::|::|::|::|:||
Db
         465 FYILTFVGAIFNGLTLLILGVIGLFTIPLLYRQHQAQIDQYVGLVTNQLSHIKAKIRAKI 524
Qу
         182 PGL-----KRKAE 189
             11
                            1 111
Db
         525 PGTGALASAAAAVSGSKAKAE 545
RESULT 9
RTN2 MOUSE
    RTN2 MOUSE
TD
                   STANDARD;
                                 PRT;
                                        471 AA.
AC
    070622; 070620;
DT
    16-OCT-2001 (Rel. 40, Created)
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
DE
    Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
DE
    protein 1) (NSPLI).
    RTN2 OR NSPL1.
GN
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
ΟX
    NCBI TaxID=10090;
RN
     [1]
    SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RP
RC
    STRAIN=FVB/N, and 129/Sv; TISSUE=Cerebellum, and Skeletal muscle;
RX
    MEDLINE=98191726; PubMed=9530622;
RA
    Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
RT
     "Molecular cloning of a novel mouse gene with predominant muscle and
RT
    neural expression.";
RI.
    Mamm. Genome 9:274-282(1998).
```

DR

```
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RC
     TISSUE=Retina;
RX
     MEDLINE=22388257; PubMed=12477932;
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RΑ
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
     human and mouse cDNA sequences.";
RT
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- SUBCELLULAR LOCATION: Membrane-bound. Endoplasmic reticulum
CC
         (Potential).
CC
     -!- ALTERNATIVE PRODUCTS:
         Event=Alternative splicing; Named isoforms=2;
CC
        Name=1; Synonyms=Brain;
CC
CC
          IsoId=070622-1; Sequence=Displayed;
CC
        Name=2; Synonyms=Muscle;
          IsoId=070622-2; Sequence=VSP 005650, VSP 005651;
CC
     -!- TISSUE SPECIFICITY: Expressed predominantly in neural and muscular
CC
CC
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
     CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
    or send an email to license@isb-sib.ch).
CC
     __________
DR
     EMBL; AF038537; AAC14906.1; -.
DR
    EMBL; AF038537; AAC14907.1; -.
DR
    EMBL; AF038538; AAC14908.1; -.
DR
    EMBL; AF038539; AAC14909.1; -.
    EMBL; AF093624; AAD13195.1; -.
DR
DR
    EMBL; BC031370; AAH31370.1; -.
DR
    MGD; MGI:107612; Rtn2.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
FT
    TRANSMEM
                295
                       315
                                POTENTIAL.
FT
    DOMAIN
                272
                       471
                                 RETICULON.
```

```
FΤ
     VARSPLIC
                       267
                                 Missing (in isoform 2).
FT
                                 /FTId=VSP 005650.
FT
     VARSPLIC
                 268
                       271
                                 PLLL -> MGSK (in isoform 2).
FT
                                 /FTId=VSP 005651.
SQ
     SEQUENCE
                471 AA;
                        51346 MW; 9BBD8F372CF63AD3 CRC64;
  Query Match
                         50.8%;
                                 Score 473; DB 1; Length 471;
  Best Local Similarity
                         47.0%; Pred. No. 6e-33;
           94; Conservative
                               38; Mismatches
                                                56;
                                                     Indels
                                                                  Gaps
                                                                          1;
Qу
            2 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 61
              Db
          272 VADLLYWKDTRTSGAVFTGLMASLLCLLHFSIVSVAAHLALLGLCATISLRVYRKVLQAV 331
Qу
           62 QKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLKFAVL 121
               Db
          332 HRGDGTNPFQAYLDMDLTLTREQTERLSQQIASHVVSTATQLRHFFLVEDLVDSLKLALL 391
∠Qy
          122 MWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAKIQAKI 181
               :: |:||:||:|||:||::||::||::||::||::||
                                                          :
Db
          392 FYILTFVGAIFNGLTLVILGVVALFTVPLLYRQHQAQIDQYVGLVTNQLSHIKAKIRAKI 451
Qу
          182 PGL-----KRKAE 189
              11
                            \perp
Db
          452 PGTGTLAPTASVSGSKAKAE 471
RESULT 10
AR61 DROME
     AR61 DROME
                   STANDARD;
                                  PRT:
                                        197 AA.
AC
     O9VES1;
DT
     16-OCT-2001 (Rel. 40, Created)
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
     10-OCT-2003 (Rel. 42, Last annotation update)
DT
DE
     ARL-6 interacting protein-1 homolog.
GN
     CG10326.
OS
     Drosophila melanogaster (Fruit fly).
     Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC
OC
     Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC
     Ephydroidea; Drosophilidae; Drosophila.
OX
     NCBI TaxID=7227;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=Berkeley;
RX
     MEDLINE=20196006; PubMed=10731132;
     Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA
RA
     Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA
     George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
     Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA
     Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA
RA
     Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA
     Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA
     Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA
     Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
     Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA
RA
     Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA
     Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
```

```
Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RΑ
     Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA
     Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA
     Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA
     Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,
RA
     Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA
     Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA
RA.
     Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA
     Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,
RA
     Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA
    Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA
    Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA
    Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA
     Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
     Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA
RA
     Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA
     Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA
     Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA
     Wang Z .- Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA
     Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA
     Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
     Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA
RA
     Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
     "The genome sequence of Drosophila melanogaster.";
RT
     Science 287:2185-2195(2000).
RT.
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein (Potential).
     -!- SIMILARITY: Belongs to the ARL6ip family.
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
CC
     the European Bioinformatics Institute. There are no restrictions on
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     EMBL; AE003714; AAF55348.1; -.
DR
     FlyBase; FBqn0038453; CG10326.
DR
KW
     Transmembrane.
FT
     TRANSMEM
                  43
                         63
                                  POTENTIAL.
FT
     TRANSMEM
                  64
                         84
                                  POTENTIAL.
FT
     TRANSMEM
                 129
                        149
                                  POTENTIAL.
                 150
                        170
                                  POTENTIAL.
FT
     TRANSMEM
               197 AA; 22233 MW; 7D35ABAD18CE272E CRC64;
SQ
     SEQUENCE
                          10.0%; Score 93.5; DB 1; Length 197;
  Query Match
                         23.9%; Pred. No. 0.45;
  Best Local Similarity
  Matches
           47; Conservative 25; Mismatches
                                                  82; Indels
                                                                43; Gaps
            5 LLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFR-----IYKGV 57
Qу
                                | | | | : : : |
                                                  | ::|: :::
                        Db
           32 VLTWEKQYYAGVVFGVISCLYLVLWYLDLSLITLLSLLGVISILLNYAFPMVSRLIFGGV 91
           58 IQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDSLK 117
Qу
                                  1: 11 1
                                                          1:
                                                                | :| ||
           92 ---NWDGDQEAKFEDVCGQVCAVKGSLVVWY-----EYLFNERKSTVFV--IVMSLG 138
Db
```

de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,

RA

```
118 FAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMAK- 176
Qу
                        :||: | | |: || : : |
                                                             11 | | | : : : : :
                 : 1
          139 LLAMAW----IGAIINNLLLMYLATLLILMWP------GLQNKDIFKAITQR 180
Db
          177 ----IQAKIPGLKRKAE 189
Qу
                  1 11
                         111:
          181 ASKIINEKIQCGKRKLQ 197
Db
RESULT 11
NPC1 HUMAN
    NPC1 HUMAN
                    STANDARD;
                                   PRT;
                                         1278 AA.
    015118; 09P130;
AC
     30-MAY-2000 (Rel. 39, Created)
DT
     30-MAY-2000 (Rel. 39, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Niemann-Pick C1 protein precursor.
DE
    NPC1.
GN
    Homo sapiens (Human).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
     [1]
     SEQUENCE FROM N.A., AND VARIANTS NPC1.
RP
    MEDLINE=97362323; PubMed=9211849;
RX
RA
    Carstea E.D., Morris J.A., Coleman K.G., Loftus S.K., Zhang D.,
     Cummings C., Gu J., Rosenfeld M.A., Pavan W.J., Krizman D.B.,
RA
    Nagle J., Polymeropoulos M.H., Sturley S.L., Ioannou Y.A.,
RA
     Higgins M.E., Comly M., Cooney A., Brown A., Kaneski C.R.,
RA
RA
     Blanchette-Mackie E.J., Dwyer N.K., Neufeld E.B., Chang T.-Y.,
    Liscum L., Strauss J.F. III, Ohno K., Zeigler M., Carmi R., Sokol J.,
RA
    Markie D., O'Neill R.R., van Diggelen O.P., Elleder M.,
RA
     Patterson M.C., Brady R.O., Vanier M.T., Pentchev P.G., Tagle D.A.;
RA
RT
     "Niemann-Pick C1 disease gene: homology to mediators of cholesterol
RT
     homeostasis.";
     Science 277:228-231(1997).
RL
RN
RP
     SEQUENCE FROM N.A., AND VARIANTS.
RX
    MEDLINE=99355599; PubMed=10425213;
    Morris J.A., Zhang D., Coleman K.G., Nagle J., Pentchev P.G.,
RA
RA
     Carstea E.D.;
RT
     "The genomic organization and polymorphism analysis of the human
RT
     Niemann-Pick C1 gene.";
RL
     Biochem. Biophys. Res. Commun. 261:493-498(1999).
RN
     [3]
RP
     SEQUENCE FROM N.A.
    MEDLINE=21623216; PubMed=11754101;
RX
     Bauer P., Knoblich R., Bauer C., Finckh U., Hufen A., Kropp J.,
RA
     Braun S., Kustermann-Kuhn B., Schmidt D., Harzer K., Rolfs A.;
RA
     "NPC1: Complete genomic sequence, mutation analysis, and
RT
RT
     characterization of haplotypes.";
     Hum. Mutat. 19:30-38(2002).
RL
RN
     [4]
RP
     CHARACTERIZATION.
RX
     MEDLINE=99128318; PubMed=9927649;
     Watari H., Blanchette-Mackie E.J., Dwyer N.K., Glick J.M., Patel S.,
RA
```

```
Neufeld E.B., Brady R.O., Pentchev P.G., Strauss J.F. III;
RA
    "Niemann-Pick C1 protein: obligatory roles for N-terminal domains and
RT
    lysosomal targeting in cholesterol mobilization.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 96:805-810(1999).
RL
RN
    VARIANT NPD TRP-992.
RP
    MEDLINE=98299797; PubMed=9634529;
RX
    Greer W.L., Riddell D.C., Gillan T.L., Girouard G.S., Sparrow S.M.,
RA
    Byers D.M., Dobson M.J., Neumann P.E.;
RA
     "The Nova Scotia (type D) form of Niemann-Pick disease is caused by a
RT
    G3097-->T transversion in NPC1.";
RT
    Am. J. Hum. Genet. 63:52-54(1998).
RL
RN
    VARIANTS NPC1 GLN-934; LEU-940; ASN-948; LEU-954; TRP-992; ALA-1007;
RP
     THR-1061 AND VAL-1213.
RP
    MEDLINE=99452586; PubMed=10521290;
RX
     Greer W.L., Dobson M.J., Girouard G.S., Byers D.M., Riddell D.C.,
RA
    Neumann P.E.;
RA
     "Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich
RT
     domain.";
RT
     Am. J. Hum. Genet. 65:1252-1260(1999).
RL
RN
     [7]
     VARIANT NPC1 THR-1061.
RP
    MEDLINE=99452593; PubMed=10521297;
RX
    Millat G., Marcais C., Rafi M.A., Yamamoto T., Morris J.A.,
RA
     Pentchev P.G., Ohno K., Wenger D.A., Vanier M.T.;
RA
     "Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant
RT
     allele in patients of Western European descent and correlates with a
RT
     classic juvenile phenotype.";
RT
     Am. J. Hum. Genet. 65:1321-1329(1999).
RL
RN
     VARIANTS NPC1, AND VARIANTS ARG-215; VAL-858 AND GLN-1266.
RP
RX
     MEDLINE=99408226; PubMed=10480349;
     Yamamoto T., Nanba E., Ninomiya H., Higaki K., Taniguchi M., Zhang H.,
RA
     Akaboshi S., Watanabe Y., Takeshima T., Inui K., Okada S., Tanaka A.,
RA
     Sakuragawa N., Millat G., Vanier M.T., Morris J.A., Pentchev P.G.,
RA
RA
     Ohno K.;
     "NPC1 gene mutations in Japanese patients with Niemann-Pick disease
RT
RT
     type C.";
     Hum. Genet. 105:10-16(1999).
RL
RN
     [9]
     VARIANTS NPC1 GLN-958 AND ALA-1007.
RP
     MEDLINE=21313111; PubMed=11349231;
RX
     Sun X., Marks D.L., Park W.D., Wheatley C.L., Puri V., O'Brien J.F.,
RA
     Kraft D.L., Lundquist P.A., Patterson M.C., Pagano R.E., Snow K.;
RA
     "Niemann-Pick C variant detection by altered sphingolipid trafficking
RT
     and correlation with mutations within a specific domain of NPC1.";
RT
     Am. J. Hum. Genet. 68:1361-1372(2001).
RL
RN
     VARIANTS NPC1 ALA-378; MET-950; ARG-992 AND THR-1061.
RP
     MEDLINE=21313105; PubMed=113333381;
RX
     Millat G., Marcais C., Tomasetto C., Chikh K., Fensom A.H., Harzer K.,
RA
RA
     Wenger D.A., Ohno K., Vanier M.T.;
     "Niemann-Pick C1 disease: correlations between NPC1 mutations, levels
RT
     of NPC1 protein, and phenotypes emphasize the functional significance
RT
     of the putative sterol-sensing domain and of the cysteine-rich
RT
RT
     luminal loop.";
```

```
Am. J. Hum. Genet. 68:1373-1385(2001).
RL
RN
    [11]
    VARIANTS NPC1 TYR-177; CYS-978 AND VAL-1035.
RP
    MEDLINE=21372069; PubMed=11479732;
RX
    Ribeiro I., Marcao A., Amaral O., Sa Miranda M.C., Vanier M.T.,
RA
RA
    "Niemann-Pick type C disease: NPC1 mutations associated with severe
RT
    and mild cellular cholesterol trafficking alterations.";
RT
    Hum. Genet. 109:24-32(2001).
RL
    -!- FUNCTION: Involved in the intracellular trafficking of
CC
CC
        cholesterol. May play a role in vesicular trafficking in glia, a
        process that may be crucial for maintaining the structural and
CC
        functional integrity of nerve terminals.
CC
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Found in late
CC
CC
        endosomes and lysosomes.
    -!- DOMAIN: A cysteine-rich N-terminal domain and a C-terminal domain
CC
        containing a di-leucine motif necessary for lysosomal targeting
CC
        are critical for mobilization of cholesterol from lysosomes.
CC
CC
    -!- PTM: Glycosylated.
    -!- DISEASE: Defects in NPC1 are the cause of Niemann-Pick disease
CC
        type C1 (NPC1) [MIM:257220]. NPC1 is an autosomal recessive lipid
CC
        storage disorder, which affects particularly the brain, liver and
CC
        spleen, and which is characterized by lysosomal accumulation of
CC
        low density lipoprotein derived cholesterol. Clinical features
CC
        include variable hepatosplenomegaly and severe progressive
CC
        neurological dysfunction such as ataxia, dystonia and dementia.
CC
        The age of onset can vary from infancy to late adulthood.
CC
     -!- DISEASE: Defects in NPC1 are the cause of Niemann-Pick disease
CC
        type D (NPD) [MIM:257250]; also known as Niemann-Pick disease
CC
        without sphingomyelinase deficiency, or Nova Scotian type. Because
CC
        of evidence from biochemical changes, lack of complementation, and
CC
        linkage mapping to the same chromosome site, NPD and NPC1 are
CC
         considered to be allelic disorders.
CC
     -!- SIMILARITY: Belongs to the patched family.
CC
     -!- SIMILARITY: Contains 1 sterol-sensing (SSD) domain.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     _____
CC
     EMBL; AF002020; AAB63982.1; -.
DR
     EMBL; AF157379; AAD48006.1; -.
DR
DR
     EMBL; AF157365; AAD48006.1; JOINED.
     EMBL; AF157366; AAD48006.1; JOINED.
DR
     EMBL; AF157367; AAD48006.1; JOINED.
DR
     EMBL; AF157368; AAD48006.1; JOINED.
DR
     EMBL; AF157369; AAD48006.1; JOINED.
DR
     EMBL; AF157370; AAD48006.1; JOINED.
DR
     EMBL; AF157371; AAD48006.1; JOINED.
DR
     EMBL; AF157372; AAD48006.1; JOINED.
DR
     EMBL: AF157373; AAD48006.1; JOINED.
DR
     EMBL; AF157374; AAD48006.1; JOINED.
DR
     EMBL; AF157375; AAD48006.1; JOINED.
DR
```

```
EMBL; AF157376; AAD48006.1; JOINED.
DR
     EMBL; AF157377; AAD48006.1; JOINED.
DR
     EMBL; AF157378; AAD48006.1; JOINED.
DR
DR
     EMBL; AF338230; AAK25791.1; -.
DR
     EMBL; AF123046; AAF28875.1; -.
     EMBL; AF123045; AAF28875.1; JOINED.
DR
     Genew; HGNC:7897; NPC1.
DR
DR
    MIM; 607623; -.
    MIM; 257220; -.
DR
    MIM; 257250; -.
DR
DR
     GO; GO:0016021; C:integral to membrane; TAS.
DR
     GO; GO:0005764; C:lysosome; TAS.
DR
     GO; GO:0005624; C:membrane fraction; TAS.
DR
     GO; GO:0005478; F:intracellular transporter activity; TAS.
DR
     GO; GO:0015248; F:sterol transporter activity; TAS.
DR
     GO; GO:0004888; F:transmembrane receptor activity; TAS.
     InterPro; IPR004765; NP C type.
DR
DR
     InterPro; IPR003392; Patched.
DR
     InterPro; IPR000731; SSD 5TM.
DR
     Pfam; PF02460; Patched; 1.
     TIGRFAMs; TIGR00917; 2A060601; 1.
DR
DR
     PROSITE; PS50156; SSD; 1.
KW
     Signal; Glycoprotein; Transmembrane; Lysosome; Polymorphism;
ΚW
     Disease mutation.
FT
     SIGNAL
                   1
                         22
                                  POTENTIAL.
FT
     CHAIN
                  23
                       1278
                                  NIEMANN-PICK C1 PROTEIN.
FT
     TRANSMEM
                 270
                        290
                                   POTENTIAL.
FT
     TRANSMEM
                 351
                        371
                                   POTENTIAL.
FT
     TRANSMEM
                 622
                        642
                                  POTENTIAL.
FT
     TRANSMEM
                 655
                        675
                                  POTENTIAL.
FT
     TRANSMEM
                 678
                        698
                                   POTENTIAL.
FT
     TRANSMEM
                 760
                        780
                                   POTENTIAL.
                        853
FT
     TRANSMEM
                 833
                                 POTENTIAL.
FT
     TRANSMEM
                1099
                       1119
                                   POTENTIAL.
FT
     TRANSMEM
                1125
                       1145
                                  POTENTIAL.
                       1216
FT
     TRANSMEM
                1196
                                  POTENTIAL.
FT
                1228
                       1248
     TRANSMEM
                                  POTENTIAL.
                        259
FT
     DOMAIN
                 249
                                  POLY-PRO.
FT
     DOMAIN
                 620
                        785
                                  SSD.
FT
     SITE
                1275
                       1278
                                  DI-LEUCINE MOTIF.
     CARBOHYD
FT
                  70
                         70
                                  N-LINKED (GLCNAC. . .) (POTENTIAL).
                                  Score 88.5; DB 1; Length 1278;
  Query Match
                           9.5%;
  Best Local Similarity
                          25.7%;
                                  Pred. No. 8.1;
                                25; Mismatches
                                                                               7:
            39; Conservative
                                                   51;
                                                        Indels
                                                                  37;
           46 SVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRR 105
Qy
                       :::::
                                             598 NLTISFTAERSIEDELNRESDSDVF-----TVVISYAIMFLYISLALGH----IKSCRR 647
Db
          106 LFLVDD--
                            --LVDSLKFAVLMWVFTYVGALFNGLTLLILALI--
Qy
                             1:
                                     | : ||:|:|
                                                     111:::::1
              1 111
          648 L-LVDSKVSLGIAGILIVLSSVACSLGVFSYIGL---PLTLIVIEVIPFLVLAVGVDNIF 703
Db
          147 SVPVIYERHO----AOIDHYLGLANKNVKDAM 174
Qy.
                   1:1:
                             :1 11
                                          | :|
Db
          704 ILVQAYQRDERLQGETLDQQLGRVLGEVAPSM 735
```

```
RESULT 12
ACH5 HUMAN
     ACH5 HUMAN
ID
                    STANDARD;
                                    PRT;
                                           468 AA.
AC
     P30532; Q15824; Q99554;
     01-APR-1993 (Rel. 25, Created)
DT
DT
     01-NOV-1997 (Rel. 35, Last sequence update)
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Neuronal acetylcholine receptor protein, alpha-5 chain precursor.
DE
GN
     CHRNA5 OR NACHRA5.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI TaxID=9606;
RN
     [1]
     SEQUENCE FROM N.A.
RΡ
RX
     MEDLINE=92179225; PubMed=1542648;
RA
     Chini B., Clementi F., Hukovic N., Sher E.;
RT
     "Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic
RT
     receptor subunit gene are expressed in neuronal and nonneuronal human
RT
     cell lines.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 89:1572-1576(1992).
RN
     [2]
RΡ
     SEQUENCE FROM N.A.
RX
     MEDLINE=97062879; PubMed=8906617;
     Elliott K.J., Ellis S.B., Berckhan K.J., Urrutia A.,
RA
RA
     Chavez-Noriega L.E., Johnson E.C., Velicelebi G., Harpold M.M.;
RT.
     "Comparative structure of human neuronal alpha 2-alpha 7 and beta
RT
     2-beta 4 nicotinic acetylcholine receptor subunits and functional
RT
     expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and
RT
     beta 4 subunits.";
     J. Mol. Neurosci. 7:217-228(1996).
RL
RN
RP
     SEQUENCE FROM N.A.
RX
     MEDLINE=97162233; PubMed=9009220;
RA
     Groot Kormelink P.J., Luyten W.H.M.L.;
     "Cloning and sequence of full-length cDNAs encoding the human neuronal
RT
RT
     nicotinic acetylcholine receptor (nAChR) subunits beta3 and beta4 and
RT
     expression of seven nAChR subunits in the human neuroblastoma cell
RT
     line SH-SY5Y and/or IMR-32.";
     FEBS Lett. 400:309-314(1997).
RL
RN
RP
     SEQUENCE FROM N.A.
RA
     Duga S., Solda G., Asselta R., Bonati M.T., Dalpra L., Malcovati M.,
RA
     Tenchini M.L.;
RT
     "Characterization of the genomic structure of human nicotinic
RT
     acetylcholine receptor CHRNA5/A3/B4 gene cluster: identification of
RT
     two novel introns in the 3' untranslated region of CHRNA3 and of a
RT
     tail-to-tail overlap between CHRNA3 and CHRNA5.";
RL
     Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN
     [5]
RP
     SEQUENCE FROM N.A.
RC
     TISSUE=Eye;
RX
     MEDLINE=22388257; PubMed=12477932;
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
```

```
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
    human and mouse cDNA sequences.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
     -!- FUNCTION: After binding acetylcholine, the AChR responds by an
CC
        extensive change in conformation that affects all subunits and
CC
        leads to opening of an ion-conducting channel across the plasma
CC
CC
        membrane.
     -!- SUBUNIT: Neuronal AChR seems to be composed of two different type
CC
        of subunits: alpha and non-alpha (betA).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC
     -!- SIMILARITY: Belongs to the ligand-gated ionic channel family.
CC
     _____
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
     ______
CC
DR
     EMBL; M83712; AAA58357.1; -.
DR
     EMBL; U62434; AAB40112.1; -.
DR
     EMBL; Y08419; CAA69696.1; -.
     EMBL; AJ306481; CAC34820.1; -.
DR
     EMBL; AJ306482; CAC34820.1; JOINED.
DR
     EMBL; AJ306483; CAC34820.1; JOINED.
DR
     EMBL; AJ306484; CAC34820.1; JOINED.
DR
     EMBL; AJ306485; CAC34820.1; JOINED.
DR
     EMBL; AJ306486; CAC34820.1; JOINED.
DR
     EMBL; BC033639; AAH33639.1; -.
DR
DR
     PIR; A38223; A38223.
DR
     Genew; HGNC:1959; CHRNA5.
DR
     MIM; 118505; -.
     InterPro; IPR006029; Neu channel memb.
DR
DR
     InterPro; IPR006202; Neur chan LBD.
     InterPro; IPR006201; Neur channel.
DR
     Pfam; PF02931; Neur chan LBD; 1.
DR
     Pfam; PF02932; Neur_chan_memb; 1.
DR
DR
     PRINTS; PR00252; NRIONCHANNEL.
DR
     TIGRFAMs; TIGR00860; LIC; 1.
     PROSITE; PS00236; NEUROTR ION CHANNEL; 1.
DR
KW
     Receptor; Postsynaptic membrane; Ionic channel; Glycoprotein; Signal;
```

Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA

```
Transmembrane; Multigene family.
KW
                                POTENTIAL.
                1
                      22
FT
    SIGNAL
                                NEURONAL ACETYLCHOLINE RECEPTOR PROTEIN,
                      468
                23
FT
    CHAIN
                                ALPHA-5 CHAIN.
FT
                                EXTRACELLULAR.
                23
                      249
    DOMAIN
FT
               250
                      274
                                POTENTIAL.
FT
    TRANSMEM
                      299
                                POTENTIAL.
    TRANSMEM
               282
FT
                316
                      337
                                POTENTIAL.
    TRANSMEM
FT
                338
                      429
                                CYTOPLASMIC.
   DOMAIN
FT
                                POTENTIAL.
                      448
                430
FT
    TRANSMEM
                                BY SIMILARITY.
                      184
                170
FT
    DISULFID
                                ASSOCIATED WITH RECEPTOR ACTIVATION
                      235
    DISULFID
               234
FT
                                (BY SIMILARITY).
FT
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
                      155
               155
FT
    CARBOHYD
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
                183
                      183
FT
    CARBOHYD
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
                229
                      229
    CARBOHYD
FT
                                RCGLAGAAGGAQ -> ALRSSRARRAAR (IN REF. 1).
               23
                      34
FT
    CONFLICT
                               V \rightarrow S (IN REF. 1).
                      128
                128
FT
    CONFLICT
                               C \rightarrow S (IN REF. 1).
                      365
                365
FT
    CONFLICT
                                D \rightarrow N (IN REF. 2 AND 4).
                      398
               398
FΤ
    CONFLICT
                              R \rightarrow T (IN REF. 1).
                     405
    CONFLICT
               405
FT
               468 AA; 53054 MW; 7FE91A2E362289C0 CRC64;
     SEQUENCE
SQ
  Query Match 9.5%; Score 88; DB 1; Length 468; Best Local Similarity 20.9%; Pred. No. 3.2;
  Matches 40; Conservative 29; Mismatches
                                                                         5;
                                               66; Indels
                                                            56; Gaps
          24 LLLSLTVFSIV-----SVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPF 70
Qу
           288 VLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNA 347
Db
          71 RAYL-----ESEVAISEELVQKYSNSALGHVNCTIKEL 103
Qу
                       |:| : :|| : :;
              1 1
          348 MAPLVRKIFLHTLPKLLCMRSHVDRYFTQKEETESGSGPKSSRNTLEAALDSIRYITRHI 407
Db
         104 RRLFLVDDLVDSLKF-----AVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQA 157
Qу
             408 MKENDVREVVEDWKFIAQVLDRMFLWTFLFVS-----IVGSLGLF-VPVIYKWANI 457
Db
          158 QIDHYLGLANK 168
Qy
             | ::| |||
          458 LIPVHIGNANK 468
Db
RESULT 13
YBZ7 YEAST
                   STANDARD;
                                 PRT:
                                        296 AA.
     YBZ7 YEAST
ID
     P38279;
AC
     01-OCT-1994 (Rel. 30, Created)
DT
     01-OCT-1994 (Rel. 30, Last sequence update)
DT
     01-OCT-1996 (Rel. 34, Last annotation update)
DT
     Hypothetical 33.5 kDa protein in MRPS9-YSW1 intergenic region.
DE
GN
     YBR147W OR YBR1124.
     Saccharomyces cerevisiae (Baker's yeast).
OS
     Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC
     Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OC
     NCBI TaxID=4932;
OX
```

```
RN
    [1]
    SEQUENCE FROM N.A.
RP
RC
    STRAIN=S288c;
    Entian K.-D., Koetter P., Rose M., Becker J., Grey M., Li Z.,
RA
    Niegemann E., Schenk-Groeninger R., Servos J., Wehner E.,
RA
    Wolter R., Brendel M., Bauer J., Braun H., Dern K., Duesterhus S.,
RA
    Gruenbein R., Hedges D., Kiesau P., Korol S., Krems B., Proft M.,
RA
    Siegers K., Baur A., Boles E., Miosga T.,
RA
    Schaaff-Gerstenschlaeger I., Zimmermann F.K.;
RA
    Submitted (AUG-1994) to the EMBL/GenBank/DDBJ databases.
RL
    -!- SUBCELLULAR LOCATION: Integral membrane protein (Potential).
CC
    -!- SIMILARITY: SOME, TO S.POMBE SPAC2E12.03C AND SPAC17C9.10.
CC
    _____
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
    EMBL; Z36016; CAA85105.1; -.
DR
    PIR; S46018; S46018.
DR
    GermOnline; 138690; -.
DR
    SGD; S0000351; YBR147W.
DR
    InterPro; IPR006603; CTNS.
DR
    Pfam; PF04193; PQ-loop; 2.
DR
    SMART; SM00679; CTNS; 2.
KW
    Hypothetical protein; Transmembrane.
                13
                       33
                                POTENTIAL.
\mathbf{FT}
    TRANSMEM
                 45
                       65
                                POTENTIAL.
FT
    TRANSMEM
    TRANSMEM
                 69
                       89
                                POTENTIAL.
FT
                164
                      184
                                POTENTIAL.
    TRANSMEM
FT
                200
                      220
                                POTENTIAL.
    TRANSMEM
FT
                      259
                                POTENTIAL.
                239
FT
    TRANSMEM
    TRANSMEM
                263
                      283
                                POTENTIAL.
FT
               296 AA; 33496 MW; 50D65896A1BAFB43 CRC64;
     SEQUENCE
SQ
                         9.4%; Score 87.5; DB 1; Length 296;
  Query Match
  Best Local Similarity 27.4%; Pred. No. 2.2;
           54; Conservative 25; Mismatches
                                               71;
                                                    Indels
                                                             47;
                                                                        11:
          17 VFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIY----KGVIQAIQKS-DEGH--- 68
Qy
             1 | | : | | ::: : | | | | | : |
                                              | | | ::| ::|: | |
          61 VMGAMMQNLLP---TMIILAAYYTLADLILLIQCMWYDKEKKSILQEVKKNVDPVHLPP 116
Db
          69 -----PFRAYLESEVAISEELVQKYSNSALGHVNCTIKELRRLFLVDDLVDS-- 115
Qу
                        1 1
                                 117 ANPINETVLQDVFNEYEPLLPRIEEEDSQSYSSLELGR-TIVVKE-RENFFNDFLIVSGV 174
Db
          116 LKFAVLMWVFTYVGALFNGLTLLILALISLFSVPVIYERHQAQIDHYLGLANKNVKDAMA 175
Qу
                 175 LIAGILSWYISYCSGLDNGIPKKKPAFEQI-NLP-----AQILGYL----SAIL 218
Db
          176 KIQAKIP----GLKRKA 188
Qу
              ::::
                        111:
          219 YLGSRIPQIVLNFKRKS 235
Db
```

```
RESULT 14
PRES RAT
                                    PRT;
                                           744 AA.
     PRES RAT
                    STANDARD;
     Q9EPH0; Q9ERC6;
AC
     28-FEB-2003 (Rel. 41, Created)
DT
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
DΤ
     10-OCT-2003 (Rel. 42, Last annotation update)
DE
     Prestin.
     SLC26A5 OR PRES.
GN
     Rattus norvegicus (Rat).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
     NCBI TaxID=10116;
RN
     [1]
RP
     SEQUENCE FROM N.A., AND TOPOLOGY.
RC
     TISSUE=Cochlea;
RX
     MEDLINE=21173705; PubMed=11274441;
     Ludwig J., Oliver D., Frank G., Kloecker N., Gummer A.W., Fakler B.;
RA
RT
     "Reciprocal electromechanical properties of rat prestin: The motor
RT
     molecule of rat outer hair cells.";
     Proc. Natl. Acad. Sci. U.S.A. 98:4178-4183(2001).
RL
RN
RP
     SEQUENCE OF 249-668 FROM N.A.
RC
     STRAIN=Spraque-Dawley;
     Beisel K.W., Nelson N.C., Beisel C.L., Delimont D.C., He D.Z.Z.,
RA
RA
     Fritzsch B.;
RT
     "Dynamic developmental expression of cochlear hair cell genes: prestin
RT
     and otoferlin.";
     Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE OF 1-20 FROM N.A.
RC
     STRAIN=Spraque-Dawley;
RA
     Weber T., Zimmermann U., Winter H., Mack A., Koepschall I.,
RA
     Rohbock K., Zenner H.P., Knipper M.;
     "Thyroid horomone is a critical determinant for the regulation of the
RT
RT
     cochlear motor protein prestin.";
RL
     Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN
     [4]
RP.
     TISSUE SPECIFICITY.
     MEDLINE=20574880; PubMed=11125015;
     Belyantseva I.A., Adler H.J., Curi R., Frolenkov G.I., Kachar B.;
RA
     "Expression and localization of prestin and the sugar transporter
RT
     GLUT-5 during development of electromotility in cochlear outer hair
RT
     cells.";
     J. Neurosci. 20:RC116-RC116(2000).
RL
RN
     [5]
RP
     MODE OF ACTION, AND MUTAGENESIS OF ASP-154; ASP-155; GLU-169; LYS-177;
RP
     ARG-197; LYS-233; LYS-235; ARG-236; GLU-277; ARG-281; LYS-283;
     LYS-285; ASP-332; ASP-342; LYS-409; LYS-557; ARG-558; LYS-559;
RP
RP
     ARG-571; ARG-572 AND LYS-577.
RX
     MEDLINE=21317458; PubMed=11423665;
RA
     Oliver D., He D.Z.Z., Kloecker N., Ludwig J., Schulte U.,
RA
     Waldegger S., Ruppersberg J.P., Dallos P., Fakler B.;
     "Intracellular anions as the voltage sensor of prestin, the outer hair
RT
RT
     cell motor protein.";
```

RL Science 292:2340-2343(2001).

CC

-!- FUNCTION: Motor protein that converts auditory stimuli to length changes in outer hair cells and mediates sound amplification in the mammalian hearing organ. Prestin is a bidirectional voltageto-force converter, it can operate at microsecond rates. It uses cytoplasmic anions as extrinsic voltage sensors, probably chloride and bicarbonate. After binding to a site with millimolar affinity, these anions are translocated across the membrane in response to changes in the transmembrane voltage. They move towards the extracellular surface following hyperpolarization, and towards the cytoplasmic side in response to depolarization. As a consequence, this translocation triggers conformational changes in the protein that ultimately alter its surface area in the plane of the plasma membrane. The area decreases when the anion is near the cytoplasmic face of the membrane (short state), and increases when the ion has crossed the membrane to the outer surface (long state). So, it acts as an incomplete transporter. It swings anions across the membrane, but does not allow these anions to dissociate and escape to the extracellular space. Salicylate, an inhibitor of outer hair cell motility, acts as competitive antagonist at the prestin anion-binding site (By similarity).

- -!- SUBCELLULAR LOCATION: Integral membrane protein; lateral wall of outer hair cells.
- -!- TISSUE SPECIFICITY: Specifically expressed in outer hair cells. Not detected in other cells of the organ of Corti.
- -!- DEVELOPMENTAL STAGE: Low levels are present in new-born rats and up to day 6. Subsequently, levels increase strongly. Adult levels are detected starting from day 9 in the basal turn of the cochlea, from day 10-11 in the middle turn, and from day 12 in the apical turn.
- -!- SIMILARITY: Belongs to the SLC26A/SulP transporter (TC 2.A.53) family.
- CC -!- SIMILARITY: Contains 1 STAS domain.
 - -!- DATABASE: NAME=Protein Spotlight; NOTE=Issue 22 of May 2002;

WWW="http://www.expasy.org/spotlight/articles/sptlt022.html".

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/or send an email to license@isb-sib.ch).

```
CC
DR
     EMBL; AJ303372; CAC21555.1; -.
DR
     EMBL; AF315652; AAG30297.1; -.
DR
     EMBL; AJ428404; CAD21439.1; -.
DR
     InterPro; IPR002645; STAS.
     InterPro; IPR001902; Sulph transpt.
DR
DR
     Pfam; PF01740; STAS; 1.
DR
     Pfam; PF00916; Sulfate transp; 1.
DR
     TIGRFAMs; TIGR00815; sulP; 1.
DR
     PROSITE; PS01130; SLC26A; 1.
     PROSITE; PS50801; STAS; 1.
DR
```

KW Motor protein; Cell shape; Transmembrane; Glycoprotein.
FT DOMAIN 1 79 CYTOPLASMIC (POTENTIAL).

```
80
                         100
                                    1 (POTENTIAL).
FT
     TRANSMEM
                  101
                         102
FT
                                    EXTRACELLULAR (POTENTIAL).
     DOMAIN
                 103
                         123
FT
     TRANSMEM
                                    2 (POTENTIAL).
FT
     DOMAIN
                 124
                         131
                                    CYTOPLASMIC (POTENTIAL).
FT
     TRANSMEM
                 132
                         152
                                    3 (POTENTIAL).
                                    EXTRACELLULAR (POTENTIAL).
FT
                 153
                         183
     DOMAIN
                 184
                         204
FT
     TRANSMEM
                                    4 (POTENTIAL).
FT
                 205
                         211
                                    CYTOPLASMIC (POTENTIAL).
     DOMAIN
     TRANSMEM
                 212
                         232
                                    5 (POTENTIAL).
FT
                 233
                         253
                                    EXTRACELLULAR (POTENTIAL).
     DOMAIN
FT
                 254
                         274
     TRANSMEM
                                    6 (POTENTIAL).
                 275
                         286
                                    CYTOPLASMIC (POTENTIAL).
FT
     DOMAIN
     TRANSMEM
                 287
                         307
                                    7 (POTENTIAL).
FT
                                    EXTRACELLULAR (POTENTIAL).
                 308
                         334
FT
     DOMAIN
     TRANSMEM
                 335
                         355
                                    8 (POTENTIAL).
FT
                  356
                         374
                                    CYTOPLASMIC (POTENTIAL).
FT
     DOMAIN
                                    9 (POTENTIAL).
     TRANSMEM
                  375
                         395
FT
                  396
                         411
                                    EXTRACELLULAR (POTENTIAL).
FT
     DOMAIN
                         432
FT
     TRANSMEM
                  412
                                    10 (POTENTIAL).
                  433
                         441
                                    CYTOPLASMIC (POTENTIAL).
FT
     DOMAIN
                  442
                         462
                                    11 (POTENTIAL).
FT
     TRANSMEM
                                    EXTRACELLULAR (POTENTIAL).
                  463
                         479
FT
     DOMAIN
                         500
FT
     TRANSMEM
                  480
                                    12 (POTENTIAL).
                  501
                         744
                                    CYTOPLASMIC (POTENTIAL).
FT
     DOMAIN
     DOMAIN
                  525
                         713
                                    STAS.
FΤ
                                    N-LINKED (GLCNAC. . .) (POTENTIAL).
     CARBOHYD
                  163
                         163
FT
FT
     CARBOHYD
                  166
                         166
                                    N-LINKED (GLCNAC. . .) (POTENTIAL).
FT
     MUTAGEN
                 154
                         154
                                    D->N: SHIFTS THE VOLTAGE-SENSITIVITY TO
FT.
                                    MORE NEGATIVE VALUES.
\mathbf{FT}
     MUTAGEN
                 155
                         155
                                    D->N: SHIFTS THE VOLTAGE-SENSITIVITY TO
                                    MORE NEGATIVE VALUES.
FT
FT
     MUTAGEN
                  169
                         169
                                    E->Q: NO EFFECT.
                  177
                         177
                                    K->Q: NO EFFECT.
FT
     MUTAGEN
FT
                 197
                         197
                                    R->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
     MUTAGEN
                                    MORE NEGATIVE VALUES.
FT
                 233
                         233
                                    K->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
FT
     MUTAGEN
                                    MORE NEGATIVE VALUES; WHEN ASSOCIATED
FT
FT
                                    WITH Q-235 AND Q-236.
FT
                 235
                         235
                                    K->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
     MUTAGEN
                                    MORE NEGATIVE VALUES; WHEN ASSOCIATED
FT
FT
                                    WITH Q-233 AND Q-236.
FT
     MUTAGEN
                  236
                         236
                                    R->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
                                    MORE NEGATIVE VALUES; WHEN ASSOCIATED
FT
                                    WITH Q-233 AND Q-235.
FT
                  277
                         277
                                    E->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
FT
     MUTAGEN
FT
                                    SLIGHTLY MORE POSITIVE VALUES.
                  281
                         281
                                    R->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
FT
     MUTAGEN
FT
                                    283 AND 0-285.
                  283
                         283
                                    K->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
FT
     MUTAGEN
FT
                                    218 AND Q-285.
                  285
                         285
                                    K->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
     MUTAGEN
FT
FT
                                    281-AND Q-283.
                  332
                         332
FT
     MUTAGEN
                                    D->O: NO EFFECT.
                                    D->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
FT
     MUTAGEN
                  342
                         342
FT
                                    MORE POSITIVE VALUES.
FT
                  409
                         409
                                    K->Q: NO EFFECT.
     MUTAGEN
                  557
                         557
                                    K->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
FΨ
     MUTAGEN
```

```
558 AND Q-559.
FТ
                              R->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
               558
                     558
    MUTAGEN
FT
                              557 AND Q-559.
FT
                              K->Q: NO EFFECT; WHEN ASSOCIATED WITH Q-
FT
    MUTAGEN
               559
                     559
                              557 AND Q-558.
FΤ
                              R->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
               571
                     571
FT
    MUTAGEN
                              SLIGHTLY MORE POSITIVE VALUES; WHEN
FT
                              ASSOCIATED WITH Q-572 AND Q-577.
FT
                              R->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
                     572
               572
FT
    MUTAGEN
                              SLIGHTLY MORE POSITIVE VALUES; WHEN
FΤ
                              ASSOCIATED WITH Q-571 AND Q-577.
FT
                     577
                              K->Q: SHIFTS THE VOLTAGE-SENSITIVITY TO
               577
FT
    MUTAGEN
                              SLIGHTLY MORE POSITIVE VALUES; WHEN
FT
                              ASSOCIATED WITH Q-571 AND Q-572.
FT
                              L \rightarrow V (IN REF. 2).
                     251
FT
    CONFLICT
               251
                              I \rightarrow M (IN REF. 2).
                    567
              567
FT
    CONFLICT
                    572
                             R \rightarrow S (IN REF. 2).
              572
FT
    CONFLICT
                     612
                             D \rightarrow G (IN REF. 2).
\mathbf{FT}
    CONFLICT
              612
                     663
                             GI -> VM (IN REF. 2).
FT
    CONFLICT
              662
    SEQUENCE 744 AA; 81278 MW; E49E842CF7A3CD58 CRC64;
SQ
 Query Match 9.0%; Score 84; DB 1; Length 744; Best Local Similarity 23.3%; Pred. No. 11;
 Matches 61; Conservative 34; Mismatches
                                            73; Indels 94; Gaps
          3 VDLLYWRDIKKTGVVFGASLFLLLSLTV-----FSIVSVTAYIALAL 44
Qу
            290 IPLEFFAVVMGTGISAGFNLHESYSVDVVGTLPLGLLPPANPDTSLFHLVYVDA-IAIAI 348
Db
         45 L--SVTISFR-----IYKGVIQAIQKSDEGHPFRAYLESEVAISEELV 85
Qу
            : [[[[]]
         349 VGFSVTISMAKTLANKHGYQVDGNQELIALGICNSI----GSLFQTFSIS-CSLSRSLV 402
Db
          86 QKYSNSALGHVNC--TIKELRRLFLVDDLVDSLKFAVL----- 121
Qу
            1:: | :: | : | :||
         403 QEGTGGKTQLAGCLASLMILLVILATGFLFESLPQAVLSAIVIVNLKGMFMQFSDLPFFW 462
Db
         122 -----MWVFTYVGALFNGL----TLLILALISLFSVPVIYERHQAQIDHYLGLANK 168
Qy
                   463 RTSKIELTIWLTTFVSSLFLGLDYGLITAVIIALLT-----VIY---RTQSPSYTVLGQL 514
Db .
         169 NVKDAMAKIQA----KIPGLK 185
Qу
              515 PDTDVYIDIDAYEEVKEIPGIK 536
RESULT 15
MDLB BUCBP
    MDLB BUCBP STANDARD; PRT; 578 AA.
ID
AC
    Q89A96;
DT
    10-OCT-2003 (Rel. 42, Created)
    10-OCT-2003 (Rel. 42, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
DT
    Multidrug resistance-like ATP-binding protein mdlB.
DE
    MDLB OR BBP424.
GN
    Buchnera aphidicola (subsp. Baizongia pistaciae).
os
    Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC
```

```
Enterobacteriaceae; Buchnera.
OC
    NCBI TaxID=135842;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    MEDLINE=22426901; PubMed=12522265;
RX
    Van Ham R.C.H.J., Kamerbeek J., Palacios C., Rausell C., Abascal F.,
RA
    Bastolla U., Fernandez J.M., Jimenez L., Postigo M., Silva F.J.,
RA
    Tamames J., Viguera E., Latorre A., Valencia A., Moran F., Moya A.;
RA
    "Reductive genome evolution in Buchnera aphidicola.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 100:581-586(2003).
RL
    -!- SUBCELLULAR LOCATION: Integral membrane protein (Potential).
CC
    -!- SIMILARITY: Belongs to the ABC transporter family. MDR subfamily.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    _____
CC
    EMBL; AE014017; AA027134.1; -.
DR
    InterPro; IPR001140; ABC TM transpt.
DR
    InterPro; IPR003439; ABC transporter.
DR
    Pfam; PF00664; ABC membrane; 1.
DR
    Pfam; PF00005; ABC_tran; 1.
DR
    PROSITE; PS50929; ABC TM1F; 1.
DR
    PROSITE; PS00211; ABC TRANSPORTER 1; FALSE_NEG.
    PROSITE; PS50893; ABC TRANSPORTER 2; 1.
DR
    ATP-binding; Transport; Transmembrane; Complete proteome.
KW
                      46
                              POTENTIAL.
    TRANSMEM
                26
FT
                      79
                              POTENTIAL.
FT
    TRANSMEM
                59
               143
                     163
                              POTENTIAL.
FT
    TRANSMEM
               166
                     186
                              POTENTIAL.
    TRANSMEM
FT
               196
                     216
                              POTENTIAL.
    TRANSMEM
FT
               260
                     280
                              POTENTIAL.
FT
    TRANSMEM
               339
                     573
                              ABC TRANSPORTER.
FT
    DOMAIN
FT
    NP BIND
               373
                     380
                              ATP (POTENTIAL).
              578 AA; 66827 MW; 3B84848CE196ADF7 CRC64;
    SEQUENCE
SQ
                        8.9%; Score 83; DB 1; Length 578;
  Query Match
                       20.3%; Pred. No. 10;
  Best Local Similarity
                                             63; Indels 54; Gaps
                                                                      9;
          40; Conservative 40; Mismatches
           1 SVVD------TV-FS 32
Qу
                             | :: | :| | |:
                                                               11:1
           3 NVIDFWPTLKRLLYYGTNVKKYLILGFTLLLFSSIFEVLNPILISCFIKHYFINNTVNYS 62
Db
          33 IVSVTAYIALALLSVTISF-----RIYKGVIQA----IQKSDEGHPFRAYLESEVAIS 81
Qу
             63 LKIITYYLILQILAAILNYHQNIIFNKISLTVIQKLRYDVMSSTLQLPIKMFDQRPIG-- 120
Db
          82 EELVQKYSNSALGHVNCTIKEL----RRLF--LVDDLVDSLKFAVLMWVFTYVGALFNG 134
Qу
                      121 -QFISRITNDTE----TIKELYDTVIKSLFQNIILILITLITMFILEWRMACIASIIFP 174
Db
         135 LTLLILALISLFSVPVI 151
Qу
```

Search completed: September 29, 2004, 18:14:47 Job time: 3.70944 secs